Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)

Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, Roqué i Figuls M, Parker LA, Caylà J, Bonfill Cosp X

Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, Roqué i Figuls M, Parker LA, Caylà J, Bonfill Cosp X. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD009913.
DOI: 10.1002/14651858.CD009913.pub2.

www.cochranelibrary.com
# TABLE OF CONTENTS

| Section                                                                 | Page |
|------------------------------------------------------------------------|------|
| ABSTRACT                                                              | 1    |
| PLAIN LANGUAGE SUMMARY                                                 | 2    |
| SUMMARY OF FINDINGS                                                    | 4    |
| BACKGROUND                                                             | 6    |
| Figure 1                                                               | 7    |
| OBJECTIVES                                                             | 7    |
| METHODS                                                                | 7    |
| RESULTS                                                                | 10   |
| Figure 2                                                               | 11   |
| Figure 3                                                               | 15   |
| Figure 4                                                               | 16   |
| Figure 5                                                               | 19   |
| DISCUSSION                                                             | 19   |
| AUTHORS’ CONCLUSIONS                                                   | 21   |
| ACKNOWLEDGEMENTS                                                       | 22   |
| REFERENCES                                                             | 23   |
| CHARACTERISTICS OF STUDIES                                             | 26   |
| DATA AND ANALYSES                                                      | 56   |

- Analysis 1.1. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 1 Treatment failure. .................................................. 57
- Analysis 1.2. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 2 Relapse. ................................................................. 57
- Analysis 1.3. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 3 Death. ................................................................. 57
- Analysis 1.4. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment. .................................................. 58
- Analysis 1.5. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 5 Sputum smear or culture conversion at end of treatment (EOT). .................................................. 58
- Analysis 1.6. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 6 Treatment adherence at 8 weeks of starting treatment. ................................................................. 59
- Analysis 1.7. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 7 Treatment adherence at EOT. ........................................ 59
- Analysis 1.8. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 8 Acquisition of drug resistance. ........................................ 60
- Analysis 1.9. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 9 Patient satisfaction. .................................................. 60
- Analysis 1.10. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 10 Serious adverse events. .................................................. 61
- Analysis 1.11. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 11 Adverse events leading to discontinuation of therapy. .................................................. 61
- Analysis 1.12. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 12 Other adverse events. .................................................. 61
- Analysis 2.1. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 1 Treatment failure. .................................................. 63
- Analysis 2.2. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 2 Relapse. .................................................. 64
- Analysis 2.3. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 3 Death. .................................................. 65
- Analysis 2.4. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment. .................................................. 65
- Analysis 2.5. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 5 Sputum smear or culture conversion at EOT. .................................................. 66
- Analysis 2.6. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 6 Acquisition of drug resistance. .................................................. 67
- Analysis 2.7. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 7 Serious adverse events. .................................................. 67
Analysis 2.8. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 8 Adverse events leading to discontinuation of therapy. ................................................................. 68
Analysis 2.9. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 9 Other adverse events. ........................................................................................................... 69
Analysis 3.1. Comparison 3 Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat (ITT), Outcome 1 Treatment failure (ITT analysis and all losses to follow-up judged as failure). ................................................................. 70
Analysis 3.2. Comparison 3 Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat (ITT), Outcome 2 Relapse (ITT analysis and all losses to follow-up judged as relapse). ........................................................................................................... 70
Analysis 3.3. Comparison 3 Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat (ITT), Outcome 3 Sputum smear or culture conversion at 2 months of starting treatment (ITT analysis and all losses to follow-up judged as conversion failure). ........................................................................................................... 71
Analysis 3.4. Comparison 3 Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat (ITT), Outcome 4 Sputum smear or culture conversion at EOT (ITT analysis and all losses to follow-up judged as conversion failure). ........................................................................................................... 71
Analysis 4.1. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 1 Treatment failure. ........................................................................................................... 73
Analysis 4.2. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 2 Relapse. ........................................................................................................... 74
Analysis 4.3. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 3 Death. ........................................................................................................... 74
Analysis 4.4. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment. ........................................................................................................... 75
Analysis 4.5. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 5 Acquisition of drug resistance. ........................................................................................................... 76
Analysis 4.6. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 6 Adverse events leading to discontinuation of therapy. ........................................................................................................... 76
Analysis 4.7. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 7 Other adverse events. ........................................................................................................... 77
Analysis 5.1. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 1 Treatment failure. ........................................................................................................... 80
Analysis 5.2. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 2 Relapse. ........................................................................................................... 80
Analysis 5.3. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 3 Death. ........................................................................................................... 81
Analysis 5.4. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment. ........................................................................................................... 82
Analysis 5.5. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 5 Sputum smear or culture conversion at EOT. ........................................................................................................... 82
Analysis 5.6. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 6 Acquisition of drug resistance. ........................................................................................................... 83
Analysis 5.7. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 7 Serious adverse events. ........................................................................................................... 84
Analysis 5.8. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 8 Adverse events leading to discontinuation of therapy. ........................................................................................................... 84
Analysis 5.9. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 9 Other adverse events. ........................................................................................................... 85
Analysis 6.1. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 1 Treatment failure. ........................................................................................................... 87
Analysis 6.2. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 2 Relapse. ........................................................................................................... 88
Analysis 6.3. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 3 Death. ........................................................................................................... 89
Analysis 6.4. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment. ........................................................................................................... 90
Analysis 6.5. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 5 Sputum smear or culture conversion at EOT. ........................................................................................................... 90
Analysis 6.6. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 6 Treatment adherence at 8 weeks of starting treatment.

Analysis 6.7. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 7 Treatment adherence at EOT.

Analysis 6.8. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 8 Serious adverse events.

Analysis 6.9. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 9 Adverse events leading to discontinuation of therapy.

Analysis 6.10. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 10 Other adverse events.

Analysis 7.1. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 1 Treatment failure.

Analysis 7.2. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 2 Relapse.

Analysis 7.3. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 3 Death.

Analysis 7.4. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 4 Adverse events leading to discontinuation of therapy.

Analysis 7.5. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 5 Sputum smear or culture conversion at EOT.

Analysis 7.6. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 6 Acquisition of drug resistance.

Analysis 7.7. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 7 Serious adverse events.

Analysis 7.8. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 8 Sputum smear or culture conversion at 2 months of starting treatment.

Analysis 7.9. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 9 Other adverse events.

ADDITIONAL TABLES

APPENDICES

CONTRIBUTIONS OF AUTHORS

DECLARATIONS OF INTEREST

SOURCES OF SUPPORT

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

INDEX TERMS
Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis

Carmen R Gallardo1, David Rigau Comas2, Angélica Valderrama Rodríguez3, Marta Roqué i Figuls4, Lucy Anne Parker5, Joan Caylà6, Xavier Bonfill Cosp7

1Preventive Medicine and Healthcare Quality Service, Hospital Universitario San Juan de Alicante, Alicante, Spain. 2Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain. 3Clinical of Pharmacology Department, Hospital Universitari Germans Trias i Pujol. Universitat Autònoma de Barcelona, Barcelona, Spain. 4Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau), CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. 5Department of Public Health, History of Science and Gynaecology, Universidad Miguel Hernández de Elche, CIBER Epidemiología y Salud Pública (CIBERESP), Alicante, Spain. 6Agència de Salut Pública de Barcelona, Biomedical Research Institute Sant Pau (IIB Sant Pau), CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. 7Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau), CIBER Epidemiología y Salud Pública (CIBERESP) - Universitat Autònoma de Barcelona, Barcelona, Spain

Contact: Carmen R Gallardo, Preventive Medicine and Healthcare Quality Service, Hospital Universitario San Juan de Alicante, Ctra. Nacional. 332 Alicante-Valencia, s/n, Alicante, Alicante, 03550, Spain. carmengrosa@yahoo.fr, cgallardoq@sescam.jccm.es.

Editorial group: Cochrane Infectious Diseases Group.

Publication status and date: Unchanged, published in Issue 5, 2016.

Citation: Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, Roqué i Figuls M, Parker LA, Caylà J, Bonfill Cosp X. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD009913. DOI: 10.1002/14651858.CD009913.pub2.

ABSTRACT

Background
People who are newly diagnosed with pulmonary tuberculosis (TB) typically receive a standard first-line treatment regimen that consists of two months of isoniazid, rifampicin, pyrazinamide, and ethambutol followed by four months of isoniazid and rifampicin. Fixed-dose combinations (FDCs) of these drugs are widely recommended.

Objectives
To compare the efficacy, safety, and acceptability of anti-tuberculosis regimens given as fixed-dose combinations compared to single-drug formulations for treating people with newly diagnosed pulmonary tuberculosis.

Search methods
We searched the Cochrane Infectious Disease Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL, published in the Cochrane Library, Issue 11 2015); MEDLINE (1966 to 20 November 2015); EMBASE (1980 to 20 November 2015); LILACS (1982 to 20 November 2015); the metaRegister of Controlled Trials; and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), without language restrictions, up to 20 November 2015.

Selection criteria
Randomized controlled trials that compared the use of FDCs with single-drug formulations in adults (aged 15 years or more) newly diagnosed with pulmonary TB.
Data collection and analysis

Two review authors independently assessed studies for inclusion, and assessed the risk of bias and extracted data from the included trials. We used risk ratios (RRs) for dichotomous data and mean differences (MDs) for continuous data with 95% confidence intervals (CIs). We attempted to assess the effect of treatment for time-to-event measures with hazard ratios and their 95% CIs. We used the Cochrane ‘Risk of bias’ assessment tool to determine the risk of bias in included trials. We used the fixed-effect model when there was little heterogeneity and the random-effects model with moderate heterogeneity. We used an I² statistic value of 75% or greater to denote significant heterogeneity, in which case we did not perform a meta-analysis. We assessed the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

Main results

We included 13 randomized controlled trials (RCTs) in the review, which enrolled 5824 participants. Trials were published between 1987 and 2015 and included participants in treatment with newly diagnosed pulmonary TB in countries with high TB prevalence. Only two trials reported the HIV status of included participants.

Overall there is little or no difference detected between FDCs and single-drug formulations for most outcomes reported. We did not detect a difference in treatment failure between FDCs compared with single-drug formulations (RR 1.28, 95% CI 0.82 to 2.00; 3606 participants, seven trials, moderate quality evidence). Relapse may be more frequent in people treated with FDCs compared to single-drug formulations, although the confidence interval (CI) includes no difference (RR 1.28, 95% CI 1.00 to 1.64; 3621 participants, 10 trials, low quality evidence). We did not detect any difference in death between fixed-dose and single-drug formulation groups (RR 0.96, 95% CI 0.67 to 1.39; 4800 participants, 11 trials, moderate quality evidence).

When we compared FDCs with single-drug formulations we found little or no difference for sputum smear or culture conversion at the end of treatment (RR 0.99, 95% CI 0.96 to 1.02; 2319 participants, seven trials, high quality evidence), for serious adverse events (RR 1.45, 95% CI 0.90 to 2.33; 3388 participants, six trials, moderate quality evidence), and for adverse events that led to discontinuation of therapy (RR 0.96, 95% CI 0.56 to 1.66; 5530 participants, 13 trials, low quality evidence).

We conducted a sensitivity analysis excluding studies at high risk of bias and this did not alter the review findings.

Authors' conclusions

Fixed-dose combinations and single-drug formulations probably have similar effects for treating people with newly diagnosed pulmonary TB.

23 April 2019

No update planned

Other

This is not a current research question.

PLAIN LANGUAGE SUMMARY

Fixed-dose combinations for treating pulmonary tuberculosis

What are fixed-dose combinations and how might they improve care of people with tuberculosis

Tuberculosis (TB) is an important health problem, especially in developing countries. The treatment for pulmonary TB in new patients includes four oral medicines taken for six months, sometimes as fixed-dose combinations (FDCs) that are combined in one tablet, or taken separately as single-drug formulations. The World Health Organization recommends prescribers use fixed-dose combinations to reduce the number of tablets that people take. On the supply side, this might reduce prescribing errors and improve drug supply efficiency; on the patient's side, FDCs simplify treatment and improve adherence.

We conducted a review to assess the efficacy, safety, and acceptability of FDCs compared with single-drug formulations for treating people with newly diagnosed pulmonary TB.

What the research says

We searched for relevant trials up to 20 November 2015, and included 13 randomized controlled trials that enrolled 5824 people. Trials were published between 1987 and 2015 and included participants in treatment with newly diagnosed pulmonary TB in countries with high TB prevalence. Only two trials reported the HIV status of included participants.

There is probably little or no difference in FDCs compared to single-drug formulations for treatment failure (moderate quality evidence); relapse may be more frequent (low quality evidence); and the number of deaths were similar (moderate quality evidence).
There is little or no difference in sputum smear or culture conversion (high quality evidence), and no difference was shown for serious adverse events (moderate quality evidence) or adverse events that led to discontinuation of therapy (low quality evidence).

Authors' conclusions

We concluded that fixed-dose combinations have similar efficacy to single-drug formulations for treating people with newly diagnosed pulmonary TB.
### Summary of findings for the main comparison. 'Summary of findings' table 1

Fixed-dose combinations compared to single-drug formulations for treating newly diagnosed pulmonary tuberculosis (TB)

**Participant or population:** treating pulmonary TB  
**Setting:** hospitals and health centres for TB treatment  
**Intervention:** fixed-dose combinations  
**Comparison:** single-drug formulations

| Outcomes                                      | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | Number of participants (trials) | Quality of the evidence (GRADE) |
|-----------------------------------------------|-----------------------------------------|--------------------------|---------------------------------|---------------------------------|
|                                               | Assumed risk single-drug formulations | Corresponding risk FDCs  |                                  |                                 |
| Treatment failure                             | 19 per 1000 (15 to 37)                  | RR 1.28 (0.82 to 2.00)   | 3606 (7 RCTs)                   | ⊕⊕⊕ moderate1,2,3,4             |
| Relapse                                       | 55 per 1000 (55 to 91)                  | RR 1.28 (1.00 to 1.64)   | 3621 (10 RCTs)                  | ⊕⊕⊕ low2,3,4,5                 |
| Death                                         | 25 per 1000 (17 to 34)                  | RR 0.96 (0.67 to 1.39)   | 4800 (11 RCTs)                  | ⊕⊕⊕ moderate1,3,6,7           |
| Sputum smear or culture conversion at end of treatment | 892 per 1000 (857 to 910) | RR 0.99 (0.96 to 1.02) | 2319 (7 RCTs)                   | ⊕⊕⊕⊕ high1,2,3,8              |
| Serious adverse events                        | 16 per 1000 (14 to 37)                  | RR 1.45 (0.90 to 2.33)   | 3388 (6 RCTs)                   | ⊕⊕⊕ moderate1,2,3,7           |
| Adverse events leading to discontinuation of therapy | 40 per 1000 (22 to 67)          | RR 0.96 (0.56 to 1.66)   | 5530 (13 RCTs)                  | ⊕⊕⊕ low3,4,5,9                |
| Combined endpoint of treatment failure, relapse, or death** | —                                       | —                        | —                               | —                              |

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  
**Outcome not reported.

**Abbreviations:** CI: confidence interval; RR: risk ratio; TB: tuberculosis; FDCs: fixed-dose combinations; RCTs: randomized controlled trial.

**GRADE Working Group grades of evidence**
Implication of Results

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect.

1. We did not downgrade the quality of the evidence due to limitations in design and execution. Analysis of studies at low risk of bias does not change the effect estimate.

2. Quality not downgraded for inconsistency (I² statistic = 0% ).

3. Quality not downgraded for indirectness. Differences in dosages probably do not affect the comparability of groups.

4. We downgraded by 1 for imprecision. The optimal information size considering an absolute > 0.5% non-inferiority margin as clinically meaningful is not reached. In addition, one side of the 95% CI does not exclude potential harm associated to FDs.

5. We downgraded by 1 for methodological limitations. Exclusion of studies at highest risk of bias does not change the estimate of the effect.

6. Quality not downgraded for inconsistency (I² statistic = 26% ).

7. We downgraded by 1 for imprecision. The optimal information size considering an absolute > 0.1% non-inferiority margin as clinically meaningful is not reached. Although the optimal information size is large, the total sample size and number of events are very large.

8. Quality not downgraded for imprecision. Although the optimal information size (considering an absolute > 0.5% non-inferiority margin as clinically meaningful) is not reached, the total sample size and number of events are very large.

9. Quality not downgraded for inconsistency. Studies of highest risk of bias contribute to explain the large heterogeneity (I² statistic = 57% ).
**BACKGROUND**

**Description of the condition**

Tuberculosis (TB) is a global pandemic and the disease caused approximately nine million new cases and 1.5 million deaths in 2014. It is a major public health problem and is one of the infectious diseases with the highest incidence in the world. It is caused by bacterial species of the *Mycobacterium tuberculosis* complex (a genetically closely-related group of *Mycobacterium* species). TB most commonly affects the lungs (pulmonary TB), although it can also affect other organs and systems (extrapulmonary TB). It is transmitted from person to person by droplets from the throat and lungs of people with active respiratory TB. The most common symptom of pulmonary TB is a persistent and productive cough, sometimes with haemoptysis (expulsion of sputum with blood). It is often accompanied by general symptoms such as fever, night sweats, and weight loss. The symptoms for extrapulmonary TB depend on the site of disease, and are usually accompanied by intermittent fever and weight loss. Anyone can contract TB, but people with prolonged and close household exposure to a person with active pulmonary TB are at greatest risk. The probability of developing TB is much higher among people infected with human immunodeficiency virus (HIV). TB is also more common among men than women, and affects mostly adults in the economically productive age groups. Accurate and early diagnosis, in addition to rapid and appropriate treatment, are the most important actions in TB care and control (ISTC 2014; NICE 2006; WHO 2015).

**Treatment of tuberculosis**

Effective treatment that ensures a rapid and lasting cure is the main component in TB control. *M. tuberculosis* is a slow-growing bacillus and treatment requires multiple drugs over a prolonged time period. The ultimate objective is to cure the disease and prevent drug resistance developing. The recommended oral drugs for first-line anti-TB treatment are isoniazid (H), rifampicin (R), pyrazinamide (Z), and ethambutol (E). The standard short-course TB treatment for new patients with pulmonary TB consists of six months of rifampicin-based regimen (2HRZE/4HR), given daily or three times per week. There are some considerations to take into account in TB treatment. Pulmonary and extrapulmonary disease should be treated with the same regimen, but in some cases of extrapulmonary TB (such as TB meningitis and bone or joint TB) the recommended therapy is longer than the standard TB regimen. Ideally, drug regimens for all patients should depend on the results of drug susceptibility testing to guide the therapy (ISTC 2014; NICE 2012; WHO 2010; WHO 2014).

The recommended doses for treatment of children with TB differ compared to treatment of adults. Correct treatment prescription for children with TB remains a challenge. Current guidance of the World Health Organization (WHO) for the treatment of children with TB is based on the last scientific evidence and recommends the use of fixed-dose combinations (FDCs) (WHO 2009; WHO 2014). Nevertheless, currently available FDCs on the market for TB treatment do not correspond with the appropriate doses for children, making treatment very difficult or unfeasible.

Assessment and promotion of treatment adherence is critical for the achievement of favourable patient outcomes, and directly observed treatment (DOT) and training for a treatment supporter (parent or responsible adult for supervised treatment) are recommended strategies when addressing this issue (ISTC 2014; WHO 2010; WHO 2014).

**Description of the intervention**

FDCs are pills that contain more than one active ingredient. Anti-TB drugs may contain two, three, or four active ingredients in one tablet. Pharmacokinetic studies of anti-TB drugs show that absorption, plasma concentrations, and other pharmacokinetic parameters are similar for FDCs and single-drug formulations (Agrawal 2002; Zwolska 1998). FDCs appear on the WHO Model List of Essential Medicines (WHO 2011). Both the WHO, WHO 2010, and the International Standards for Tuberculosis Care, ISTC 2014, recommend the use of FDCs for standard TB treatment regimens. The national TB programmes of most high-burden TB countries have adopted FDCs as standard TB treatment regimens (Wells 2011).

**How the intervention might work**

The increase in drug resistance amongst species of the *M. tuberculosis* complex has become a critical issue in global TB control. With the use of single-drug formulations the treatment adherence could be lower, the patient could choose to stop using one or more drugs (perceived by them as problematic in terms of side effects) while continuing use of the other drugs, or some patients may interrupt treatment completely. This may lead to the selection of drug-resistant *M. tuberculosis* strains.

The main reasons for the use of FDCs are the improvement in treatment adherence and reduced rates of drug resistance (Figure 1). By using FDCs the number of pills to be taken by the patient is considerably reduced (ISTC 2014), making it possible to increase patient satisfaction and decrease medication errors, burden, and cost for patients. Prescription mistakes may be lowered and the efficiency in the drug supply system may be increased due to fewer drug orders and shipments (Blomberg 2001; CDC 2003; Rieder 2002). The major advantages of using FDCs to treat people with TB are simplified treatment and drug management and decreased probability of monotherapy (Blomberg 2001). Moreover, FDCs tend to improve adherence in various settings (Connor 2004).
There are some disadvantages to the use of FDCs. It may be difficult to identify the relationship between an adverse drug reaction and one of the components of FDCs if any toxicity issues occur. In addition, FDCs may impede further dose adjustments. Another disadvantage of FDCs is poor rifampicin bioavailability if strict manufacturing procedures are not followed or poor quality materials are used (Blomberg 2001).

Why it is important to do this review

The effectiveness of FDCs has been tested in randomized controlled clinical trials, but small sample sizes and differences in treatment doses or schedule have limited the applicability of their results. This Cochrane review on the effectiveness of FDCs versus single-drug formulations for the treatment of pulmonary TB will help to evaluate the benefits and disadvantages of FDCs based on the existing scientific evidence.

OBJECTIVES

To compare the efficacy, safety, and acceptability of anti-tuberculosis regimens given as fixed-dose combinations compared to single-drug formulations for treating people with newly diagnosed pulmonary tuberculosis.

METHODS

Criteria for considering studies for this review

Types of studies

Randomized controlled trials (RCTs).

Types of participants

Male and female adolescents and adults (aged 15 years or older), newly diagnosed with pulmonary TB, confirmed by sputum smear or culture, or both, or according to the World Health Organization (WHO) definition for a case of tuberculosis (TB): participants in which a health worker has diagnosed TB and has decided to treat with a full course of TB treatment (WHO 2010).

We excluded children, people with extrapulmonary TB, and those previously treated for TB. We excluded children due to difficulties in childhood TB treatment with the available fixed-dose combinations (FDCs) (WHO 2009; WHO 2014).

We excluded studies that included both adults and children, unless subgroup data for adults were available from the study report.
Types of interventions

**Intervention**
FDC chemotherapy.

**Control**
Multiple single-drug formulation chemotherapy.

For all included trials, the intervention and control groups had to use the same components and dose schedule. We included trials in which TB treatment was administered for a minimum of two months, but did not exceed nine months.

Types of outcome measures

**Primary outcomes**
1. A combined endpoint of treatment failure, relapse, or death.
2. Treatment failure.
3. Relapse.
4. Death.

We reported death due to any cause.

**Secondary outcomes**
1. Sputum smear or culture conversion.
2. Time to sputum smear or culture conversion.
3. Time to relapse.
4. Treatment adherence (as defined by the trial authors).
5. Acquisition of drug resistance (as defined by the trial authors).
6. Patient satisfaction characterized as:
   a. general satisfaction;
   b. no problems swallowing;
   c. acceptable taste.
7. Adverse events characterized as:
   a. serious (death, hospitalizations);
   b. those leading to discontinuation of therapy;
   c. other adverse events.

For sputum smear or culture conversion we took culture conversion data instead of sputum smear data when both were available. We assessed dichotomous outcomes at two to three months, at the end of treatment (EOT), and at follow-up when data were available. For treatment adherence and acquisition of drug resistance, we used the definitions suggested by the trial authors (see Table 1).

Search methods for identification of studies

We searched for all relevant trials regardless of language or publication status (published, unpublished, in press, and ongoing).

Electronic searches

We searched the following databases: the Cochrane Infectious Disease Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL, published in the Cochrane Library, Issue 11 2015); MEDLINE (1966 to 20 November 2015); EMBASE (1980 to 20 November 2015); and LILACS (1982 to 20 November 2015), using the search terms detailed in Appendix 1. We also searched the metaRegister of Controlled Trials (mRCT) (20 November 2015) and the search portal of the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (www.who.int/trialsearch) (20 November 2015), to identify ongoing trials, using “tuberculosis” and “fixed dose OR combination” as search terms.

Searching other resources

We contacted trial authors in the field to identify additional studies that may have met the inclusion criteria. We checked projects of relevant organizations, including the WHO, the Tuberculosis Trials Consortium (TBTC), the International Union Against Tuberculosis and Lung Disease, and the WHO Global TB Programme to identify any unpublished and ongoing trials.

We also checked the reference lists of all relevant studies identified by the above methods.

Data collection and analysis

Selection of studies

Two review authors (CRG and AVR) independently screened the titles and abstracts of all citations retrieved by the search to identify potentially eligible studies. We obtained the full-text articles of potentially eligible studies and independently evaluated these studies for inclusion in the review, based on the inclusion and exclusion criteria. When we found multiple publications for the same study, we ensured that we counted these as the same study. In case of disagreements, we consulted a third review author (DRC) to resolve them. We documented the reasons for exclusion of studies.

Data extraction and management

Two review authors (CRG and AVR) independently extracted data from the included trials using a standardized data extraction sheet. For all included trials, we extracted information regarding the number of randomized participants and the number of participants whose outcomes were measured. We extracted the number of events and the number of participants assessed in each treatment arm for dichotomous outcomes. For continuous outcomes, we extracted the arithmetic means and standard deviations, together with the number of participants in each group. We resolved discrepancies regarding the extracted data with another two review authors (MRF and DRC) when necessary. When we required additional details, we contacted the trial authors by email.

For all included trials we extracted the following information when available.

1. Trial details: publication details, study design, methodological criteria, country and trial setting (hospital or clinic).
2. Participant characteristics: age, gender, inclusion and exclusion criteria, sputum smear status if available, mycobacterial culture data, baseline drug susceptibility testing, and HIV status.
3. TB treatment details: types of regimen, dosage, frequency (daily or intermittent), mode of administration (self-administered or supervised treatment), duration of follow-up, withdrawal, and loss to follow-up.
4. Outcome details (see the 'Types of outcome measures' section).

Assessment of risk of bias in included studies

Two review authors (CRG and AVR) independently assessed the risk of bias in the included trials using a standardized assessment form. In case of disagreement, we consulted a third review author (DRC). We assessed the following six components in each included study:
Measures of treatment effect

We analysed the effect of treatment for dichotomous outcomes using the risk ratio (RR) and 95% confidence interval (CI). For continuous data, we planned to measure the effect of treatment with differences in means and their 95% CIs. We planned to assess the effect of treatment for time-to-event measures with hazard ratios (HRs) and their 95% CIs.

Dealing with missing data

For the main analysis, we did not take missing data into account and presented the data as “available data” according to data given in the original trials for all outcomes (see Data and analyses: Comparison 1 ‘Fixed-dose combinations versus single-drug formulations as available data’). The same approach was taken for the sensitivity analysis that considered the ‘Risk of bias’ assessment of included trials (see Data and analyses: Comparison 2 ‘Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias’).

We performed a sensitivity analysis using an intention-to-treat (ITT) approach for the primary and secondary dichotomous outcomes relating to treatment efficacy (treatment failure, relapse, and sputum smear or culture conversion at 2 months or end of treatment). See Data and analyses: Comparison 3 ‘Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat (ITT)’. The ITT sensitivity analyses were performed under the hypothesis that all participants lost during follow-up presented negative events for the considered outcomes. We didn’t perform a similar sensitivity analysis for death, because any hypothesis regarding participants lost to follow-up seemed unreasonable.

Assessment of heterogeneity

We assessed heterogeneity among trials by visual inspection of forest plots, application of the Chi² test with a 10% level of statistical significance, and consideration of the I² statistic. We used an I² statistic value of 50% to denote moderate heterogeneity and 75% or greater to denote substantial heterogeneity.

Assessment of reporting biases

We assessed the likelihood of small study effects, such as publication bias, by visual examination of the funnel plot for asymmetry when there where at least 10 included trials.

Data synthesis

We calculated a pooled estimate of treatment using a fixed-effects model when minimal heterogeneity was present and a random-effects model when moderate heterogeneity was present. We did not attempt to perform a meta-analysis if the I² statistic value was greater than 75%.

For the main analysis, we presented an “available case analysis” according to data presented in the original trials for all outcomes (see Data and analyses: Comparison 1 ‘Fixed-dose combinations versus single-drug formulations as available data’).

We pooled trial data for continuous or dichotomous outcomes with the Mantel-Haenszel method. If HRs had been available for time-to-event data, we would have pooled them with the inverse-variance method.

We performed statistical analyses using RevMan (RevMan 2014) and presented the results with 95% CIs.

We assessed the quality of the evidence using the Grading of Recommendations Assessment, Evaluation and Development (GRADE) approach. We summarized the quality of evidence for the main outcomes and the RCT data in ‘Summary of findings’ tables. We constructed the ‘Summary of findings’ tables using GRADEpro Guideline Development Tool (GDT) software (available from wwwGRADEpro.org).

Subgroup analysis and investigation of heterogeneity

We explored potential sources of heterogeneity by analysing the following subgroups.

1. FDCs administered only during the intensive phase versus FDCs administered for the whole treatment.
2. Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase.
3. Supervised treatment versus self-administered treatment during the intensive phase.
4. Trials with four drugs as FDCs versus trials with three or two drugs as FDCs during the intensive phase.
5. HIV-positive participants versus HIV-negative participants.
6. Clinically diagnosed participants versus laboratory diagnosed participants.

For the subgroup analysis we presented an ‘available case analysis’.

Sensitivity analysis

We performed the following sensitivity analyses.

1. We conducted a sensitivity analysis to explore the impact of the ‘Risk of bias’ assessment on the main analysis. We analysed separately the two trials at low risk of selection bias (Bartacek 2009; Lienhardt 2011) (see Data and analyses: Comparison 2 ‘Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias’).
2. We performed a sensitivity analysis to explore the impact of missing data on the main analysis, for primary and secondary dichotomous outcomes related to treatment efficacy. We conducted this analysis as an ITT analysis. We kept participants in the intervention groups to which they were randomized, regardless of the intervention to which they ended the follow-up, and included all randomized participants in the analysis. We imputed missing data for patients lost to follow-up under the hypothesis that all of them presented negative events (see Data and analyses: Comparison 2 ‘Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias’).
Cochrane Database of Systematic Reviews

**Results**

**Description of studies**

See the 'Characteristics of included studies' and 'Characteristics of excluded studies' sections.

**Results of the search**

We retrieved 619 records, of which we selected 50 as potentially relevant after we screened the title and abstract. After we excluded four further articles, we assessed the full text of 46 articles and 14 trials met the inclusion criteria. We included 13 trials in the meta-analysis. We illustrated the selection process in a flow diagram (see Figure 2).
Figure 2. Flow diagram of the trial selection process.

612 records identified through database searches
7 additional records identified through other sources

619 records screened
569 records excluded based on title/abstract

4 records excluded:
- a RCT that met the inclusion criteria but not yet published (N = 1);
- a RCT available only as an abstract or congress poster (N = 3), of which 1 did not meet the inclusion criteria.

50 records evaluated as potentially relevant

27 articles excluded
- RCTs awaiting classification (N = 4);
- RCTs not meet inclusion criteria (N = 8, from 9 articles);
- Controlled clinical trials (N = 2);
- Not clear if Controlled clinical trial (N = 1);
- Descriptive studies (N = 3);
- Articles did not answer the review question (N = 8).

46 full-text articles obtained

14 studies included in qualitative synthesis (from 19 articles):
- studies published as one article (N = 10);
- studies published in two articles (N = 3);
- study published in three articles (N = 1).

1 study excluded:
- no disaggregated results.
Among the potentially relevant records, we retrieved one unpublished trial that met the inclusion criteria (ISRCTN95204603). We also retrieved four studies that were not yet classified (see the 'Characteristics of studies awaiting classification' section).

**Included studies**

In the qualitative synthesis, we included 14 RCTs, published between 1987 and 2015, that compared the use of fixed-dose combinations (FDCs) versus single-drug formulations to treat participants with newly diagnosed pulmonary tuberculosis (TB). We included 13 trials in the meta-analysis. All but one trial, Suryanto 2008, described the follow-up duration, and ranged from four months to five years after initiation of treatment. We have described details of the 14 trials in the 'Characteristics of included studies' section.

**Participants**

We included 14 trials in the qualitative analysis which included 6211 randomized participants. The meta-analysis included 13 RCTs with 5824 randomized participants, with a range of 40 to 1585 participants per trial (see Table 2). All participants were 15 years of age or older. The proportion of male participants ranged between 27.8% and 88.6% across the included trials.

All trials included participants with pulmonary TB whose status had been confirmed by microbiological diagnosis (sputum smear or culture, or both). Only two included trials described the HIV status of the participants (Bartacek 2009; Lienhardt 2011).

**Location and setting**

Most included trials were conducted in high TB-burden countries, or low- and middle-income countries, or both (see the 'Characteristics of included studies' section).

The RCTs were conducted in different continents and countries. Eight trials were conducted in Asia (RCTAI 1989; Su 2002; Suryanto 2008; Teo 1999; Wu 2015; Zaka-Ur-Rehman 2008; Zhang 1996; Zhu 1998), two in Europe (Munteanu 2004; Semenova 2003), one in Africa (Chuatet 1995), and one in the USA (Geiter 1987). Two trials involved several countries (Bartacek 2009; Lienhardt 2011). All trials but two (Bartacek 2009 and Su 2002) gave details of the trial setting: hospital (six trials), clinics (four trials), hospital and health centre (one trial), and a different setting in each included country (one trial). We have provided the details of the country where each trial was conducted in "Characteristics of included studies".

**Interventions**

All but three included trials, Lienhardt 2011, RCTAI 1989, and Semenova 2003, used a six-month treatment regimen. Lienhardt 2011 and RCTAI 1989 used a 26-week regimen, and Semenova 2003 employed a four-month regimen (see Table 2).

Although all included RCTs compared FDCs versus single-drug formulations for treatment of pulmonary TB in newly diagnosed participants and used the same drugs and a comparable dose schedule in the intervention and control group, there were some differences in treatment administration between trials.

We included trials which gave drugs for a minimum of two months, but did not exceed nine months. We included one trial, Teo 1999, where 33% of the participants received drugs for the intensive phase for only a month, and for two months in the case of the remaining trial population (N = 209).

All but four included trials, Lienhardt 2011, Munteanu 2004, Semenova 2003, and Teo 1999, compared FDCs versus single-drug formulations during the whole treatment. The four remaining trials, Lienhardt 2011, Munteanu 2004, Semenova 2003, and Teo 1999, compared FDCs versus single-drug formulations exclusively during the intensive phase. In Lienhardt 2011 and Munteanu 2004 all participants received FDCs during the continuation phase. Semenova 2003 did not report the continuation phase, and in Teo 1999 all participants received single-drug formulations during the continuation phase. No trial compared FDCs versus single-drug formulations exclusively during the continuation phase.

In Table 3, we describe the doses administered during the intensive phase in all trials for both treatment groups (FDCs and single-drug formulations). Table 3 also shows a simulation of doses received by participants during the intensive phase according to body weight.

In Bartacek 2009 and Suryanto 2008, there were some differences in doses between the intervention and control groups. In Bartacek 2009, "the mean daily dosage of H, Z and E in FDCs group was lower than in single-drug formulations group". Moreover, FDCs were administered on the basis of body weight according to international recommendations (the World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease; Blomberg 2001), and single-drug formulations were administered according to the national treatment standards of each included country. In Suryanto 2008, compared with FDCs (given according to WHO recommendations; WHO 2002), single-formulation regimens contained higher doses of isoniazid and pyrazinamide and lower doses of ethambutol. However, the dose was adjusted to body weight in both groups (intervention and control) (see Table 3).
Nine included trials used daily medication during the intensive and continuation phase (Bartacek 2009; Chaulet 1995; Geiter 1987; RCTAI 1989; Su 2002; Wu 2015; Zaka-Ur-Rehman 2008; Zhang 1996; Zhu 1998). Four included trials used daily medication during the intensive phase, and intermittent medication during the continuation phase (Lienhardt 2011; Munteanu 2004; Suryanto 2008; Teo 1999). One trial (Semenova 2003) reported daily medication for the intervention groups and did not report the frequency of treatment in control groups. None of the clinical trials used treatment twice a week.

Seven trials used directly observed treatment (DOT); five during the whole treatment (Lienhardt 2011; Munteanu 2004; Teo 1999; Wu 2015; Zhang 1996) and two only during the intensive phase (Chaulet 1995; Zaka-Ur-Rehman 2008). In Chaulet 1995 and Zaka-Ur-Rehman 2008, treatment was self-administered during the continuation phase. Four trials used self-administered treatment during the whole therapy (Geiter 1987; RCTAI 1989; Su 2002; Suryanto 2008). Two trials did not report the mode of treatment supervision (Bartacek 2009; Semenova 2003). In Zhu 1998, there were three kinds of treatment management combined with three supervision models, respectively.

During the intensive phase, five trials used four drugs in FDC (Bartacek 2009; Lienhardt 2011; Semenova 2003; Suryanto 2008; Zaka-Ur-Rehman 2008), eight trials used three drugs in FDC (Chaulet 1995; Geiter 1987; RCTAI 1989; Su 2002; Teo 1999; Zhang 1996; Zhu 1998), and one trial used two drugs in FDC and two additional single drugs (Munteanu 2004). We have detailed each FDC used by each included trial in the 'Characteristics of included studies' section.

Semenova 2003 compared daily treatment with four FDCs versus four single-drug formulations during the intensive phase. It is unclear whether treatment was supervised or self-administered, and when follow-up concluded. The trial gave data precisely up to the end of the intensive phase (four months after initiation of treatment).

**Outcomes**

We have described below the outcomes for the 13 trials we included in the quantitative analyses.

**A combined endpoint of treatment failure, relapse, or death**

No included trials examined the combined outcome.

**Treatment failure**

Seven included trials assessed this outcome (Bartacek 2009; Chaulet 1995; Lienhardt 2011; Su 2002; Suryanto 2008; Teo 1999; Wu 2015). All but one trial, Lienhardt 2011, reported treatment failure based only on bacteriological confirmation in all participants. Lienhardt 2011 also reported failure based on “clinical or radiographic deterioration in absence of bacteriological confirmation” in only one participant. See Table 1 for each included trials’ suggested definition of treatment failure.

**Relapse**

This outcome was available in nine included trials (Bartacek 2009; Chaulet 1995; Lienhardt 2011; RCTAI 1989; Su 2002; Suryanto 2008; Teo 1999; Zaka-Ur-Rehman 2008; Zhang 1996). All but two included trials, RCTAI 1989 and Suryanto 2008, reported relapse based only on bacteriological confirmation in all participants. These two RCTs reported relapse confirmed by bacteriological results but also based on other methods, such as information from interviews and verbal autopsies in 19 participants (Suryanto 2008), or X-ray in one participant (RCTAI 1989). See Table 1 for each included trials’ definition of relapse.

**Death**

Eleven trials assessed this outcome (Bartacek 2009; Geiter 1987; Lienhardt 2011; RCTAI 1989; Su 2002; Suryanto 2008; Teo 1999; Wu 2015; Zaka-Ur-Rehman 2008; Zhang 1996; Zhu 1998). We included all causes of death.

The included trials were published between 1987 and 2015, which made it impossible to present the same definitions of treatment failure and relapse across all trials. For these two outcomes, we used the trial authors’ proposed definitions and collected data based on bacteriological confirmation (sputum smear or culture results) (see Table 1).

**Sputum smear or culture conversion**

For this outcome, all included trials reported data at two months and only seven trials reported data at six months (Bartacek 2009; RCTAI 1989; Su 2002; Suryanto 2008; Wu 2015; Zhang 1996; Zhu 1998).

**Time to sputum smear or culture conversion**

Only Zaka-Ur-Rehman 2008 reported on this outcome.

**Time to relapse**

Only Teo 1999 reported on this outcome.

**Treatment adherence**

Five included trials reported on this outcome (Chaulet 1995; Geiter 1987; RCTAI 1989; Su 2002; Zhu 1998) at the end of treatment (EOT) and three trials also reported on it during the first eight weeks of treatment (Chaulet 1995; Geiter 1987; RCTAI 1989). Each trials used different adherence assessment methods.

1. Chaulet 1995 determined adherence by testing urine for isoniazid metabolites and considered participants with at least one negative urine test as non-adherent.
2. Geiter 1987 assessed appointment-keeping behaviour, by asking participants about missed doses, by pill counts, and by testing urine for isoniazid metabolites. Geiter 1987 considered participants who missed more than 14 days of any study drug without medical advice, or participants that had four consecutively missed appointments as non-adherent.
3. RCTAI 1989 determined adherence by delay in drug collection and surprise pill count (surprise visit once a month). The delay was measured in drug-days, expressed as a percentage of total treatment days and classified as either: none, 1% to 10% and greater than 10%. For this Cochrane review, we considered participants with no drug-days lost as adherent.
4. Su 2002 determined adherence by “cases lost to follow-up and cases changed to another regimen during treatment”.
5. In Zhu 1998, the supervision process was unclear (by testing urine or by indirect methods).

See Table 1 for details on treatment adherence in each trial.
Acquisition of drug resistance

Three trials reported on this outcome (Chaulet 1995; Lienhardt 2011; Teo 1999). See Table 1 for details on acquisition of drug resistance in each trial.

Patient satisfaction

General satisfaction

Only Chaulet 1995 reported on this outcome, and assessed it by semi-directed interviews with targeted questions posed by non-medical staff at the end of the eighth week of treatment.

Problems swallowing, convenient number of tablets, and acceptable taste

Only Bartacek 2009 reported on this outcome, and noted it at two months.

Adverse events

Serious (death, hospitalizations)

Six trials reported serious adverse events (Bartacek 2009; Lienhardt 2011; Munteanu 2004; RCTAI 1989; Wu 2015; Zaka-Ur-Rehman 2008).

Adverse events leading to discontinuation of therapy

All trials reported this outcome.

Other adverse events

All included trials but four, RCTAI 1989, Su 2002, Suryanto 2008, and Wu 2015, reported other adverse events. The most frequent adverse events in this category were gastrointestinal and skin disorders (Bartacek 2009; Chaulet 1995; Lienhardt 2011; Teo 1999; Zaka-Ur-Rehman 2008). Other adverse events mentioned were joint and nerve disorders (Chaulet 1995); rheumatic and hepatic disorders (Lienhardt 2011); vestibular reactions (Teo 1999); and jaundice, numbness, and joint pain (Zaka-Ur-Rehman 2008). In Zhu 1998, the other most frequent adverse event was liver damage combined with either jaundice or gastrointestinal disorders. Geter 1987 and Zhang 1996 gave no details of the type of other adverse events reported. In Munteanu 2004, no participant experienced further adverse events.

Outcomes not reported in this Cochrane review

See the 'Characteristics of included studies' section for the outcomes assessed in each clinical trial that we did not report in this Cochrane review.

Excluded studies

We have stated the reasons for exclusion of studies in the 'Characteristics of excluded studies' section.

Risk of bias in included studies

We rated only one trial as free from risk of bias in all assessed domains (Bartacek 2009), and another one as at low risk of bias (Lienhardt 2011). Overall, we rated the risk of bias as suboptimal in the remaining included trials. We have listed the 'Risk of bias' details for all included trials in the 'Risk of bias' tables in the 'Characteristics of included studies' section. For a summary of the 'Risk of bias' assessments see Figure 3 and Figure 4.
Figure 3. 'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial.

| Study                | Allocation concealment (selection bias) | Random sequence generation (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias |
|----------------------|----------------------------------------|--------------------------------------------|----------------------------------------------------------|------------------------------------------------|--------------------------------------|-------------------------------------|------------|
| Bartacek 2009        | +                                      | +                                         | +                                                        | +                                              | +                                    | +                                   | +          |
| Chaulet 1995         | ?                                      | ?                                         | +                                                        | +                                              | ?                                    | +                                   | +          |
| Geiter 1987          | ?                                      | ?                                         | +                                                        | +                                              | ?                                    | +                                   | +          |
| Lienhardt 2011       | +                                      | +                                         | +                                                        | +                                              | +                                    | ?                                   | +          |
| Munteanu 2004        | ?                                      | ?                                         | +                                                        | +                                              | ?                                    | +                                   | +          |
| RCTAI 1989           | ?                                      | ?                                         | +                                                        | +                                              | ?                                    | ?                                   | +          |
| Semenova 2003        | +                                      | +                                         | +                                                        | ?                                              | +                                    | ?                                   | ?          |
| Su 2002              | ?                                      | ?                                         | +                                                        | +                                              | +                                    | +                                   | +          |
| Suryanto 2008        | -                                      | -                                         | +                                                        | +                                              | -                                    | +                                   | +          |
| Teo 1999             | ?                                      | ?                                         | +                                                        | +                                              | ?                                    | +                                   | +          |
| Wu 2015              | +                                      | ?                                         | +                                                        | +                                              | ?                                    | +                                   | +          |
| Zaka-Ur-Rehman 2008  | +                                      | -                                         | +                                                        | +                                              | ?                                    | +                                   | +          |
| Zhang 1996           | +                                      | ?                                         | +                                                        | +                                              | ?                                    | +                                   | +          |
| Zhu 1998             | ?                                      | ?                                         | +                                                        | +                                              | ?                                    | +                                   | +          |
Allocation

We judged only two trials as free from selection bias (Bartacek 2009; Lienhardt 2011). We considered four trials at low risk of bias for random sequence generation, but not for allocation concealment (Semenova 2003; Wu 2015; Zaka-Ur-Rehman 2008; Zhang 1996).

Suryanto 2008 was at high risk of bias for both random sequence generation and allocation concealment, because it performed randomization by the judgment of the clinician through alternate allocation of eligible participants to each regimen to obtain equal numbers for both groups.

The remaining trials were at unclear risk of bias for selection bias.

Blinding

We considered all trials to be free of performance and detection bias. Four trials were described as open trials (Bartacek 2009; Geiter 1987; Lienhardt 2011; Wu 2015), and blinding was not stated in the remaining trials.

For open trials and for those that did not describe the blinding methods, we concluded that outcomes were unlikely to be influenced by the lack of blinding because most outcomes were objective and measurable.

Incomplete outcome data

We considered seven trials to be at low risk of bias (Bartacek 2009; Lienhardt 2011; Munteanu 2004; Su 2002; Teo 1999; Zaka-Ur-Rehman 2008; Zhang 1996). In Bartacek 2009, Lienhardt 2011, Su 2002, and Teo 1999, the missing outcome data were balanced in numbers across intervention groups and the reasons for missing data were similar. In Munteanu 2004, the trial authors used appropriate methods for imputing missing data. In Zaka-Ur-Rehman 2008, there were no missing outcome data. There were few missing data in Zhang 1996 and reasons for loss were given.

We judged six trials at high risk of bias (Chaulet 1995; Geiter 1987; Semenova 2003; Suryanto 2008; Wu 2015; Zhu 1998).

Some of these trials did not fully report the reasons for participants’ withdrawal or were likely to be related to lack of efficacy, or adverse events, or the number of withdrawals was unbalanced between the intervention and control group.

We considered RCTAI 1989 as unclear regarding attrition bias.

Selective reporting

We judged two trials to be free from risk of reporting bias because the published reports included most of the expected outcomes (Bartacek 2009; Su 2002).

We rated three trials at high risk of bias (Lienhardt 2011; Semenova 2003; Suryanto 2008). In Lienhardt 2011, most of the primary and secondary outcomes differed from those stated in the available protocol. In Semenova 2003 and Suryanto 2008, the published reports failed to include key results expected to be reported in clinical trials in this field.

We considered selective reporting to be unclear in nine trials (Chaulet 1995; Geiter 1987; Munteanu 2004; RCTAI 1989; Teo 1999; Wu 2015; Zaka-Ur-Rehman 2008; Zhang 1996; Zhu 1998).

Other potential sources of bias

We judged all but two included trials free from other potential sources of bias (Geiter 1987; Semenova 2003).

We rated Geiter 1987 at high risk of bias because this trial was designed with an amended protocol of a former study, and followed an unbalanced randomization scheme. We considered Semenova 2003 to be at unclear risk as it provided insufficient information to enable us to assess whether an important risk of bias existed.

Effects of interventions

See: Summary of findings for the main comparison ‘Summary of findings’ table 1

See ‘Summary of findings’ table 1 and ‘Summary of findings’ table 2 (Summary of findings for the main comparison; Table 4).
We included 13 RCTs in quantitative analyses, which included 5824 randomized participants. All trials compared FDCs versus single-drug formulations for the treatment of pulmonary TB in newly diagnosed participants.

The trials and the meta-analyses were underpowered to allow us to confidently detect or exclude clinically important changes on the primary dichotomous outcomes related to treatment efficacy (treatment failure and relapse), the sputum smear or culture conversion at EOT, death, and adverse events (see Table 5).

A combined endpoint of treatment failure, relapse, or death
We did not identify any trials that examined the combined outcome.

Treatment failure
The proportion of participants that experienced treatment failure was similar with FDCs and single-drug formulations (3606 participants, seven trials, Analysis 1.1).

Relapse
Overall, there is a trend towards a higher number of relapses with the use of FDCs although the confidence interval (CI) included no difference (RR 1.28, 95% CI 1.00 to 1.64; I² statistic = 0; 3621 participants, 10 trials, Analysis 1.2). In the analysis of trials at high or unclear risk of bias, we found a statistically significant increase in relapse with FDCs (RR 2.84, 95% CI 1.34 to 6.00; I² statistic = 0; 1328 participants, eight trials, Analysis 2.2). Inclusion of only the trials at low risk of bias showed no difference between FDCs or single-drug formulations (2293 participants, two trials, Analysis 2.2).

Death
There was no significant difference between the two groups for all causes of death (4800 participants, 11 trials, Analysis 1.3).

Sputum smear or culture conversion
Data were available to assess sputum smear or culture conversion at two and six months. There was no significant difference between treatment with FDCs or single-drug formulations in sputum smear or culture conversion either at two months (4836 participants, 13 trials, Analysis 1.4), or at six months (2319 participants, seven trials, Analysis 1.5).

Time to sputum smear or culture conversion
Only one trial reported data for this outcome (Zaka-Ur-Rehman 2008), but data were insufficient to estimate hazard ratios (HRs) and we could not assess any treatment effect. The mean number of days for sputum conversion was 34.85 days (standard deviation (SD) 17.39) for FDCs with 194 participants, and 37.97 days (SD 18.35) for single-drug formulations with 99 participants.

Time to relapse
Only one trial reported data for this outcome (Teo 1999), but data were insufficient to estimate HRs, and we could not assess any treatment effect. The mean number of months to relapse was 15 months (SD 16.722) for FDCs with 12 participants, and 18 months (SD 20.232) for single-drug formulations with three participants.

Treatment adherence
Data were available to evaluate treatment adherence at eight weeks and at the EOT. There was no significant difference in treatment adherence between the two interventions either at eight weeks (881 participants, three trials, Analysis 1.6) or at the EOT (1229 participants, five trials, Analysis 1.7).

Acquisition of drug resistance
There was no significant difference in the probability of acquiring drug resistance (491 participants, three trials, Analysis 1.8).

Patient satisfaction
General satisfaction
One trial, Chaulet 1995, recorded general satisfaction and did not show any differences (222 participants, Analysis 1.9).

Problems swallowing
One trial, Bartacek 2009, reported problems swallowing and there was no significant difference between treatments (1023 participants, Analysis 1.9).

Convenient number of tablets
Only Bartacek 2009 reported this outcome. Participants treated with FDCs found the number of tablets more convenient compared with participants treated with single-drug formulations (RR 1.50, 95% CI 1.37 to 1.64; 1045 participants, one trial, Analysis 1.9).

Acceptable taste
Bartacek 2009 reported on this outcome. Participants treated with FDCs recognized that the tablets tasted better compared to participants who were treated with single-drug formulations (RR 1.39, 95% CI 1.27 to 1.51; 1044 participants, one trial, Analysis 1.9).

Adverse events
Serious adverse events (death, hospitalizations)
There was no statistically significant difference in the number of serious adverse events in the meta-analysis of the six trials that reported this outcome (3388 participants, six trials, Analysis 1.10).

Adverse events leading to discontinuation of therapy
There was no difference between the treatment groups regarding the adverse events that led to discontinuation of treatment (5530 participants, 13 trials, Analysis 1.11).

Other adverse events
There was a trend of fewer other adverse events with treatment with FDCs, which just reaches standard levels of statistical significance (RR 0.85, 95% CI 0.72 to 1.00; I² statistic = 38%; 4639 participants, nine trials, Analysis 1.12).

Subgroup analysis
We were able to perform four subgroup analyses based on the available data.

1. FDCs administered only during the intensive phase versus FDCs administered for the whole treatment.
2. Daily regimen for the whole treatment versus daily regimen during in the intensive phase followed by intermittent regimen in the continuation phase.

3. Supervised treatment versus self-administered treatment during the intensive phase.

4. Trials with four drugs as FDCs versus trials with three or two drugs as FDCs during the intensive phase.

There were subgroup differences on relapse in three subgroup analyses.

1. FDCs administered only in the intensive phase versus FDCs for the whole treatment: relapses were more frequent in participants treated with FDCs when combined tablets were administered only in the intensive phase (RR 3.94, 95% CI 1.13 to 13.78; 251 participants, one trial, Analysis 4.2).

2. Daily medication for the whole treatment versus daily medication in the intensive phase followed by intermittent treatment in the continuation phase: relapses were more frequent in participants treated daily with FDCs during the intensive phase and intermittently during the continuation phase (RR 1.72, 95% CI 1.07 to 2.75; 1771 participants, three trials, Analysis 5.2).

3. Four drugs as FDCs versus trials with three or two drugs as FDCs in the intensive phase: relapses were more frequent with FDCs in participants treated with three or two drugs as FDCs in the intensive phase (RR 2.55, 95% CI 1.07 to 6.06; 848 participants, five trials, Analysis 7.2).

These differences are due almost exclusively to one trial, Teo 1999, which used a FDCs with three active oral ingredients (H, R and Z) in the intensive phase for the intervention group and single-drug formulations for all participants in the continuation phase. In addition, there was a daily treatment during the intensive phase which was followed by intermittent treatment in the continuation phase. This trial had a higher number of relapses in the intervention arm, possibly due to the change from FDCs given daily during the intensive phase to single-drug formulations given three times a week during the continuation phase.

Overall, we did not observe any statistically significant subgroup differences in the remaining outcomes for the rest of the performed analyses.

There were no available data for subgroup analyses of HIV-positive versus HIV-negative participants or for clinically diagnosed versus laboratory diagnosed participants. Only two trials reported the HIV status of participants and neither of them stratified their results according to this status (Bartacek 2009; Lienhardt 2011). All included trials reported pulmonary TB diagnosed by bacteriological results, and in no case by clinical diagnosis.

**Sensitivity analysis**

**Risk of bias**

We performed a sensitivity analysis by risk of bias of included trials. We pooled results from Bartacek 2009 and Lienhardt 2011, the two trials at low risk of selection bias.

Relapse: the analysis restricted to the trials at low risk of bias showed no difference between treatment with FDCs or single-drug formulations (2293 participants, two trials, Analysis 2.8).

Adverse events leading to discontinuation of therapy: the risk of experiencing this outcome was higher among those who received FDCs than among those who received single-drug formulations in the analysis of trials at low risk of selection bias (RR 1.71, 95% CI 1.04 to 2.81; I² statistic = 0%; 2703 participants, two trials, Analysis 2.8).

For the remaining outcomes, the analyses reached similar results to those of the main comparison (see Data and analyses: Comparison 2 ‘Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias’).

**ITT analysis**

We also performed a sensitivity analysis under an ITT analysis. We performed this analysis for the following outcomes: a) failure; b) relapse; and c) sputum smear or culture conversion (at two months of starting treatment and at EOT). There was no significant difference in relapse between the two interventions (4716 participants, 10 trials, Analysis 3.2). For the rest of the outcomes, this analysis showed similar results to those of the main analysis (see Data and analyses: Comparison 3 ‘Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat’).

**Assessment of reporting biases**

The funnel plot for sputum smear or culture conversion at two months in the comparison of treatment with FDCs versus single-drug formulations showed no inherent risk of publication bias in the trials included in the meta-analyses, although these analyses included few trials (Figure 5). The funnel plot for death showed a similar result (figure not shown).
DISCUSSION

Summary of main results
This Cochrane review included 13 RCTs with a total of 5824 participants, and overall did not find any difference between fixed-dose combinations (FDCs) and single-drug formulations for the treatment of pulmonary tuberculosis (TB) in newly diagnosed people. We have presented a summary of the evidence in 'Summary of findings' table 1 (Summary of findings for the main comparison) (there is an additional 'Summary of findings' table using data from the sensitivity analysis in the Additional tables section, Table 4).

We did not detect any difference in treatment failure and death between people treated with FDCs or single-drug formulations (moderate quality evidence). Relapse may slightly more frequent in people treated with FDCs compared to single-drug formulations (low quality evidence).

FDCs and single-drug formulations have similar effects on sputum smear or culture conversion at the end of treatment (EOT) (high quality evidence) and on serious adverse events (moderate quality evidence). There were no differences in adverse events leading to discontinuation of therapy (low quality evidence) between people treated with FDCs or single-drug formulations.

The analyses for these outcomes were underpowered to detect clinically important differences (Table 5).

Overall completeness and applicability of evidence
All included trials except Geiter 1987 were conducted in high TB-burden countries and low- and middle-income countries. All included trials compared the use of FDCs with single-drug formulations in adults, and administered a standard first-line treatment regimen for people newly diagnosed with pulmonary TB (Table 2). Overall, the doses of anti-TB drugs used were equivalent to the currently recommended doses for pulmonary TB patients (WHO 2010). Although not all the included trials used uniform definitions of outcomes and comparable follow-up time, we consider these review findings to be widely applicable.

In TB treatment, the dose administered of each drug is crucial. Ideally in clinical trials, FDCs and single-drug formulations should be compared using equal doses to assess the real effect of the administered dose. Although the included trials administered similar doses in both treatment arms, doses generally were unequal. Only Lienhardt 2011 gave equal doses to both treatment arms. Imbalances between treatment arms were more pronounced in some trials with higher doses of some drugs in the single-drug formulations arm: higher doses of isoniazid and pyrazinamide (Su 2002; Suryanto 2008); higher doses of pyrazinamide and ethambutol (Zaka-Ur-Rehman 2008); and higher doses of pyrazinamide (Zhang 1996; Zhu 1998) (see Table 3). This may explain the favourable results with single-drug formulations in some included trials.
There is a lack of data regarding some important outcomes such as acceptability (outcome concerning patients) and acquisition of drug resistance (clinically and bacteriologically relevant outcomes). We analysed general satisfaction, which only Chaulet 1995 recorded, and no problems swallowing and acceptable taste, which Bartacek 2009 recorded. There rest of the included trials had limited data about acceptability. Only three trials reported acquisition of drug resistance (Chaulet 1995; Lienhardt 2011; Teo 1999; see the ‘Characteristics of included studies’ section).

TB therapy in real clinical practice may differ from the procedures in clinical trials. Firstly, clinical trials implement interventions that are more similar to directly observed treatments (DOT) than to self-administered treatments. In clinical practice, self-administered treatments are more frequent and also, with this mode of administration, participants may interrupt the treatment or take fewer pills than those needed or prescribed, which can lead to drug resistance of the bacteria. In this case, feasibility of administration (potentially better for single-drug formulations in terms of smaller pills, but better for FDCs in terms of fewer pills to take) and ensuring dosing of all drugs together (better for FDC pills) would be important issues to prevent treatment discontinuation and acquisition of resistance. Additionally, participants included in clinical trials are selected, whereas those participating in clinical practice are not. This means that participants with TB in clinical practice often present with co-morbid conditions, such as human immunodeficiency virus (HIV) and other diseases that could increase the number of tablets taken daily, which may be a key factor in treatment withdrawal/defaulting. The included trials reported a low percentage of HIV participants, which possibly makes the results less applicable to this population.

The applicability of the evidence from this Cochrane review to a specific country depends on the strength of its healthcare system. Issues in TB treatment in developed countries or urban settings differ from those in resource-limited countries or rural settings. Factors such as ease of administration, need for directly observed treatment (DOT), and costs of therapy differ in importance depending on the country or setting. Even the implementation of the intervention will differ between settings; for example, methods for DOT may include weekly drug delivery with treatment intake under the supervision of relatives, or daily drug delivery with treatment intake under supervision of a medical staff member. Moreover, differences can occur depending on the way drugs are dispensed to participants: by giving participants appointments at the clinic or hospital, visiting them at home, or applying mixed approaches.

Achievement of high TB cure rates is the most important goal of intervention in TB control. This systematic review provides moderate quality evidence that FDCs present similar efficacy to separate formulations. Nevertheless, FDCs have important features that should be expected to greatly influence the improvement of TB outcomes in the medium and long term and, of course, its control. The recommendation for use of FDCs should also be supported by the characteristics of FDCs. FDCs contain similar doses of individual drugs which can lead to non-inferior efficacy and similar safety. With FDCs the number of daily tablets can be reduced, and drug management and storage by the patient should be easy; thus making it possible to increase patient satisfaction and decrease medication errors, burden, and cost for patients. Treatment simplifications can reduce the risk of monotherapy and improve treatment compliance. FDC use could improve sputum and culture conversion rate and lower the failure rate, relapse rate, treatment resistance, and morbidity and mortality rates (Figure 1).

Two advantages of FDCs are feasibility and ease of administration, which favour treatment compliance and increase patients’ quality of life, especially the quality of life of patients that may need additional therapy for concomitant diseases such as HIV. However, single-drug formulations allow a better dose adjustment to the body weight and avoid the issue of complete interruption of therapy when drug-specific adverse effects occur (Figure 1).

Quality of the evidence
We assessed the quality of the evidence using the GRADE approach and presented the results in ‘Summary of findings’ table 1 (Summary of findings for the main comparison) and ‘Summary of findings’ table 2 (Table 4).

The quality of evidence for the efficacy and safety of FDCs is high to low, depending on reported outcomes, due to two main concerns.

1. Imprecision of results: the quality of the evidence was moderate for treatment failure, death, and serious adverse events, and low for relapse and adverse events leading to discontinuation of therapy. We downgraded the quality of the evidence for these outcomes because the meta-analysis remained significantly underpowered to confidently prove or exclude clinically important effects.

2. Risk of bias of included studies: the quality of the evidence was low for relapse and adverse events leading to discontinuation of therapy. We downgraded these two outcomes for the difference in results of pooled estimate of effect when we excluded trials at high risk of bias.

The quality of evidence was high for sputum smear or culture conversion at the EOT, which we did not downgrade because the analysis with trials at low risk of bias did not change the effect estimate and the difference in drug doses probably does not affect the comparability of intervention and control group. In addition, there was no statistical heterogeneity among trials that reported this outcome. Moreover, although the optimal information size was not reached (considering an absolute non-inferiority margin of greater than 0.5% as clinically meaningful), the total sample size and number of events for this outcomes are very large.

Potential biases in the review process
We minimized the biases in the review process by performance of an exhaustive search strategy, which included the most important bibliographic databases of clinical trials, without time or language limitations. The Information Specialist of the Cochrane Infectious Diseases Group, Vittoria Lutje, performed the search and we checked the reference lists of relevant studies, which decreased the probability that we missed important studies. We were able to obtain all the published papers of the trials and all available data.

Two review authors independently performed study selection and ‘Risk of bias’ assessments of included trials. We consulted a third review author to resolve any disagreements. Two review authors independently performed data extraction. We excluded one RCT that met the inclusion criteria from the quantitative analysis because disaggregate results were unavailable.
The assessment of reporting biases did not show a small study effect.

Although we tried to minimize all forms of potential biases in this Cochrane review, we cannot completely exclude the possibility of bias.

Agreements and disagreements with other studies or reviews

We found two other systematic reviews that compared the use of FDCs and single-drug formulations in the treatment of pulmonary TB (Albanna 2013; Zhang 2015).

Albanna 2013 included 15 RCTs, and coincided with this Cochrane review regarding 10 trials. Zhang 2015 included 22 studies, and coincided only regarding six trials.

This Cochrane review, Albanna 2013, and Zhang 2015 present almost the same results for relapse. Albanna 2013 found a trend towards higher risk for “treatment failure or disease relapse” (as a combined outcome) with the use of FDCs (risk ratio (RR) 1.28, 95% confidence interval (CI), 0.99 to 1.7). Zhang 2015 found a trend towards higher risk of relapse (as a single outcome) with the use of FDCs (RR 1.72, 95% CI, 0.98 to 3.02). We also found a similar result of relapse (also as a single outcome) with FDCs (RR 1.28, 95% CI 1.00 to 1.64; Analysis 1.2). None of these cases reached statistical significance.

For the remaining coinciding outcomes (acquisition of drug resistance, sputum conversion at two months, overall adverse events, and treatment adherence) neither this Cochrane review nor Albanna 2013 found any difference between treatment with FDCs or single-drug formulations.

Overall, in Zhang 2015 there were no differences between FDCs and single-drug formulations in the reported outcomes: sputum smear rate (at two months and at the EOT) and adverse events.

Despite the similar results obtained, this Cochrane review presents some methodological differences compared with Albanna 2013 and Zhang 2015.

1. Included studies: we had different inclusion criteria in this Cochrane review. Albanna 2013 included randomized clinical trials and cohort studies (the latter should include 50 subjects or over) with participants diagnosed with active TB (new patients and patients already treated) with bacteriological confirmation (and treated with FDCs or single-drug formulations). Zhang 2015 included RCTs and controlled clinical trials that compared anti-TB treatment given as FDCs with non-FDC regimens (single drugs or plate-type-combined drugs) in the initial treatment of smear-positive pulmonary TB. Neither Albanna 2013 nor Zhang 2015 accounted for the comparability of treatment regimens between intervention and control groups (same regimens in both groups). We included only RCTs that compared FDCs and single-drug formulations with the same drugs in both treatment arms for new participants with pulmonary TB.

2. Treatment failure and relapse, types of outcomes measured: Albanna 2013 presented treatment failure and relapse as a combined outcome. It is known that treatment failure and relapse are not the same thing; consequently, two different variables were analysed jointly. Also, the trial authors provided definitions of these two variables, which already differ from each other, that differed widely. Zhang 2015 presented the relapse rate as a single outcome. Treatment failure was not reported. We presented both outcomes (treatment failure and relapse) as single outcomes.

3. Data synthesis: Albanna 2013 calculated a pooled estimate of treatment using a fixed-effect model and Zhang 2015 used a fixed-effect model when P was greater than 0.05 with the Q-test, or a random-effects model otherwise. We calculated a pooled estimate of treatment using a fixed-effect model when minimal heterogeneity was present ($I^2$ statistic value of less than 50%) and a random-effects model when moderate heterogeneity was present ($I^2$ statistic value of greater than 50%). We did not perform a meta-analysis with a substantial $I^2$ statistic value (greater than 75%).

4. Linking overall quality of the evidence with the effect estimates: Albanna 2013 adopted the PRISMA statement for the methods and results sections, but did not summarize the main findings, including the strength of evidence, for each main outcome. Zhang 2015 stated that “quality evaluation was performed on the incorporated studies according to the ‘Risk of bias’ Assessment Tool in the System Assessor Handbook 5.1.0 of Cochrane Collaboration update in March 2011.” Nevertheless, the authors did not report results of this assessment. Additionally, Zhang 2015 had some errors or inconsistencies, which made some results difficult to understand. For example: a. treatment regimens in the experimental group in several trials are not well described, because the drug delivered does not correspond to the treatment strategy for the same trial, according to the trial authors (in their Table 1); b. text related to their Figure 2 is not about sputum smear rate at EOT; c. Lienhardt 2011 is mentioned twice in the references section.

We assessed the risk of bias of the included trials using the ‘Risk of bias’ assessment tool and in accordance with the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), recorded the results in a standard table in RevMan (RevMan 2014), and summarized the findings in a ‘Risk of bias’ table (Figure 3) and a ‘Risk of bias’ graph (Figure 4). We summarized the quality of the evidence for the main outcomes, and reported the RCT data in ‘Summary of findings’ tables (Summary of findings for the main comparison; Summary of findings table 2).

Authors’ Conclusions

Implications for practice

This systematic review shows similar efficacy in relation to treatment failure, death, and sputum smear or culture conversion with the use of FDCs compared with single-drug formulations. Although relapses were more common in people treated with FDCs, this was not statistically significant. FDCs and single-drug formulations presented no differences with respect to acquisition of drug resistance, serious adverse events, or adverse effects leading to therapy discontinuation. These results come from trials that were mostly implemented under DOT.

When deciding which is the most appropriate therapeutic scheme in a particular setting, efficacy and safety must be carefully weighed up in addition to other important factors, such as comfort of intake and patient convenience, which could increase treatment...
adherence and compliance. Based on these advantages, FDCs are strongly recommended by the WHO (WHO 2010). In addition, FDCs may be more advisable than single-drug formulations in settings where there is no DOT, in order to ensure treatment compliance and avoid resistance.

Implications for research

The trials included in this Cochrane review had different definitions of the main outcomes, reporting standards, and also important drawbacks in methodological quality. The use of standard definitions for outcomes, standard approaches to report these outcomes, and improvement of the methodological quality is necessary for improving research in the TB area. The WHO has already defined treatment outcomes for TB patients (WHO 2010; WHO 2013) and, thus, can be a relevant reference to take into account.

In this review, all but two included trials reported initial drug resistance and only two trials reported the HIV status of the participants. Future clinical trials that compare FDCs and single-drug formulations should report a comparable baseline susceptibility test for the drugs used; this means they should report the initial resistance for all first-line drugs allowing comparison of resistance results between clinical trials. Moreover, future trials should stratify their results by HIV status of participants. This would permit assessment of the outcomes in HIV-seropositive populations and enable comparison with HIV-negative people in future updates or evidence compilations.

We identified one large clinical trial awaiting publication, ISRCTN95204603, and we will update this review when its data are published. We also found four RCTs awaiting classification (Liang 2007; Ma 2010; Zhao 2007; Zhu 2000), whose data we will add based on their classification in the next review update.

ACKNOWLEDGEMENTS

CRG is a PhD candidate at the Paediatrics, Obstetrics and Gynaecology, and Preventive Medicine Department, Universitat Autònoma de Barcelona, Spain. The editorial base of the Cochrane Infectious Diseases Group is funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this Cochrane review do not necessarily reflect UK government policy.
References to studies included in this review

Bartacek 2009 (published data only)
Bartacek A, Schütt D, Panosch B, Borek M, Rimstar 4-FDC Study Group. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. *International Journal of Tuberculosis and Lung Disease* 2009;13(6):760-6.

Chaulet 1995 (published data only)
Agounitesteane D, Chiheb M, Khaled S, Ait Khaled N, Boulahbal F, Chaulet P. A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment. *Revue des Maladies Respiratoires* 1990;7(3):209-13.

Bellabas M, Khaled S, Khaled NA, Boulahbal F, Chaulet P. Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis. *Revue des Maladies Respiratoires* 1989;6(1):59-64.

* Chaulet P, Boulahbal F, Groupe de Travail sur la Chimiothérapie de la Tuberculose. Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. *Tuberculosis and Lung Disease* 1995;76(5):407-12.

Geiter 1987 (published data only)
Geiter LJ, O’Brien RJ, Combs DL, Snider DE Jr. United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampicin and pyrazinamide. *Tubercle* 1987;68(2 Suppl):41-6.

Lienhardt 2011 (published data only)
Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. *The Journal of the American Medical Association* 2011;305(14):1415-23.

Nunn AJ, Cook SV, Burgos M, Rigouts L, Yorke-Edwards V, Anyo G, et al. Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis. *International Journal of Tuberculosis and Lung Disease* 2014;18(10):1252-4.

Munteanu 2004 (published data only)
Munteanu I, Husar I, Didilescu C, Stoicescu IP. Considerations about the efficiency of treatment regimens with fixed Rifampicin-Isoniazid combinations in pulmonary tuberculosis. *Pneumologia* 2004;53(1):23-5.

RCTAI 1989 (published data only)
Research Committee of the Tuberculosis Association of India. Fifth tuberculosis association of India: short course chemotherapy trial. *Indian Journal of Tuberculosis* 1989;36(2):95-101.

Semenova 2003 (published data only)
Semenova OV. Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis. *Problemy Tuberkulezi i Bolezněi Legkikh* 2003;11:22-5.

Su 2002 (published data only)
Su WJ, Perng RP. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. *International Journal of Tuberculosis and Lung Disease* 2002;6(11):1029-32.

Suryanto 2008 (published data only)
Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. *Tuberculosis* 2003;83(1-3):183-6.

* Suryanto AA, Van den Broek J, Hatta M, de Soldenhoff R, van der Werf MJ. Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia?. *International Journal of Tuberculosis and Lung Disease* 2008;12(2):174-9.

Teo 1999 (published data only)
Anonymous. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in the initial phase of multidrug therapy for pulmonary tuberculosis. *International Journal of Tuberculosis and Lung Disease* 1999;3(2):707-12.

Wu 2015 (published data only)
Wu JT, Chiu CT, Wei YF, Lai YF. Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. *Clinics (São Paulo)* 2015;70(6):429-34.

Zaka-Ur-Rehman 2008 (published data only)
Zaka-Ur-Rehman Z, Jamshaid M, Chaudhry A. Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients. *Pakistan Journal of Pharmaceutical Sciences* 2008;21(2):185-94.

Zhang 1996 (published data only)
Zhang LX, Kan GQ, Tu DH, Wan LY, Faruqi AR. Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis. *Current Therapeutic Research* 1996;57(11):849-56.
Zhu 1998 (published data only)
Zhu L, Yan B, Ma W. Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy. Zhonghua Jie He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Disease] 1998;21(11):645-7.

References to studies excluded from this review
Brändli 1989 (published data only)
Brändli O, Haegi V, Villiger B, Bohn W, Baumann HR, Zäch R. Short-term therapy of lung tuberculosis using a fixed combination ofisoniazid, rifampicin and pyrazinamide. Results after 2 years. Schweizerische Medizinische Wochenschrift 1989;119(10):299-305.

Brändli 1993 (published data only)
Brändli O, Dreher D, Morger D. Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide. Schweizerische Medizinische Wochenschrift 1993;123(25):1300-6.

Chu 2004 (published data only)
Chu N, Gao M, Ma L. Controlled clinical study on efficacy of national fixed-dose compounds in antituberculosis chemotherapy. Respirology. Proceedings of the 9th Congress of the Asian Pacific Society of Respirology; 2004 Dec 10-13; Hong Kong. Hong Kong; 2004; Vol. 9 Suppl:72.

Cowie 1990 (published data only)
Cowie RL, Brink BA. Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet. South African Medical Journal 1990;77(8):390-1.

Dubra 1972 (published data only)
Dubra F. Controlled therapeutic trial with the combination rifampicin-isoniazid given for six months to previously untreated patients with pulmonary tuberculosis. Bulletin of the International Union against Tuberculosis and Lung Disease 1972;47:37-40.

Ferreira 2013 (published data only)
Ferreira AC, Silva Júnior JL, Conde MB, Rabahi MF. Clinical treatment outcomes of tuberculosis treated with the basic regimen recommended by the Brazilian National Ministry of Health using fixed-dose combination tablets in the greater metropolitan area of Goiânia, Brazil. Jornal Brasileiro de Pneumologia [Brazilian Journal of Pulmonology] 2013;39(1):76-83.

Glatthaar 1991 (published data only)
Glatthaar E, Summers FS, Carleir ND. A comparative community-based therapy trial with single combination product (Rifater-80). CHASA; Journal of Comprehensive Health 1991;2:155-8.

González Montaner 1978 (published data only)
González Montaner LJ, Palma Beltran O, Abbate E, Gini G. A comparison of the therapeutic efficacy of two drug combinations in cases of previously untreated open tuberculosis. Praxis und Klinik der Pneumologie 1978;32(11):717-20.

Herman 2007 (published data only)
Herman N, Aditama TY, Ikhsan M. Comparison of antituberculosis drugs between fixed dose combination and combipack for new cases of pulmonary tuberculosis in community health centres. Respirology. Proceedings of the 12th Congress of the Asian Pacific Society of Respirology. 2007; Vol. 12 (Suppl 4):A238.

HKCS/BMRC 1989 (published data only)
Anonymous. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation ofisoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. The American Review of Respiratory Disease 1989;143[4 Pt 1]:700-6.

Hong Kong Chest Service/British Medical Research Council. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. The American Review of Respiratory Disease 1989;140(6):1618-22.

ISRCTN95204603 (published data only)
ISRCTN95204603. Comparison of four Fixed Dose Combinations versus standard treatment with separate anti-TB drugs for treatment of pulmonary tuberculosis. http://www.controlled-trials.com/ISRCTN95204603 (accessed 14 July 2014). [ISRCTN95204603]

Macnab 1994 (published data only)
Macnab MF, Bohmer PD, Seager JR. Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. South African Medical Journal 1994;84(6):325-8.

Merle 2012 (published data only)
Merle CS, Sismanidis C, Sov OB, Gninafon M, Horton J, Lapujade O, et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project. Trials 2012;13:61.

Punnotok 1995 (published data only)
Punnotok J, Pumprueg U, Chakorn T. A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up. Journal of the Medical Association of Thailand 1995;78(6):298-304.

Soekhardiman 2007 (published data only)
Soekhardiman D, Soepandi P, Nawas A. Comparison of Antituberculosis Drugs Between Fixed Dose Combinationand Combi-pack for New Cases of Pulmonary Tuberculosis in Persahabatan Hospital. Respirology. Proceedings of the 12th Congress of the Asian Pacific Society of Respirology. 2007; Vol. 12 (Suppl 4):A237.
Sokolova 1993 (published data only)
Sokolova GB, Koriakin VA, Khalbavea IV, Elistratova NA, Zia AV. Combined chemotherapy of patients with tuberculosis - new regimens and dosage forms. Problemy tuberkuleza 1993;[5]:21-3.

Xu 2004 (published data only)
Xu WG, Lu W, He HJ, Gu XR. Randomized control study on domestic fixed-dose combinations in the initial treatment of smear positive tuberculosis. Zhonghua Jie He He Xi Zi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases] 2004;27(10):690-3.

References to studies awaiting assessment
Liang 2007 (published data only)
Liang Y, Yan XX, Wang JY, et al. Curative effect of fixed-dose anti-tuberculosis combinations in primary treatment of tuberculosis. Chinese Journal of Anti-tuberculosis Association 2007;29(2):180-1.

Ma 2010 (published data only)
Ma LP, Wu XG, Chu NH, Zhu L, Shan B, Wang M, et al. Feasibility study of domestic four-drug fixed-dose combination under DOTs as initial treatment in patients with smear positive pulmonary tuberculosis. Chinese Journal of Anti-tuberculosis Association 2010;61(5):21-5.

Zhao 2007 (published data only)
Zhao QP, Tian M, Pan R, Huang B, Gan L, Shan B, et al. Randomized control study on domestic 4FDC/2FDC combinations in initial treatment of smear positive tuberculosis patients. Parastosis and Infectious Disease 2007;15(3):122-7.

Zhu 2000 (published data only)
Zhu LZ, Yan BY. Controlled clinical study on efficacy of fixed-dose compounds rifinah in anti-tuberculosis chemotherapy: results of two-year follow-up. Tuberculosis and Thoracic Tumor 2000;48(5):320.

Additional references
Agounitestane 1990
Agounitestane D, Chiheb M, Khaled S, Ait Khaled N, Boulahbal F, Chaulet P. A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment. Revue des Maladies Respiratoires 1990;7(3):209-13.

Agrawal 2002
Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations. International Journal of Clinical Pharmacology and Therapeutics 2002;40(10):474-81.

Albanna 2013
Albanna AS, Smith BM, Cowan D, Menzies D. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. The European Respiratory Journal 2013;42(3):721-32.

Bellabas 1989
Bellabas M, Khaled S, Khaled NA, Boulahbal F, Chaulet P. Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis. Revue des Maladies Respiratoires 1989;6(1):59-64.

Blomberg 2001
Blomberg B, Spinaci S, Foure B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bulletin of the World Health Organization 2001;79(1):61-8.

CDC 2003
Centers for Disease Control and Prevention. Treatment of Tuberculosis. Vol. MMWR 52[RR-11], American Thoracic Society, CDC, and Infectious Diseases Society of America, 2003.

Connor 2004
Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bulletin of the World Health Organization 2004;82(12):935-9.

Gravendeel 2003
Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis 2003;83(1-3):183-6.

Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

ISTC 2014
TB CARE I. International Standards for Tuberculosis Care (ISTC). 3. The Hague: TB CARE I, 2014.

Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

NICE 2006
National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Clinical Guidelines, CG33. London: National Collaborating Centre for Chronic Conditions, 2006.

NICE 2011
National Collaborating Centre for Chronic Conditions and Centre for Clinical Practice at National Institute for Health
and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: NICE, 2011.

**Nunn 2014**
Nunn AJ, Cook SV, Burgos M, Rigouts L, Yorke-Edwards V, Anyo G, et al. Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis. *The International Journal of Tuberculosis and Lung Disease* 2014;18(10):1252-4.

**RevMan 2014 [Computer program]**
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

**Rieder 2002**
Rieder HL. Interventions for Tuberculosis Control and Elimination. Paris: International Union Against Tuberculosis and Lung Disease, 2002.

**STS/BMRC 1991**
Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. *American Review of Respiratory Disease* 1991;143(4 Pt 1):707-12.

**Wells 2011**
Wells WA, Konduri N, Chen C, Lee D, Ignatius HR, Gardiner E, et al. Implications of the current tuberculosis treatment landscape for future regimen change. *The International Journal of Tuberculosis and Lung Disease* 2011;15(6):746-53.

**WHO 2002**
World Health Organization. Operational guide for National Tuberculosis Control Programmes on the introduction and use of fixed-dose combination drugs. WHO/CDS/TB/2002.308. http://apps.who.int/medicinedocs/en/d/Js4872e/ (accessed 13 March 2016).

**WHO 2009**
World Health Organization. Dosing instructions for the use of currently available fixed-dose combination TB medicines for children. September 2009. http://www.who.int/tb/challenges/interim_paediatric_fdc_dosing_instructions_sept09.pdf (accessed 13 March 2016).

**WHO 2010**
World Health Organization. Guidelines for treatment of tuberculosis. WHO/HTM/TB/2009.420. 4th Edition. Geneva: World Health Organization, 2010.

**WHO 2011**
World Health Organization. WHO Model List of Essential Medicines. 17th Edition. Geneva: World Health Organization, 2011.

**WHO 2013**
World Health Organization. Definitions and reporting framework for tuberculosis — 2013 revision (updated December 2014). http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf (accessed 9 March 2016).

**WHO 2014**
World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd Edition. Geneva: World Health Organization, 2014.

**WHO 2015**
World Health Organization. Global Tuberculosis Report 2015. Geneva: World Health Organization, 2015.

**Zhang 2015**
Zhang HQ, Xi YE, Wang YL, Han W, Zhang CX, Jiao JH. Side effects of tuberculosis treatment with fixed-dose combinations. *Journal of Biological Regulators and Homeostatic Agents* 2015;29(2):379-88.

**Zwolska 1998**
Zwolska Z, Niemirska-Mikulska H, Augustynowicz-Kopers E, Walkiewicz R, Stambrowska H, Safianowska A, et al. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules. *The International Journal of Tuberculosis and Lung Disease* 1998;2(10):824-30.

**References to other published versions of this review**
Gallardo 2012
Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, Roqué i Figuls M, Parker LA, Caylà J, et al. Fixed-dose combinations of drugs versus single drug formulations for treating pulmonary tuberculosis. *Cochrane Database of Systematic Reviews* 2012, Issue 7. [DOI: 10.1002/14651858.CD009913]

* Indicates the major publication for the study

**CHARACTERISTICS OF STUDIES**

**Characteristics of included studies [ordered by study ID]**

**Bartacek 2009**

| Methods | Design: open, multicentre, multinational RCT |
|---------|---------------------------------------------|
|         | Generation of allocation: generated by computer by an independent central randomization institute |

Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)

Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Allocation concealment: sealed, serially numbered, opaque randomization envelopes

Blinding: none

Duration: not mentioned

Participants

Number of participants: 1159 randomized

Males: 68% (per-protocol population)

Inclusion criteria: new pulmonary tuberculosis (TB) participants, aged 15 years or more with at least 2 sputum specimens positive for acid-fast bacilli (AFB) on direct smear microscopy or 1 sputum specimen positive for AFB on direct microscopy and postero-anterior chest X-ray consistent with pulmonary TB; with written informed consent form to participate in the study and willingness to comply with the protocol

Exclusion criteria: a body weight < 30 kg, known or suspected hypersensitivity to rifamycins and/or to isoniazid, and/or to pyrazinamide and/or to etambutol hydrochloride and/or any of excipients; history of drug-induced hepatitis; suspected or known as case of acute and chronic liver disease regardless of their origin; suspected or known as case of renal failure; suspected or known as case of peripheral optic neuritis, acute gouty arthritis (on clinical diagnosis), or history of gout; TB meningitis; any conditions (except HIV infection) that might prove fatal during the study (for example, metastatic cancer); poor general condition requiring additional measures to ensure survival; immunosuppressive treatment (for example, corticosteroids) during the whole study period; history of alcohol or drug abuse and history of psychiatric illness likely to lead to uncooperative behaviour, or pregnancy

Completeness of follow-up: 60.7% of participants (per-protocol population)

Baseline drug susceptibility test: results not reported

HIV status: included only 6 HIV-positive participants; 1 in the 4FD Cs group and 5 in the single-drug formulations group

Interventions

Six months treatment regimen (2HRZE/4HR)

Intervention: 4 fixed-dose combinations (FDCs)

1. FDC tablets: Rimstar® (isoniazid 75 mg, rifampicin 150 mg, pyrazinamide 400 mg, and ethambutol 275 mg per tablet) given for the first 2 months (intensive phase), followed by Rimactazid® (isoniazid 75 mg and rifampicin 150 mg) for the succeeding 4 months (continuation phase) (N = 582).

Doses used: “on the basis of body weight according to the international recommendations [WHO and International Union Against Tuberculosis and Lung Disease [The Union]]” (Blomberg 2001)

Control

1. Single formulations of the same drugs in both phases (intensive and continuation) (N = 577).

Doses used: the trial authors stated: “according to the national treatment standards of each respective country”

The mean daily dosage of H, Z, and E at intensive phase in FDCs group was lower compared with single-drug formulations group, the R dose were similar in both groups.

Drugs were taken daily and according to the body weight for the total of participants, for whole treatment

Mode of drugs administration: it was not reported whether the treatment was self-administered or supervised

Outcomes

Outcomes used in this review

1. Sputum smear conversion rate at 2 and at 6 months after initiation of treatment.
2. Treatment failure.
3. Relapse rate at months 12.
4. Adverse events: serious; those leading to discontinuation of therapy and other adverse events.
5. Death.
6. Patient satisfaction with tablets: problems on swallowing, convenient number of tablets, and acceptable taste.

Notes

Locations: Egypt, Indian, Pakistan, the Philippines, and Thailand
Setting: not described
Source of funding: not mentioned
Comments: follow-up duration was 12 months after initiation of treatment. Sputum smear conversion rate was measured at 2, 4, 6, 9, and 12 months after initiation of treatment. Adverse events were assessed at each visit. Participant satisfaction with tablets was noted at 2 months

Risk of bias

| Bias                              | Authors’ judgement | Support for judgement                                                                                                                                 |
|----------------------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Random sequence generation       | Low risk           | Using a computer random number generator.                                                                                                               |
| Allocation concealment           | Low risk           | Central randomization institute which provided sequentially numbered, opaque, sealed envelopes.                                                         |
| Blinding of participants         | Low risk           | No blinding, but outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes).                                  |
| and personnel                    |                    |                                                                                                                                                      |
| All outcomes                     |                    |                                                                                                                                                      |
| Blinding of outcome assessment   | Low risk           | No blinding of outcome assessment, but outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes).       |
| (detection bias)                 |                    |                                                                                                                                                      |
| All outcomes                     |                    |                                                                                                                                                      |
| Incomplete outcome data          | Low risk           | Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data.                                         |
| (attrition bias)                 |                    |                                                                                                                                                      |
| All outcomes                     |                    |                                                                                                                                                      |
| Selective reporting              | Low risk           | Most of expected outcomes are included in the published report.                                                                                       |
| (reporting bias)                 |                    |                                                                                                                                                      |
| Other bias                       | Low risk           | The study appears to be free of other sources of bias.                                                                                              |
|                                  |                    |                                                                                                                                                      |

Chaulet 1995

Methods

Design: RCT

Generation of allocation: not stated
Allocation concealment: not stated
Blinding: not stated
Duration: not mentioned

Participants

Number of participants: 250 randomized
Males: 74% (of 196 participants initially sensitive to isoniazid)

Inclusion criteria: new pulmonary TB participants (aged 15 or more) confirmed by chest x-ray and sputum smear. They should lived in Algiers and accepted medical monitoring for 2 years
Exclusion criteria: not reported

Completeness of follow-up: 86% (ITT population)

Baseline drug susceptibility test: initially drug resistant participants 8.4% (16/190 tested); (FDCs H:2, S:4, H&S:4 and single-drug formulations H:2, S:2, H&S:4)

HIV status of participants: not reported

Interventions

Six months treatment regimen (2HRZ/4HR)

Intensive phase (8 weeks)

Intervention

1. 3FDCs (isoniazid 50 mg, rifampicin 120 mg and pyrazinamide 300 mg per tablet) (N = 124).

Doses used: 4 tablets for participants weighing less than 44 kg, 5 tablets for participants weighing 44 to 50 kg and 6 tablets for participants weighing ≥ 50 kg

Control

1. The same drugs as single formulations (N = 126).

Doses used: isoniazid 300 mg; rifampicin 450 mg for participants weighing < 50 kg and 600 mg for ≥ 50 kg; and pyrazinamide 1500 mg for participants weighing < 50 kg and 2000 mg for ≥ 50 kg

Continuation phase (20 weeks)

1. 2FDCs (isoniazid and rifampicin) for all participants: 3 tablets (isoniazid 100 mg and rifampicin 150 mg per tablet) for participants weighing < 50 kg and 2 tablets (isoniazid 150 mg and rifampicin 300 mg per tablet) for participants weighing ≥ 50 kg.

Treatment was administered daily for the whole course, as directly observed treatment (DOT) with participants kept at hospital under supervision of health personnel at the beginning of intensive phase and as outpatients and self-administered the rest of the time

Outcomes

Outcomes used in this review

1. Culture conversion at 2 months after initiation of treatment.
2. Treatment failure.
3. Relapse.
4. Adverse events: those leading to discontinuation of therapy and other adverse events.
5. Acquisition of drug resistance.
6. Treatment adherence.
7. General satisfaction with formulations.

Notes

Three publications for the same clinical trial (Agounitestane 1990; Bellabas 1989; Chaulet 1995). Most outcomes were assessed according to the data provided in Chaulet 1995, the most recent publication. Preliminary results had been previously published (Agounitestane 1990; Bellabas 1989)

Location: Algeria

Setting: The Matiben Chest Clinic at the West Algiers University Teaching Hospital and 3 other outpatient clinics in Algiers

Source of funding: National Institute of Higher Medical Sciences in Algiers and the Ministry of Health

Comments follow-up duration was 2 years after initiation of treatment. Sputum smears and culture were examined at 8, 24, and 28 weeks, and every 6 months (follow-up) after initiation of treatment. Adverse events were assessed at each visit and at 2 months. For the treatment adherence time to follow-up was not reported. Patient satisfaction with formulations was noted at 2 months
### Chaulet 1995 (Continued)

**Risk of bias**

| Bias                                      | Authors' judgement | Support for judgement                                                                                                                                 |
|-------------------------------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Random sequence generation (selection bias) | Unclear risk       | Insufficient information about random sequence generation process to permit judgement of 'low risk' or 'high risk'.                                    |
| Allocation concealment (selection bias)   | Unclear risk       | Insufficient information to permit judgment of 'low risk' or 'high risk'.                                                                             |
| Blinding of participants and personnel (performance bias) All outcomes | Low risk           | Due to difficulties in blinding participants and personnel to the intervention, when the study did not specify blinding methods we considered it as an open design. In addition, outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk           | No blinding of outcome assessment, but outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes).         |
| Incomplete outcome data (attrition bias) All outcomes | High risk          | Reasons for missing outcome data were not reported.                                                                                                  |
| Selective reporting (reporting bias)       | Unclear risk       | Insufficient information to permit judgement of 'low risk' or 'high risk'.                                                                             |
| Other bias                                | Low risk           | The trial appears to be free of other sources of bias.                                                                                                 |

### Geiter 1987

**Methods**

- **Design:** open multicentre RCT
- **Generation of allocation sequence:** not stated
- **Allocation concealment:** not stated
- **Blinding:** none
- **Duration:** 4 years and 5 months (from October 1981 to March 1986)

**Participants**

- **Number of participants:** 701 randomized
- **Males:** 27.8% (protocol population)
- **Inclusion criteria:** adults, newly diagnosed with pulmonary TB due to Mycobacterium tuberculosis and freely consenting to participate in the trial
- **Exclusion criteria:** not reported
- **Completeness of follow-up:** 87.2% (of 538 "eligible patients")
- **Baseline drug susceptibility test:** initially drug resistant participants 4.6% (32/701 randomized); FDCs: 13 and single-drug formulations: 19. Also 56 participants with "likelihood of initial isoniazid resistance" of "eligible patients": FDCs: 28 and single-drug formulations: 28
- **HIV status of participants:** not reported

**Interventions**

- Six months treatment regimen (2HRZ/4HR)
Intervention

1. 3FD C tablets Rifater® (isoniazid 75 mg, rifampicin 150 mg and pyrazinamide 400 mg per tablet) given for the first 2 months, followed by 2FDCs tablets Rifamate® (isoniazid and rifampicin) for the next 4 months (N = 169).

Doses used: 3 tablets for participants weighing < 50 kg, 4 tablets for participants weighing 50 to 70 kg and 5 tablets for participants weighing > 70 kg during the intensive phase. Doses given during continuation phase were not reported

Control

1. The same drugs given as separate formulations (N = 532).

Doses used: not reported

For whole treatment, drugs were taken daily and self-administered as outpatients in both groups

Outcomes

Outcomes used in this review

1. Sputum conversion at 8 weeks after initiation of treatment.
2. Adverse drug reactions: those leading to discontinuation of therapy and other adverse events.
3. Compliance.
4. Death.

Notes

Location: USA

Setting: TB clinics

Source of funding: not mentioned

Comments: follow-up duration was 2 years after completion of treatment. Time of assessment of reported outcomes: “during the first 8 weeks of therapy”

Risk of bias

| Bias                              | Authors’ judgement | Support for judgement                                                                 |
|-----------------------------------|--------------------|----------------------------------------------------------------------------------------|
| Random sequence generation (selection bias) | Unclear risk       | Insufficient information about random sequence generation process to permit a judgement of ‘low risk’ or ‘high risk’. |
| Allocation concealment (selection bias) | Unclear risk       | Insufficient information to permit judgment of ‘low risk’ or ‘high risk’.               |
| Blinding of participants and personnel (performance bias) All outcomes | Low risk           | No blinding, but outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk           | No blinding, but outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Incomplete outcome data (attrition bias) All outcomes | High risk          | The reason for missing outcome data is likely to be related to true outcome, with either imbalance in numbers for missing data across intervention and control groups. |
| Selective reporting (reporting bias) | Unclear risk       | Insufficient information to permit judgement of ‘low risk’ or ‘high risk’.              |
The trial was designed with the amended protocol of a former study and followed an unbalanced randomization scheme (60% of participants were randomized to the FDCs regimen and 20% to each of the 2 original treatment arms).

### Lienhardt 2011

**Methods**

- **Design:** parallel-group, open-label, non inferiority, multicentre RCT
- **Generation of allocation sequence:** using a computer random number generator
- **Allocation concealment:** by sealed opaque envelopes with a serial number and details of treatment regimen
- **Blinding:** none
- **Duration:** 5 years (from 2003 to 2008)

**Participants**

- **Number of participants:** 1585 randomized
  - **Males:** 66.6% (per-protocol population)
  - **Mean age:** 34 years (SD: 13.5) (protocol population)
- **Inclusion criteria:** newly diagnosed pulmonary TB adults (aged 18 years or more) with 2 sputum specimens positive for acid-fast bacilli on direct-smear microscopy, had received either no previous anti-TB chemotherapy or < 4 weeks of chemotherapy for the current disease episode, had a firm home address that is readily accessible for visiting for the total duration of the trial (including follow-up period), and had provided written informed consent form to participate in the study
- **Exclusion criteria:** had tuberculous meningitis or other extrapulmonary disease, insulin-dependent diabetes, chronic liver or kidney disease, blood disorders, peripheral neuritis; were known to be pregnant or were breast feeding; had a history of psychiatric illness or alcoholism; or had any contraindication to any medications used in the study. Participants with no positive culture result at entry or rifampicin resistance before treatment were excluded postrandomization
- **Completeness of follow-up:** 85% (participants included at modified intention-to-treat (ITT) analysis at 18 months)
- **Baseline drug susceptibility test:** initially isoniazid-resistant isolates participants 11.2% (127/1132 with initial result), FDCs: 65 and single-drug formulations: 62
- **HIV status of participants:** reported (HIV positive N = 77)

**Interventions**

- **26-week treatment regimen (8HRZE/18HR)**
- **Intensive phase** (8 weeks of daily treatment)

**Intervention**

1. 4FDCs (isoniazid 75 mg, rifampicin 150 mg, pyrazinamide 400 mg and ethambutol 275 mg per tablet) (N = 798).

**Doses used:**

- 2 tablets for participants weighing 30 to 37 kg, 3 tablets for participants weighing 38 to 54 kg, 4 tablets for participants weighing 55 to 70 kg, and 5 tablets for patients weighing > 70 kg

**Control:**
1. The same drugs as single formulations with isoniazid 100 mg, rifampicin 150 mg, pyrazinamide 400 mg, and ethambutol 400 mg per tablet (N = 787).

**Doses used**

For participants weighing 30 to 37 kg H: 1.5; R: 2; Z: 2, and E: 1.5 tablets
Participants weighing 38 to 54 kg H: 2.5; R: 3; Z: 3, and E: 2 tablets
Participants weighing 55 to 70 kg H: 3; R: 4; Z: 4, and E: 3 tablets
Participants weighing > 70 kg H: 3.5; R: 5; Z: 5, and E: 3.5 tablets

**Continuation phase** (18 weeks of 3 times weekly treatment):

1. 2FDCs (isoniazid 150 mg and rifampicin 150 mg) for all participants.

**Doses used**: 2

tablets for participants weighing 30 to 37 kg, 3 tablets for participants weighing 38 to 54 kg, 4 tablets for participants weighing 55 to 70 kg, and 5 tablets for participants weighing >70 kg

The trial authors stated: "Patients were required to attend the treatment facility daily during the initial phase (first 8 weeks) and then 3 times weekly during the continuation phase. Every treatment dose was to be taken under supervision of a member of the medical staff as DOT".

In most trial centres, DOT was done 6 days a week and on Sundays treatment intake was checked by health workers through unplanned visit to participants' home and pill counts.

### Outcomes

**Outcomes used in this review**

1. Culture conversion at 2 months after initiation of treatment.
2. Treatment failure at 18 months.
3. Relapse at 18 months.
4. Adverse events in the first 2 months: serious, those leading to discontinuation of therapy and other adverse events.
5. Acquisition of drug resistance.
6. Death.

**Outcomes reported and not used in this review**

1. Unfavorable outcome: a combined endpoint of:
   a. bacteriological failure or relapse by 18 months after treatment initiation;
   b. treatment changed after 5 months because of 2 positive sputum smear results or a clinical or radiographic deterioration in the absence of bacteriological confirmation; and
   c. death, definitely or probably attributable to TB.
2. Favorable response: sputum culture negative at 18 months (or 24 months, if the 18 months result was unavailable).

### Notes

Two publications for the same clinical trial (Lienhardt 2011; Nunn 2014). All outcomes were assessed according to the data provided in Lienhardt 2011. In Nunn 2014 the assessment was done at 30 months after initiation of treatment and is the most recent publication, but the results confirm those found in Lienhardt 2011 and the trial authors suggest that the follow-up should be limited to 18 months after initiation of treatment in this kind of clinical trials.

**Locations**: Algeria, Bolivia, Colombia, Guinea, Mozambique, Nepal, Peru, Tanzania, and Vietnam

**Setting**: "clinical trial sites" (different in each country)

**Source of funding**: United States Agency for International Development

**Comments**: follow-up duration was 30 months after initiation of treatment. Participants were seen at the end of the second, third, fifth, and sixth month during treatment and then at 8, 10, 12, 15, 18, 24,
and 30 months in the follow-up phase. Adverse events were assessed in each visit. Sputum sample was collected at each visit.

### Risk of bias

| Bias                                      | Authors' judgement | Support for judgement                                                                 |
|-------------------------------------------|--------------------|---------------------------------------------------------------------------------------|
| Random sequence generation (selection bias) | Low risk           | Random allocations were computer generated.                                             |
| Allocation concealment (selection bias)   | Low risk           | Sequentially numbered, opaque sealed envelopes were used.                               |
| Blinding of participants and personnel (performance bias) | Low risk           | No blinding, but the outcome is unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Blinding of outcome assessment (detection bias) | Low risk           | No blinding of outcome assessment, but the outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Incomplete outcome data (attrition bias)   | Low risk           | Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. |
| Selective reporting (reporting bias)      | High risk          | Most primary and secondary outcomes were changed compared to the available protocol.    |
| Other bias                                | Low risk           | The trial appears to be free of other sources of bias.                                   |

### Munteanu 2004

**Methods**
- **Design:** RCT
- **Generation of allocation sequence:** not stated
- **Allocation concealment:** not stated
- **Blinding:** not stated
- **Duration:** 1 year and 1 month (from August 2001 to September 2002)

**Participants**
- **Number of participants:** 40 randomized
- **Males:** 63.2% (per-protocol population)
- **Age range:** 20 to 50 years
- **Inclusion criteria:** newly diagnosed pulmonary TB adults (aged 16 years or older) confirmed by sputum smear and culture; and freely consented to participate in the trial
- **Exclusion criteria:** presence of hepatic, renal, or hematological disorders that impose an individualization of dosage; presence of any type of ocular retro bulbar neuritis that may contraindicate ethambutol; pregnancy; presence of severe neuropsychiatric disorders, alcoholism, or other conditions that endanger the participant’s life (cancer, HIV-positive) and mean the participant is unlikely to complete the study; contacts of participants with TB with demonstrated resistant organisms; recurrences
- **Completeness of follow-up:** 95% (ITT population)
## Baseline drug susceptibility test
Initially drug resistant participants 0% (0/38 tested)

### HIV status of participants
Not reported

## Interventions

### 6 months treatment regimen (2HRZE/4HR)

#### Intervention
1. 2FDCs (isoniazid 150 mg and rifampicin 300 mg per tablet) during all treatment, complemented with pyrazinamide and ethambutol as single-drug formulations in the intensive phase. In continuation phase isoniazid supplementary was done to achieve the dose of 10 mg/kg (N = 20).

#### Control
1. The same drugs, but in separate formulations (N = 20).

#### Doses used
Not reported.

Treatment was administered as DOT in both groups, daily and admitted to the hospital during the intensive phase and 3 times per week as outpatients during the continuation phase.

## Outcomes

#### Outcomes used in this review
1. Culture conversion rate at 2 months after initiation of treatment.
2. Adverse events: serious, those leading to discontinuation of therapy and other adverse events.

#### Outcomes reported and not used in this review
1. Therapeutic success rate at follow-up.

## Notes

### Location
Romania

### Setting
Hospital

### Source of funding
Not mentioned

### Comments
The follow-up duration was 1 year after initiation of treatment. Time for assessment of reported outcomes was not informed

## Risk of bias

| Bias                                                                 | Authors' judgement | Support for judgement |
|----------------------------------------------------------------------|--------------------|-----------------------|
| Random sequence generation (selection bias)                         | Unclear risk       | There was insufficient information about the random sequence generation process. |
| Allocation concealment (selection bias)                             | Unclear risk       | There was insufficient information to permit a judgement of ‘low risk’ or ‘high risk’. |
| Blinding of participants and personnel (performance bias)           | Low risk           | Due to difficulties in blinding the participants and personnel to the intervention, when the study did not provide specification of blinding methods, we considered it an open design. In addition, the outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| All outcomes                                                       |                    |                       |
| Blinding of outcome assessment (detection bias)                     | Low risk           | No blinding of outcome assessment, but the outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| All outcomes                                                       |                    |                       |
| Incomplete outcome data (attrition bias)                            | Low risk           | We imputed missing data using appropriate methods. |
### Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)

**Cochrane Database of Systematic Reviews**

**Munteanu 2004** (Continued)

| Selective reporting (reporting bias) | Unclear risk | There was insufficient information to permit a judgement of ‘low risk’ or ‘high risk’. |
|-------------------------------------|--------------|----------------------------------------------------------------------------------|
| Other bias                          | Low risk     | The trial appears to be free of other sources of bias.                           |

**RCTAI 1989**

**Methods**

- **Design**: RCT
- **Generation of allocation**: not stated
- **Allocation concealment**: serially numbered envelopes
- **Blinding**: not stated
- **Duration**: 1 year (from August 1986 to August 1987)

**Participants**

- **Number of participants**: 229 randomized
- **Males**: 70% (of included population on final analysis)
- **Inclusion criteria**: new pulmonary TB patients, aged at least 15 years and weighing not less than 30 kg, without complications (TB or non-TB) that could interfere with TB treatment
- **Exclusion criteria**: participants with "poor condition or were moribund" and "cases with pleural effusion if the effusion obscured more than one third of lung field"
- **Completeness of follow-up**: 91.7% of participants (ITT population)
- **Baseline drug susceptibility test**: initially drug resistant participants 16.2% (34/210 tested) (H: 26, R: 5, H&R: 3; FDCs: 19, and single-drug formulations: 15)
- **HIV status of participants**: not reported

**Interventions**

- **26-week treatment regimen (8HRZ/18HR)**

**Intervention**

1. 3FDCs tablets Rifater (isoniazid 80 mg, rifampicin 120 mg and pyrazinamide 250 mg per tablet) given for the first 8 weeks, followed by 2FDCs tablets Rifinah (isoniazid 100 mg and rifampicin 150 mg per tablet) for the next 18 weeks (N = 102).

**Doses used**

- **Intensive phase**: 3 tablets for participants weighing 30 to 39.9 kg, 4 tablets for participants weighing 40 to 49.9 kg, and 5 tablets for participants weighing 50 to 60 kg
- **Continuation phase**: 3 tablets for participants weighing 30 to 39.9 kg, 3 tablets for participants weighing 40 to 49.9 kg and 4 tablets for participants weighing 50 to 60 kg

**Control:**

1. The same drugs given as separate formulations (N = 108).

**Doses used (mg/kg):**

**Intensive phase**

- For participants weighing 30 to 39.9 kg: H: 7.5 to 10; R: 11.2 to 15; Z: 18.8 to 25
- Participants weighing 40 to 49.9 kg: H: 6 to 7.5; R: 9 to 11.2; Z: 20 to 25
- Participants weighing 50 to 60 kg: H: 6.6 to 8; R: 10 to 12; Z: 20.8 to 25

---

**Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.**
Continuation phase

For participants weighing 30 to 39.9 kg: H: 7.5 to 10; R: 11.2 to 15
participants weighing 40 to 49.9 kg: H: 6 to 7.5; R: 9 to 11.2
participants weighing 50 to 60 kg: H: 6.6 to 8; R: 10 to 12

Treatment was daily and self-administered for the whole therapy

Outcomes

Outcomes used in this review

1. Culture conversion rate at 8 and 26 weeks after initiation of treatment.
2. Relapse rates 26 to 52 weeks after treatment initiation.
3. Patient compliance at 8 and 26 weeks after treatment initiation.
4. Adverse events: serious and those leading to discontinuation of therapy.
5. Death.

Outcomes reported and not used in this review

1. Bio-availability: serum levels of H, R, and Z.
2. Acceptability of treatment.

Notes

Locations: India
Setting: "four centres" (2 hospital and 2 ambulatory centres)
Source of funding: "Tata Pharma Indian Limited made available a free supply of Rifater, Rifinah, Ryzaminamide and Rifampicine"

Comments: follow-up duration was 26 weeks after completion of treatment. Culture conversion rate and participant compliance were measured at 8 and 26 weeks after treatment initiation. Compliance was assessed by delay in drug collection and surprise pill counting. Participants were expected to collect their drugs every fortnight during the intensive phase and every month during the continuation phase. Time of assessment for the other outcomes was not reported

Risk of bias

| Bias                                      | Authors' judgement | Support for judgement |
|-------------------------------------------|--------------------|-----------------------|
| Random sequence generation (selection bias) | Unclear risk       | There was insufficient information about the random sequence generation process to permit a judgement of ‘low risk’ or ‘high risk’. |
| Allocation concealment (selection bias)   | Unclear risk       | There was insufficient information to permit a judgement of ‘low risk’ or ‘high risk’. |
| Blinding of participants and personnel (performance bias) | Low risk | Due to difficulties in blinding the participants and personnel to the intervention, when the study did not provide specification of blinding methods we was considered it an open design. In addition, the outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Blinding of outcome assessment (detection bias) | Low risk | No blinding of outcome assessment, but outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Incomplete outcome data (attrition bias)   | Unclear risk       | There was insufficient reporting of attrition/exclusions to permit a judgement of ‘low risk’ or ‘high risk’ (reasons for missing data provided but not disaggregated). |
RCTAI 1989 (Continued)

| Selective reporting (reporting bias) | Unclear risk | Insufficient information to permit judgement of ‘low risk’ or ‘high risk’. |
|-------------------------------------|--------------|-------------------------------------------------------------------------|
| Other bias                          | Low risk     | The trial appears to be free of other sources of bias.                  |

Semenova 2003

Methods

- **Design:** RCT
- **Generation of allocation sequence:** "by the method of random numbers"
- **Allocation concealment:** not stated
- **Blinding:** not stated
- **Duration:** 2 years and 1 month (from October 1999 to November 2001)

Participants

- **Number of participants:** 387 randomized
- **Males:** 58.9% (ITT population)
- **Inclusion criteria:** newly diagnosed pulmonary TB adults, aged from 16 to 50 years
- **Exclusion criteria:** not reported
- **Completeness of follow-up:** not reported
- **Baseline drug susceptibility test:** initially drug resistant participants 4.9% (19/387 randomized)
- **HIV status of participants:** not reported

Interventions

Four months treatment regimen (4HRZE)

Participants were randomly placed into 4 groups (groups 1 and 3 were intervention groups; and 2 and 4 control groups):

1. **Group 1** received 4FDCs Mairin-P (daily) (isoniazid 60 mg, rifampicin 120 mg, pyrazinamide 300 mg, and ethambutol 225 mg per tablet) + isoniazid tablet + streptomycin (N = 207). **Dose used:** FDCs was dosed by rifampicin, calculating it by 10 mg/kg of body weight, but not more than 6 tablets. Additional isoniazid was given at 5 mg/kg and streptomycin was dosed at 16 mg/kg.
2. **Group 2** received the same drugs constituting Mairin-P, but as single formulations + streptomycin (N = 92). **Dose used:** isoniazid 10 mg/kg, rifampicin 10 mg/kg, pyrazinamide 20 mg/kg, ethambutol 25 mg/kg, and streptomycin 16 mg/kg.
3. **Group 3** received the same fixed-combinations as group 1 (daily) without streptomycin (N = 51). **Dose used:** the same than group 1.
4. **Group 4** received the same drugs than group 2 without streptomycin (N = 18). **Dose used:** the same than group 2.

The mode of treatment administration was not reported for all participants, neither the frequency of treatment in control groups. The treatment was reported only for initial 4 months (intensive phase).

The first and second groups were considered "patients with advanced pulmonary TB" and the third and fourth groups "patients with pulmonary TB of limited localised spread"

Outcomes

1. Rate of disappearance of clinical symptoms of TB.
2. Sputum conversion at 4 months after initiation of treatment.
3. Cavity closure rate.
4. Adverse events: those leading to discontinuation of therapy and other adverse events.
We did not use all reported outcomes in this Cochrane review because losses were not imputed according to the intervention or control groups.

**Notes**
- **Location:** Russia
- **Setting:** clinic
- **Source of funding:** not mentioned
- **Comments:** follow-up duration was 4 months after initiation of treatment, the time for assessment of the reported outcomes

### Risk of bias

| Bias                                           | Authors' judgement | Support for judgement                                                                 |
|------------------------------------------------|--------------------|---------------------------------------------------------------------------------------|
| Random sequence generation (selection bias)   | Low risk           | Random numbers method.                                                                 |
| Allocation concealment (selection bias)       | Unclear risk       | There was insufficient information to permit a judgement of ‘low risk’ or ‘high risk’. |
| Blinding of participants and personnel (performance bias) | Low risk           | Due to difficulties in blinding the participants and personnel to the intervention, when the study did not provide specification of blinding methods we considered it an open design. In addition, outcomes were unlikely to be influenced by a lack of blinding (objective and measurable outcomes). |
| Blinding of outcome assessment (detection bias) | Low risk           | No blinding of outcome assessment, but outcome measurement was not likely to be influenced by lack of blinding (objective and measurable outcomes). |
| Incomplete outcome data (attrition bias)      | High risk          | The reason for missing outcome data is likely to be related to the true outcome.      |
| Selective reporting (reporting bias)          | High risk          | The trial report fails to include results for a key outcome that would be expected to have been reported. |
| Other bias                                    | Unclear risk       | There was insufficient information to assess whether there was an important risk of bias. |

### Methods

**Design:** RCT

**Generation of allocation sequence:** not stated

**Allocation concealment:** not stated

**Blinding:** not stated

**Duration:** not mentioned

**Participants**
- **Number of participants:** 105 randomized
- **Males:** 88.6% (ITT population)
Inclusion criteria: participants aged 18 years or more with active pulmonary TB, confirmed by sputum smear or culture or both, and with no history of previous TB treatment

Exclusion criteria: not reported

Completeness of follow-up: 48.6% (ITT population)

Baseline drug susceptibility test: initially drug resistant participants 23.5% (12/51 included in analysis); FDCs: 4 resistant to Z and single-drug formulations: 2 resistant to E and 6 to Z

HIV status of participants: not reported

Interventions

Six months treatment regimen (2HRZE/4HRE)

Intervention

1. FDCs tablets with Rifater® (isoniazid 50 mg, rifampicin 120 mg and pyrazinamide 250 mg per tablet) + etambutol as single-drug formulation for the first 2 months (intensive phase) followed by Rifinah® 150 (isoniazid 100 mg and rifampicin 150 mg per tablet) or Rifinah® 300 (isoniazid 150 mg and rifampicin 300 mg per tablet) + etambutol as single-drug formulation for 4 months (continuation phase) (N = 57).

Doses used

Rifater: 3 tablets for participants weighing 30 to 39 kg, 4 tablets for participants weighing 40 to 49 kg, and 5 tablets for participants weighing ≥ 50 kg

Rifinah: 3 tablets of Rifinah 150 for participants weighing < 50 kg, or 2 tablets of Rifinah 300 for participants weighing ≥50 kg

The ethambutol dose was not reported

Control

1. The same drugs given as separate formulations (N = 48).

Doses used

Isoniazid 300 mg, rifampicin 450 mg, pyrazinamide 1500 mg, and etambutol 800 mg for participants weighing < 50 kg during the first 2 months, followed by isoniazid 300 mg, rifampicin 450 mg, and etambutol 800 mg for 4 months. The dosages for participants weighing ≥ 50 kg followed the same dosing schedule, except that rifampicin 600 mg was administered.

For whole treatment, drugs were taken daily and self-administered as outpatients

Outcomes

Outcomes used in this review

1. Sputum smear or culture conversion rate at 2 and 6 months after initiation of treatment.
2. Treatment failure.
3. Relapse.
4. Patient compliance.
5. Adverse reactions: those leading to discontinuation of therapy.
6. Death.

Outcomes reported and not used in this review

1. Patient response to TB treatment (microbiological, clinical, and radiological improvement).

Notes

Location: Taiwan

Setting: hospital (outpatient clinic at chest department)

Source of funding: not mentioned
Su 2002 (Continued)

Comments: follow-up duration was 12 months after completion of treatment. Sputum specimens were examined monthly during therapy and after 3, 6, and 12 months of completion of treatment. Adverse events were assessed monthly. Relapse was assessed after 3, 6, and 12 months of completion of treatment or any time relapse was suspected. Patient compliance was evaluated by losses and regimen changes during treatment.

Risk of bias

| Bias                              | Authors' judgement | Support for judgement                                                                 |
|----------------------------------|--------------------|---------------------------------------------------------------------------------------|
| Random sequence generation (selection bias) | Unclear risk       | There was insufficient information about random sequence generation process to permit a judgement of 'low risk' or 'high risk'. |
| Allocation concealment (selection bias)   | Unclear risk       | There was insufficient information to permit a judgement of 'low risk' or 'high risk'. |
| Blinding of participants and personnel (performance bias) | Low risk           | Due to difficulties in blinding the interventions for participants and personnel, when the study did not provide specification of blinding methods, we considered it an open design. In addition, the outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Blinding of outcome assessment (detection bias) | Low risk           | No blinding of outcome assessment, but outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Incomplete outcome data (attrition bias) | Low risk           | Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. |
| Selective reporting (reporting bias)   | Low risk           | The trial authors included most of the expected outcomes in the published report. |
| Other bias                         | Low risk           | The trial appears to be free of other sources of bias. |

Suryanto 2008

Methods

Design: RCT

Generation of allocation: not stated

Allocation concealment: “alternate allocation of eligible patients to each regimen to obtain equal number for both groups”

Blinding: not stated

Duration: 2 years for Gravendeel 2003 (from 1999 to 2001) and 2 months for Suryanto 2008 (from December 2004 to January 2005)

Participants

Number of participants: 434 randomized

Males: 59.7% (ITT population)

Mean age: 37.1 years (ITT population)

Inclusion criteria: new smear-positive TB participants with body weight between 33 and 50 kg and written informed consent form to participate in the trial

Exclusion criteria: not reported
Completeness of follow-up: 63.1% (ITT population)

Baseline drug susceptibility test: drug sensitivity test not performed (either at the beginning or during follow-up)

HIV status of participants: not reported

Interventions

Five months treatment regimen (2HRZE/3HR)

Intervention

1. 4FDCs (isoniazid, rifampicin, pyrazinamide, and ethambutol) daily for 2 months during the intensive phase; followed by 2FDCs (isoniazid and rifampicin) 3 times per week for 3 months during the continuation phase (N = 236).

Doses used

Intensive phase: the average adult dose contained isoniazid 225 mg, rifampicin 450 mg, pyrazinamide 1200 mg, and ethambutol 825 mg

Continuation phase: the averaged adult dose contained isoniazid 450 mg and rifampicin 450 mg

Control:

1. The same drugs as separate formulations (N = 198).

Doses used

Intensive phase: the average adult dose contained isoniazid 300 mg, rifampicin 450 mg, pyrazinamide 1500 mg, and ethambutol 750 mg

Continuation phase: the average adult dose contained isoniazid 600 mg and rifampicin 450 mg

Both FDCs and single-drug formulations were given under direct supervision at health centres, once weekly during the intensive phase and fortnightly during the continuation phase. The remaining days, drugs were self-administered at home. For all participants, the dose were adjusted to the body weight

Outcomes

Outcomes used in this review

1. Sputum smear conversion at 2 and 5 to 6 months after initiation of treatment.
2. Failure.
3. Relapse.
4. Death.

Outcomes reported and not used in this Cochrane review

1. Cured.

Notes

Two publications for the same clinical trial (Gravendeel 2003; Suryanto 2008). All outcomes but 1 (sputum smear conversion) were recorded with data found in Suryanto 2008, because it was the most recent document. Sputum smear conversion (at 2 and 6 months) was available only in the preliminary report (Gravendeel 2003)

Location: Republic of Indonesia

Setting: "health centres"

Source of funding: Royal Netherlands Tuberculosis Association

Comments: follow-up duration was not reported. Sputum smear conversion was examined at the beginning and at 2, 5, and 6 months from treatment initiation. Cured participants were followed up during 2004 to 2005 for relapse. The assessment for the other outcomes was not reported
### Suryanto 2008 (Continued)

**Risk of bias**

| Bias                                      | Authors’ judgement | Support for judgement                                                                                                                                 |
|-------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Random sequence generation (selection bias) | High risk          | Judgement of personal or clinicians.                                                                                                                                                                      |
| Allocation concealment (selection bias)   | High risk          | Alternate allocation of eligible participants.                                                                                                                                                           |
| Blinding of participants and personnel (performance bias) All outcomes | Low risk           | Due to difficulties in blinding the interventions for participants and personnel, when the study did not provide specification of blinding methods we considered it an open design. In addition, outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk           | No blinding of outcome assessment, but outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes).                                                             |
| Incomplete outcome data (attrition bias) All outcomes | High risk          | Potentially inappropriate application of simple imputation.                                                                                                                                               |
| Selective reporting (reporting bias)      | High risk          | The trial report fails to include results for a key outcome that would be expected to have been reported for such a trial.                                                                           |
| Other bias                                | Low risk           | The trial appears to be free of other sources of bias.                                                                                                                                                     |

### Teo 1999

**Methods**

- **Design:** RCT
- **Generation of allocation:** not stated
- **Allocation concealment:** not stated
- **Blinding:** not stated
- **Duration:** 3 years and 10 months (from October 1983 to August 1987)

**Participants**

- **Number of participants:** 310 randomized
- **Males:** 66% (of 179 participants with drug-susceptible bacilli on admission)
- **Inclusion criteria:** participants aged 15 years or more who had been newly diagnosed for pulmonary TB, with sputum smear positive for acid-fast bacilli and yielded *M. tuberculosis* on culture
- **Exclusion criteria:** not reported
- **Completeness of follow-up:** 81% (ITT population)
- **Baseline drug susceptibility test:** initially drug resistant participants 5.5% (17/307 treated)
- **HIV status of participants:** not reported

**Interventions**

- Six months treatment regimen

**Intervention and control groups:**
Intensive phase:
1. Regimen 1: isoniazid, rifampicin and pyrazinamide + streptomycin for 2 months (2SHRZ regimen).
2. Regimen 2: the same regimen, but given for only 1 month (1SHRZ regimen).
3. Regimen 3: the same as regimen 1 but without streptomycin (2HRZ regimen).

The 3 regimens were given daily as FDCs or as separate formulations.

Rifater (isoniazid 50 mg, rifampicin 120 mg, pyrazinamide 300 mg per tablet) was used as a FDC

Doses used:
Rifater
1. 4 tablets for participants weighing ≤ 42 kg.
2. 5 tablets for participants weighing 43 to 57 kg.
3. 6 tablets for participants weighing ≥ 58 kg.

Regimens given as single-drug formulations:
1. H 300 mg, R 450 mg, Z 1500 mg.
2. H 300 mg, R 600 mg, Z 1500 mg.
3. H 300 mg, R 600 mg, Z 2000 mg.

Streptomycin: 750 mg for the regimen 1 and 2 regardless of body weight

Continuation phase: isoniazid and rifampicin given 3 times a week as single-drug formulation for both treatment groups (intervention and control)

Doses used:
Isoniazid:
1. 6 tablets (600 mg) for participants weighing ≤ 42 kg.
2. 8 tablets (800 mg) for participants weighing 43 to 57 kg.
3. 10 tablets (1000 mg) for participants weighing ≥ 58 kg.

Rifampicin: 2 capsules (600 mg) for all participants

Treatment was given as DOT for the whole treatment

Outcomes used in this review
1. Culture conversion at 2 months after initiation of treatment.
2. Treatment failure.
3. Relapse.
4. Adverse events: those leading to discontinuation of therapy and other adverse events.
5. Death.
6. Acquisition of drug resistance.

Outcomes reported and not used in this review
1. Default.
2. Complaints.

Notes
Two publications of the same clinical trial (STS/BMRC 1991; Teo 1999). All outcomes were assessed according to the data provided in Teo 1999, because it is the most recent publication; except sputum conversion at 2 months and adverse events as these outcomes were available only in the preliminary report (STS/BMRC 1991).

Location: Singapore
Teo 1999 (Continued)

**Setting:** medical clinic

**Source of funding:** not mentioned

**Comments:** follow-up duration was 5 years after initiation of treatment. A clinician performed a clinical evaluation on admission and monthly up to 18 months, then once every 3 months up to 30 months, and once every 6 months up to 5 years from the date of admission to the study. Five sputum smears were examined bacteriologically (smear and culture) before treatment; thereafter 1 specimen was examined monthly during the first 6 months, then 2 specimens were examined once every month up to 18 months and at each follow-up visit up to 60 months.

### Risk of bias

| Bias                                      | Authors' judgement | Support for judgement                                                                 |
|-------------------------------------------|--------------------|---------------------------------------------------------------------------------------|
| Random sequence generation (selection bias) | Unclear risk       | There was insufficient information about random sequence generation process to permit a judgement of 'low risk' or 'high risk'. |
| Allocation concealment (selection bias)   | Unclear risk       | There was insufficient information to permit a judgement of 'low risk' or 'high risk'. |
| Blinding of participants and personnel (performance bias) | Low risk           | Due to difficulties in blinding participants and personnel to the intervention, when the trial did not specify blinding methods we considered it an open design. In addition, outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Blinding of outcome assessment (detection bias) | Low risk           | No blinding of outcome assessment, but outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Incomplete outcome data (attrition bias)  | Low risk           | The missing outcome data balanced in numbers across intervention groups with similar reasons for missing data. |
| Selective reporting (reporting bias)      | Unclear risk       | There was insufficient information to permit a judgement of 'low risk' or 'high risk'. |
| Other bias                                | Low risk           | The trial appears to be free of other sources of bias. |

**Wu 2015**

**Methods**

**Design:** open RCT

**Generation of allocation:** used a random number table

**Allocation concealment:** unclear

**Blinding:** none

**Duration:** 1 year, from October 2008 to November 2009

**Participants**

**Number of participants:** 161 randomized

**Males:** 67.7% of ITT population

**Inclusion criteria:** participants aged 18 years and older with suspected pulmonary TB (at least 2 sputum specimens positive for acid-fast bacilli on direct smear microscopy or 1 positive specimen and a
Exclusion criteria: participants with a history of receiving anti-TB treatment, had a life expectancy of < 6 months, had abnormal baseline liver function (alanine aminotransferase or aspartate aminotransferase values > 3 times the upper limit of normal or total bilirubin values > 2 mg/dL, or both), or had received immunosuppressive treatment

Completeness of follow-up: 60.9% (ITT population)

Baseline drug susceptibility test: initially drug resistant participants 3.1% (5/161 randomized participants)

HIV status of participants: not reported

Interventions

Six months treatment regimen (2HRZE/4HRE)

Intervention

1. FDCs tablets with Rifater (isoniazid 80 mg, rifampicin 120 mg, and pyrazinamide 250 mg per tablet) + etambutol as single-drug formulations for the first 2 months (intensive phase) followed by Rifinah® 150 (isoniazid 100 mg and rifampicin 150 mg per tablet) or Rifinah® 300 (isoniazid 150 mg and rifampicin 300 mg per tablet) + etambutol as single-drug formulations for 4 months (continuation phase) (N = 75).

Doses used:

Rifater: 3 tablets for participants weighing 30 to 39 kg, 4 tablets for participants weighing 40 to 49 kg, and 5 tablets for participants weighing ≥ 50 kg

Rifinah: 3 tablets of Rifinah 150 for participants weighing < 50 kg or 2 tablets of Rifinah 300 for participants weighing ≥ 50 kg

The ethambutol dose was not reported

Control:

1. The same drugs given as separate formulations (N = 86).

Doses used: not reported. For whole treatment, drugs were taken daily. Treatment was given as directly-observed treatments during work-week and self-administered during weekends.

The trial authors state: "a trained supervisor observed the participant during medication administration 5 days/week, whereas weekend doses were self-administered. However, treatment intake was still checked by the supervisor by unplanned visits to participants' homes and by pill counting"

Outcomes

Outcomes used in this review

1. Culture conversion after 2 and 6 months of treatment initiation.
2. Treatment failure.
3. Relapse.
4. Adverse events: serious and those leading to discontinuation of therapy.
5. Death.

Outcomes reported and not used in this review

1. Culture conversion after 4 months of treatment initiation.
2. Liver function fluctuation during anti-TB drug treatment.

Notes

Location: Taiwan

Setting: hospital
Wu 2015 (Continued)

**Source of funding:** by a grant (EDAHP99037) from E-DA hospital/I-Shou University, Kaohsiung, Taiwan

**Comments:** follow-up duration was 1 year after treatment completion. Sputum was collected from the participants at 2 and 4 months of treatment and at the end of treatment. Adverse effects were assessed at each visit during the first and second weeks of the first month of treatment and were then assessed monthly over the next 4 months. Relapse was assessed at the end of follow-up

### Risk of bias

| Bias                                         | Authors' judgement | Support for judgement                                                                 |
|----------------------------------------------|--------------------|----------------------------------------------------------------------------------------|
| Random sequence generation (selection bias) | Low risk           | Using a random number table.                                                           |
| Allocation concealment (selection bias)      | Unclear risk       | There was insufficient information to permit a judgment of ‘low risk’ or ‘high risk’. |
| Blinding of participants and personnel (performance bias) All outcomes | Low risk           | No blinding, but the outcomes were unlikely to be influenced by a lack of blinding (objective and measurable outcomes). |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk           | No blinding of outcome assessment, but the outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Incomplete outcome data (attrition bias) All outcomes | High risk           | All missing data were not reported.                                                     |
| Selective reporting (reporting bias) All outcomes | Unclear risk       | There was insufficient information to permit a judgement of ‘low risk’ or ‘high risk’. |
| Other bias                                   | Low risk           | The trial appears to be free of other sources of bias.                                  |

### Zaka-Ur-Rehman 2008

**Methods**

- **Design:** RCT
- **Generation of allocation sequence:** unclear
- **Allocation concealment:** unclear
- **Blinding:** not stated
- **Duration:** not mentioned

**Participants**

- **Number of participants:** 293 randomized
- **Males:** 63.8% (ITT population)
- **Inclusion criteria:** participants aged between 15 to 55 years with sputum positive pulmonary TB, who gave consent to participate
- **Exclusion criteria:** participants with renal, hepatic, diabetic, and cardiac problems, and pregnancy
- **Completeness of follow-up:** 70% (ITT population)
- **Baseline drug susceptibility test:** results not reported
**Interventions**

Six months treatment regimen (2HRZE/4HRE): participants were randomly selected into 3 groups (A, B, and C)

**Intervention** (groups A and B):

1. **Group A** (N = 97)
   - **Intensive phase**: 4FDCs (isoniazid 75 mg, rifampicin 120 mg, pyrazinamide 350 mg, and ethambutol 250 mg per tablet)
   - **Doses used**: 4 tablets for participants weighing < 50 kg and 5 tablets for participants weighing > 50 kg
   - **Continuation phase**: 3FDCs (isoniazid 100 mg, rifampicin 150 mg, and ethambutol 300 mg per tablet)
   - **Doses used**: 3 tablets for participants weighing < 50 kg and 4 tablets for participants weighing > 50 kg

2. **Group B** (N = 97)
   - **Intensive phase**: 4FDCs (isoniazid 60 mg, rifampicin 120 mg, pyrazinamide 300 mg, and ethambutol 225 mg per tablet)
   - **Doses used**: 4 tablets for participants weighing < 50 kg and 5 tablets for participants weighing > 50 kg
   - **Continuation phase**: 3FDCs (isoniazid 75 mg, rifampicin 150 mg, and ethambutol 300 mg per tablet)
   - **Doses used**: 3 tablets for participants weighing < 50 kg and 4 tablets for participants weighing > 50 kg

**Control group**:

1. **Group C**: the same drugs as single formulations (N = 99).
   - **Intensive phase**
     - Isoniazid 100 mg, rifampicin (150 mg and 450 mg capsules), pyrazinamide 500 mg, and ethambutol 400 mg
     - **Doses used**:
       - Participants weighing < 50 kg: isoniazid 3 tablets, rifampicin (450 mg) 1 capsule, pyrazinamide 3 tablets, and ethambutol 3 tablets
       - Participants weighing > 50 kg: isoniazid 4 tablets, rifampicin 1 capsule 450 mg, + 1 capsule 150 mg, pyrazinamide 4 tablets and ethambutol 4 tablets
   - **Continuation phase**
     - Isoniazid 100 mg, rifampicin (150 mg and 450 mg capsules) and ethambutol 400 mg
     - **Doses used**:
       - Participants weighing < 50 kg: isoniazid 3 tablets, rifampicin (450 mg) 1 capsule and ethambutol 3 tablets
       - Participants weighing > 50 kg: isoniazid 4 tablets, rifampicin 1 capsule 450 mg + 1 capsule 150 mg, and ethambutol 4 tablets

In all groups, treatment was administered daily, by DOT at the hospital for 2 months (during the intensive phase) and self-administered at home for 4 months (during the continuation phase)
Zaka-Ur-Rehman 2008 (Continued)

1. Sputum smear conversion at 2 months after initiation of treatment.
2. Relapse.
3. Adverse events: serious; those leading to discontinuation of therapy and other adverse events.
4. Death.
5. Average days for sputum conversion.

Outcomes reported and not used in this review

1. Socio economic status: marital status, literacy, working status and geographic area (urban or rural).
2. Laboratory examination (average of haemoglobin level improvement and average decrease of erythrocyte sedimentation rate).
3. Average of weight increase.
4. Chest X-rays changes (average of chest X-rays lesions decrease (at 2 months and between 2 and 6 months), and average decrease of the total lesions).

Notes

Location: Pakistan
Setting: hospital
Source of funding: not mentioned
Comments: follow-up duration was 6 months after treatment completion. Time for assessment of reported outcomes was not clearly informed. During the intensive phase participants were admitted to the hospital and during the continuation phase they self-administered the treatment at home and returned to the hospital once a month for check-up

Risk of bias

| Bias                                         | Authors' judgement | Support for judgement |
|----------------------------------------------|--------------------|-----------------------|
| Random sequence generation (selection bias)  | Low risk           | Drawing of lots.      |
| Allocation concealment (selection bias)      | High risk          | Assignment envelopes were used without appropriate safeguards ("sealed envelopes with group name in a bag from which the patient chose an envelope"). |
| Blinding of participants and personnel (performance bias) All outcomes | Low risk           | Due to difficulties in blinding the participants and personnel to the intervention, when the study did not specify the blinding methods, we considered it an open design. In addition, the outcomes were unlikely to be influenced by a lack of blinding (objective and measurable outcomes). |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk           | No blinding of outcome assessment, but outcome measurement was unlikely to be influenced by lack of blinding (objective and measurable outcomes). |
| Incomplete outcome data (attrition bias) All outcomes | Low risk           | No missing outcome data. |
| Selective reporting (reporting bias)         | Unclear risk       | There was insufficient information to permit a judgement of ‘low risk’ or ‘high risk’. |
| Other bias                                   | Low risk           | The trial appears to be free of other sources of bias. |
**Zhang 1996**

### Methods

**Design:** RCT  
**Generation of allocation:** referring to a random number table  
**Allocation concealment:** not stated  
**Blinding:** not stated  
**Duration:** not mentioned

### Participants

**Number of participants:** 209 randomized  
**Males:** 64.4% (per-protocol population)  
**Inclusion criteria:** newly diagnosed uncomplicated pulmonary TB adults (aged 15 or more) with sputum positive by both smear and culture  
**Exclusion criteria:** participants with extrapulmonary or miliary TB, severe impairment of hepatic or renal function, malignancy, a history of eye disease or hematologic problems, or gout; if they were pregnant, if they had taken corticosteroids or other immunosuppressive drugs; or if they had any other conditions that would introduce risk during chemotherapy  
**Completeness of follow-up:** 98% (ITT population)  
**Baseline drug susceptibility test:** initially drug resistant participants 7.7% (13/169 tested).  
FDCs: 2 S, 2 H, 2 S+H, 1 S+H+R and single-drug formulations: 1 S, 2 H, 1 R, 1 S+H, 1 S+E+R  
**HIV status of participants:** not reported

### Interventions

Six months treatment regimen (2HRZ/4HR):  
**Intervention**  
1. 3 FDCs tablets: Rifater® (isoniazid 80 mg, rifampicin 120 mg, and pyrazinamide 250 mg per tablet) for 2 months (intensive phase); followed by 2 FDCs: Rifinah® (isoniazid 100 mg and rifampicin 150 mg or isoniazid 150 mg and rifampicin 300 mg) for the succeeding 4 months (continuation phase) (N = 104).

**Doses used**  
Intensive phase: 3 tablets for participants weighing 30 to 39 kg, 4 tablets for participants weighing 40 to 49 kg, 5 tablets for participants weighing ≥ 50 kg  
Continuation phase: 3 tablets of Rifinah contained isoniazid 100 mg for participants weighing < 50 kg and 2 tablets of Rifinah contained isoniazid 150 mg for participants weighing ≥ 50 kg  
**Control:**  
1. The same drugs as single formulations (N = 105).

**Doses used**  
Intensive phase: participants weighing < 50 kg: 3 isoniazid 100 mg tablets, 3 rifampicin 150 mg tablets, and 6 pirazinamide 250 mg tablets  
Continuation phase: participants weighing < 50 kg: 3 isoniazid 100 mg tablets and 3 rifampicin 150 mg tablets; participants weighing ≥ 50 kg followed the same dosing schedule for intensive, with exception that 4 rifampicin 150 mg rather than 3  
All drugs were administered daily by DOT under "supervision of a health care provider" and participants were kept at hospital for both treatment groups

### Outcomes

**Outcomes used in this review**  
1. Culture conversion at 2 and 6 months after initiation of treatment.
2. Relapse.
3. Adverse reactions: those leading to discontinuation of therapy and other adverse events.
4. Death.

Outcomes reported and not used in this review
1. Dosage compliance.
2. Preference for participants: data were not imputed according to the intervention or control group (presented as a percentage for the total of participants).
3. Preference of physicians, pharmacists, and administrators.

Notes
Location: urban districts and rural areas of Beijing, China
Setting: hospital
Source of funding: Hoechst Marion Roussel, Singapore
Comments: follow-up duration was 2 years after completion of treatment. During the 6 months of treatment, sputum smears were examined each month and cultures were examined at 2, 4, and 6 months. Participants who had completed treatment and who had sputum conversion from positive to negative were followed with sputum smear at 3, 6, 9, 12, 15, and 24 months. Sputum cultures were tested at 6, 12, 18, and 24 months.

Risk of bias

| Bias                                      | Authors' judgement | Support for judgement                                                                 |
|-------------------------------------------|--------------------|---------------------------------------------------------------------------------------|
| Random sequence generation                | Low risk           | Referred to a random number table.                                                     |
| Allocation concealment                    | Unclear risk       | There was insufficient information to permit a judgement of ‘low risk’ or ‘high risk’.|
| Blinding of participants and personnel    | Low risk           | Due to difficulties in blinding the participants and personnel, when the study did not specify blinding methods we considered it an open design. In addition, the outcomes were unlikely to be influenced by a lack of blinding (objective and measurable outcomes). |
| Blinding of outcome assessment            | Low risk           | There was no blinding of outcome assessment, but outcome measurement was unlikely to be influenced by a lack of blinding (objective and measurable outcomes). |
| Incomplete outcome data                   | Low risk           | There were few missing data from both treatment groups and the reasons of losses were reported. |
| Selective reporting                       | Unclear risk       | There was insufficient information to permit a judgement of ‘low risk’ or ‘high risk’. |
| Other bias                                | Low risk           | The trial appears to be free of other sources of bias.                                 |

Zhu 1998
Methods
Design: RCT
Generation of allocation: not stated
Allocation concealment: not stated (with ratio of 2:1 in treatment and control groups)

Blinding: not stated

Duration: not mentioned

Participants

Number of participants: 348 randomized
Males: 70.1% (protocol population)
Inclusion criteria: newly diagnosed pulmonary infiltrative TB participants, confirmed by sputum smear and chest X-ray, aged 15 to 70 years and > 40 kg
Exclusion criteria: participants with serious heart, hepatic or renal diseases, and psychosis, epilepsy, or pregnant

Completeness of follow-up: 88.5% (ITT population)

Baseline drug susceptibility test: initially drug resistant participants 14% (43/308 included in analysis). FDCs: 5 S, 13 H, 7 R, 6 H+R, 1 S+E, 3 S+H and single-drug formulations: 1 S, 2 H, 2 R, 3 H+R

HIV status of participants: not reported

Interventions

Six months treatment regimen (2HRZ/4HR)

Intervention

1. 3FDCs tablets: Rifater® (isoniazid 80, rifampicin 120 mg, pyrazinamide 250 mg per tablet) for 2 months (intensive phase); followed by 2FDCs tablets: Rifinah® (A: isoniazid 100 mg and rifampicin 150 mg per tablet) and/or (B: isoniazid 150 and rifampicin 300 mg per tablet) for the succeeding 4 months (continuation phase) (N = 227).

Doses used:

1. Intensive phase: 4 tablets of Rifater for participants that weighed ≤ 60 kg and 5 tablets for participants weighing ≥ 60 kg.
2. Continuation phase: 1 A + 1 B of Rifinah tablets for participants weighing ≤ 50 kg or less; and 2 B of Rifinah tablets for participants weighing > 50 kg.

Control

1. The same drugs as separate formulations (N = 81).

Doses used

1. Intensive phase: daily isoniazid 300 mg and pyrazinamide 500 mg 3 times a day, regardless of body weight; rifampicin 450 mg for participants weighing ≤ 50 kg and 600 mg for participants weighing > 50 kg.
2. Continuation phase: the dose of isoniazid and rifampicin were the same as for the intensive phase.

In both cases (FDCs and single-drug formulations), drugs were administered daily, except pyrazinamide during the intensive phase as separated formulation given 3 times a day. There were 3 kinds of treatment management (whole-course hospitalization; outpatients treatment during the entire treatment course and hospitalization only during intensive phase), combined with 3 supervision models respectively (supervision by medical staff; supervision by non-medical staff who had been trained by the medical staff (relatives, colleagues) and supervision by medical staff in the intensive phase but non-medical staff in the continuation phase). Treatment and supervision was established according to participants economic status.

Outcomes

Outcomes used in this review

1. Sputum conversion rate at 2 and 6 months after initiation of treatment.
2. Compliance.
3. Adverse events: those leading to discontinuation of therapy and other adverse events.
4. Death.
Outcomes reported and not used in this review
1. Resolution of pulmonary lesion in chest radiography.
2. Cavity closure rates in X-rays at 6 months.
3. Laboratory examination (blood routine, platelet, and urine routine).

Notes
Location: China
Trial setting: hospital
Source of funding: not mentioned
Comments: follow-up duration was to the EOT. Sputum smear and culture were examined each month during the 6 months of treatment. X-ray was taken at 2 months and at EOT. Blood and urine tests were done every month, as for hepatic and renal function.

Risk of bias

| Bias                                           | Authors' judgement | Support for judgement                                                                 |
|------------------------------------------------|--------------------|---------------------------------------------------------------------------------------|
| Random sequence generation (selection bias)   | Unclear risk       | There was insufficient information about random sequence generation process to permit a judgment of ‘low risk’ or ‘high risk’. |
| Allocation concealment (selection bias)       | Unclear risk       | There was insufficient information to permit a judgement of ‘low risk’ or ‘high risk’. |
| Blinding of participants and personnel (performance bias) All outcomes | Low risk           | Due to difficulties in blinding the interventions for participants and personnel, when the trial did not provide specification of blinding methods, we considered it to be an open design. In addition, we judged that the outcomes were unlikely to have been influenced by lack of blinding (objective and measurable outcomes). |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk           | No blinding of outcome assessment, but the outcome measurement was unlikely to have been influenced by lack of blinding (objective and measurable outcomes). |
| Incomplete outcome data (attrition bias)      | High risk          | Potentially inappropriate application of simple imputation.                           |
| Selective reporting (reporting bias)          | Unclear risk       | Insufficient information to permit judgement of ‘low risk’ or ‘high risk’.             |
| Other bias                                    | Low risk           | The trial appears to be free of other sources of bias.                                |

Abbreviations: RCT: randomized controlled trial; TB: tuberculosis; AFB: acid-fast bacilli; kg: kilograms of body weight; HIV: human immunodeficiency virus; FDCs: fixed-dose combinations; H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; mg: milligrams; WHO: World Health Organization; ITT: intention-to-treat; S: streptomycin; DOT: directly observed treatment; USA: United States of America; SD: standard deviation; EOT: end of treatment.

Characteristics of excluded studies [ordered by study ID]

| Study      | Reason for exclusion                                                                 |
|------------|--------------------------------------------------------------------------------------|
| Brändli 1989 | Controlled clinical trial that compared FDCs versus single-drug formulations for pulmonary TB, but with 2 different treatment regimens in intervention and control groups. |
| Study               | Reason for exclusion                                                                                                                                 |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Brändli 1993       | RCT that compared FDCs versus single-drug formulations for pulmonary TB, but with 2 different treatment regimens in intervention and control groups. |
| Chu 2004           | RCT that compared 2 FDCs: Chinese fixed-dose compounds (2FEISU/4FEINING regimen) with 2RIFANAH/4RIFINAH regimen for new smear positive pulmonary TB participants, presented as an abstract for the 9th Congress of the Asian Pacific Society of Respiratology 10–13 December 2004, Hong Kong. Complete data were unavailable. |
| Cowie 1990         | RCT that compared FDCs versus single-drug formulations for pulmonary TB, but with 2 different treatment regimens in intervention and control groups. |
| Dubra 1972         | RCT that compared 2 different regimens of treatment for pulmonary TB administered as single-drug formulations.                                           |
| Ferreira 2013      | Descriptive study of use of 4FDCs tablets for pulmonary TB.                                                                                            |
| Glatthaar 1991     | RCT that compared FDCs versus single-drug formulations for pulmonary TB, but with 2 different treatment regimens in intervention and control groups. |
| González Montaner 1978 | RCT that compared 2 different regimens for pulmonary TB.                                                                                              |
| Herman 2007        | RCT that compared FDCs versus single-drug formulations for pulmonary TB, and was presented as a poster in the 12th Congress of the Asian Pacific Society of Respiratology. Completed data were unavailable. |
| HKCS/BMRC 1989     | RCT that compared FDCs versus single-drug formulations for pulmonary TB, but also included TB participants that were already treated.                   |
| ISRCTN95204603     | RCT that met the inclusion criteria of this Cochrane review according to published protocol, but is not yet published. Data were unavailable.         |
| Macnab 1994        | Controlled clinical trial that compared FDCs versus single-drug formulations for pulmonary TB, but had 2 different treatment regimens in intervention and control groups. |
| Merle 2012         | Descriptive study of methodological issue of unpublished RCTs (registration: ClinicalTrial.gov database: NCT00216385). Compared 4FDCs tablets versus 3FDCs + Gatifloxacin for pulmonary TB. |
| Punnotok 1995      | RCT that compared different treatment regimens (2Rifater/4Rifinah versus 2Rifater+E/6H+Thiacetazone) for untreated, sputum positive pulmonary TB.       |
| Soehardiman 2007   | RCT that compared FDCs versus single-drug formulations for pulmonary TB, and was presented as a poster in the 12th Congress of the Asian Pacific Society of Respiratology. Completed data were unavailable. |
| Sokolova 1993      | Study compared FDCs versus single-drug formulations for pulmonary TB. It is unclear whether or not this is a clinical trial, as there is no mention of allocation or randomization. |
| Xu 2004            | RCT that compared FDCs versus single-drug formulations, but with 2 different treatment regimens in intervention and control groups.                  |

**Abbreviations:** FDCs: fixed-dose combinations; TB: tuberculosis; RCT: randomized controlled trial.

**Characteristics of studies awaiting assessment** [ordered by study ID]
| Study    | Methods       | Participants | Interventions                                                                 | Outcomes | Notes                                                                 |
|----------|---------------|--------------|-------------------------------------------------------------------------------|----------|----------------------------------------------------------------------|
| Liang 2007 | RCT           | Unknown      | Fixed-dose combinations (FDCs) versus "Plate-type combined drug"               | Unknown  | We identified this study through other sources, not through database searches. We did not find the Chinese article. |
| Ma 2010   | RCT           | Unknown      | FDCs versus "Plate-type combined drug"                                       | Unknown  | We identified this study through other sources, not through database searches. We did not find the Chinese article. |
| Zhao 2007 | RCT           | Unknown      | FDCs versus single-drug formulations                                           | Unknown  | We identified this study through other sources, not through database searches. We did not find the Chinese article. |
| Zhu 2000  | RCT           | Unknown      | FDCs versus single-drug formulations                                           | Unknown  | We identified this study through other sources, not through database searches. We did not find the Chinese article. |
### Abbreviations:
RCT: randomized controlled trial; FDCs: fixed-dose combinations.

### DATA AND ANALYSES

#### Comparison 1. Fixed-dose combinations versus single-drug formulations as available data

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---------------------------|----------------|---------------------|--------------------|-------------|
| 1 Treatment failure       | 7              | 3606                | Risk Ratio (M-H, Fixed, 95% CI) | 1.28 [0.82, 2.00] |
| 2 Relapse                 | 10             | 3621                | Risk Ratio (M-H, Fixed, 95% CI) | 1.28 [1.00, 1.64] |
| 3 Death                   | 11             | 4800                | Risk Ratio (M-H, Fixed, 95% CI) | 0.96 [0.67, 1.39] |
| 4 Sputum smear or culture conversion at 2 months of starting treatment | 13              | 4836                | Risk Ratio (M-H, Fixed, 95% CI) | 1.01 [0.99, 1.03] |
| 5 Sputum smear or culture conversion at end of treatment (EOT) | 7              | 2319                | Risk Ratio (M-H, Fixed, 95% CI) | 0.99 [0.96, 1.02] |
| 6 Treatment adherence at 8 weeks of starting treatment | 3              | 881                 | Risk Ratio (M-H, Random, 95% CI) | 1.04 [0.96, 1.12] |
| 7 Treatment adherence at EOT | 5              | 1229                | Risk Ratio (M-H, Fixed, 95% CI) | 1.01 [0.97, 1.06] |
| 8 Acquisition of drug resistance | 3              | 491                 | Risk Ratio (M-H, Fixed, 95% CI) | 0.76 [0.15, 3.77] |
| 9 Patient satisfaction    | 2              |                     | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only |
| 9.1 General satisfaction  | 1              | 222                 | Risk Ratio (M-H, Fixed, 95% CI) | 1.04 [0.97, 1.12] |
| 9.2 No problems on swallowing | 1              | 1023                | Risk Ratio (M-H, Fixed, 95% CI) | 1.03 [1.00, 1.06] |
| 9.3 Convenient number of tablets | 1              | 1045                | Risk Ratio (M-H, Fixed, 95% CI) | 1.50 [1.37, 1.64] |
| 9.4 Acceptable taste      | 1              | 1044                | Risk Ratio (M-H, Fixed, 95% CI) | 1.39 [1.27, 1.51] |
| 10 Serious adverse events | 6              | 3388                | Risk Ratio (M-H, Fixed, 95% CI) | 1.45 [0.90, 2.33] |
| 11 Adverse events leading to discontinuation of therapy | 13              | 5530                | Risk Ratio (M-H, Random, 95% CI) | 0.96 [0.56, 1.66] |
| 12 Other adverse events   | 9              | 4639                | Risk Ratio (M-H, Fixed, 95% CI) | 0.85 [0.72, 1.00] |
### Analysis 1.1. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 1 Treatment failure.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-------------------------------|--------|-------------------------------|
| Chaulet 1995      | 1/102    | 1/107   | 2.91%                         | 2.91%  | 1.05[0.07,16.55]              |
| Teo 1999          | 2/154    | 1/153   |                               | 2.99%  | 1.99[0.18,21.69]              |
| Su 2002           | 0/26     | 0/25    |                               | 12.97% | 1.89[0.18,21.69]              |
| Suryanto 2008     | 9/236    | 4/198   |                               | 56.91% | 1.15[0.63,2.1]               |
| Bartacek 2009     | 22/582   | 19/577  |                               | 24.21% | 1.21[0.48,3.06]              |
| Lienhardt 2011    | 10/684   | 8/664   |                               | 1.89[0.59,6.04] |
| Wu 2015           | 0/49     | 0/49    |                               | Not estimable |
| **Total (95% CI)** | **1833** | **1773** |                               | **100%** | **1.28[0.82,2]**             |

Heterogeneity: Tau²=0; Chi²=6.72, df=7(P=0.45); I²=0%

Test for overall effect: Z=1.09(P=0.28)

Favours FDCs

### Analysis 1.2. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 2 Relapse.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-------------------------------|--------|-------------------------------|
| RCTAI 1989        | 1/64     | 1/71    | 0.96%                         | 0.49%  | 3.15[0.13,76.34]             |
| Chaulet 1995      | 1/102    | 0/107   |                               | 2.02%  | 1.09[0.81,1.48]             |
| Zhang 1996        | 2/101    | 2/101   |                               | 2.93%  | 3.94[1.13,13.78]            |
| Teo 1999          | 11/121   | 3/130   |                               | 0.52%  | 2.89[0.12,67.75]            |
| Su 2002           | 1/26     | 0/25    |                               | Not estimable |
| Zaka-Ur-Rehman 2008 | 0/141 | 0/69    |                               | 2.33%  | 3.69[0.83,16.32]            |
| Suryanto 2008     | 10/99    | 2/73    |                               | 69.18% | 1.09[0.81,1.48]            |
| Bartacek 2009     | 74/468   | 69/477  |                               | 21.57% | 1.2[0.68,2.11]             |
| Lienhardt 2011    | 26/684   | 21/664  |                               | Not estimable |
| Wu 2015           | 0/49     | 0/49    |                               | Not estimable |
| **Total (95% CI)** | **1855** | **1766** |                               | **100%** | **1.28[1.16,1.44]**         |

Heterogeneity: Tau²=6.72; Chi²=7(P=0.45); I²=0%

Test for overall effect: Z=1.93(P=0.05)

Favours FDCs

### Analysis 1.3. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 3 Death.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-------------------------------|--------|-------------------------------|
| Geiter 1987       | 2/122    | 13/416  |                               | 16.67% | 0.52[0.12,2.29]             |
| RCTAI 1989        | 1/102    | 0/108   |                               | 0.88%  | 3.17[0.13,77.05]            |
| Zhang 1996        | 2/102    | 1/103   |                               | 1.8%   | 2.02[0.19,21.93]            |

Favours FDCs
| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| Zhu 1998         | 0/227    | 0/81    |                             |        |                             |
| Teo 1999         | 8/132    | 6/139   |                             |        |                             |
| Su 2002          | 7/57     | 2/48    |                             |        |                             |
| Suryanto 2008    | 11/173   | 18/140  |                             |        |                             |
| Zaka-Ur-Rehman 2008 | 0/141    | 1/69    |                             |        |                             |
| Bartacek 2009    | 11/558   | 4/564   |                             |        |                             |
| Lienhardt 2011   | 4/684    | 7/664   |                             |        |                             |
| Wu 2015          | 6/75     | 8/86    |                             |        |                             |
| **Total (95% CI)** | **2373** | **2427** | **100%** |        | **0.96[0.67,1.39]** |
| Zhu 1998         | 207/227  | 70/81   |                             |        |                             |
| Teo 1999         | 124/129  | 133/140 |                             |        |                             |
| Su 2002          | 23/26    | 24/25   |                             |        |                             |
| Munteanu 2004    | 14/20    | 15/18   |                             |        |                             |
| Zaka-Ur-Rehman 2008 | 187/194  | 101/103 |                             |        |                             |
| Zhang 1996       | 198/198  | 143/160 |                             |        |                             |
| Bartacek 2009    | 449/582  | 501/579 |                             |        |                             |
| Lienhardt 2011   | 47/49    | 47/49   |                             |        |                             |
| Wu 2015          | 47/49    | 47/49   |                             |        |                             |
| **Total (95% CI)** | **2405** | **2431** | **100%** |        | **1.01[0.99,1.03]** |

### Analysis 1.4. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| Geiter 1987      | 106/122  | 323/416 |                             |        |                             |
| RCTAI 1989       | 67/70    | 73/76   |                             |        |                             |
| Chaulet 1995     | 90/95    | 99/108  |                             |        |                             |
| Zhang 1996       | 101/102  | 99/103  |                             |        |                             |
| Zhu 1998         | 207/227  | 70/81   |                             |        |                             |
| Teo 1999         | 124/129  | 133/140 |                             |        |                             |
| Su 2002          | 23/26    | 24/25   |                             |        |                             |
| Munteanu 2004    | 14/20    | 15/18   |                             |        |                             |
| Zaka-Ur-Rehman 2008 | 187/194  | 101/103 |                             |        |                             |
| Zhang 1996       | 198/198  | 143/160 |                             |        |                             |
| Bartacek 2009    | 449/582  | 501/579 |                             |        |                             |
| Lienhardt 2011   | 47/49    | 47/49   |                             |        |                             |
| Wu 2015          | 47/49    | 47/49   |                             |        |                             |
| **Total (95% CI)** | **2405** | **2431** | **100%** |        | **1.01[0.99,1.03]** |

### Analysis 1.5. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 5 Sputum smear or culture conversion at end of treatment (EOT).

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| RCTAI 1989       | 64/66    | 71/74   |                             |        |                             |
| Zhang 1996       | 101/102  | 101/103 |                             |        |                             |
## Analysis 1.6. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 6 Treatment adherence at 8 weeks of starting treatment.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Random, 95% CI | Weight | Risk Ratio M-H, Random, 95% CI |
|------------------|----------|---------|-------------------------------|--------|-------------------------------|
| Geiter 1987      | 108/122  | 363/416 | 39.2%                         | 0.99   | 1.01 [0.94, 1.09]             |
| RCTAI 1989       | 70/97    | 62/104  | 12.6%                         | 1.21   | 1.01 [0.99, 1.48]             |
| Chaulet 1995     | 70/71    | 69/71   | 48.1%                         | 1.01   | 1.01 [0.97, 1.06]             |
| Total (95% CI)   | 290      | 591     | 100%                          | 1.04   | 1.04 [0.96, 1.12]             |

Total events: 248 (FDCs), 494 (SDF)
Heterogeneity: Tau²=0; Chi²=5.32, df=2 (P=0.07); I²=62.42%
Test for overall effect: Z=0.89 (P=0.37)

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Random, 95% CI | Weight | Risk Ratio M-H, Random, 95% CI |
|------------------|----------|---------|-------------------------------|--------|-------------------------------|
| Geiter 1987      | 118/122  | 408/416 | 45.39%                        | 0.99   | 1.01 [0.95, 1.02]             |
| RCTAI 1989       | 35/95    | 37/101  | 8.8%                          | 1.01   | 1.01 [0.71, 1.45]             |
| Chaulet 1995     | 44/44    | 50/52   | 11.38%                        | 1.04   | 1.04 [0.97, 1.11]             |
| Zhu 1998         | 247/258  | 83/90   | 30.19%                        | 1.04   | 1.04 [0.97, 1.11]             |
| Su 2002          | 18/26    | 17/25   | 4.25%                         | 1.02   | 1.02 [0.71, 1.48]             |
| Total (95% CI)   | 545      | 684     | 100%                          | 1.01   | 1.01 [0.97, 1.06]             |

Total events: 462 (FDCs), 595 (SDF)
Heterogeneity: Tau²=0; Chi²=3.1, df=4 (P=0.54); I²=0%
Test for overall effect: Z=0.47 (P=0.64)

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Random, 95% CI | Weight | Risk Ratio M-H, Random, 95% CI |
|------------------|----------|---------|-------------------------------|--------|-------------------------------|
| Geiter 1987      | 108/122  | 363/416 | 39.2%                         | 0.99   | 1.01 [0.94, 1.09]             |
| RCTAI 1989       | 70/97    | 62/104  | 12.6%                         | 1.21   | 1.01 [0.99, 1.48]             |
| Chaulet 1995     | 70/71    | 69/71   | 48.1%                         | 1.01   | 1.01 [0.97, 1.06]             |
| Total (95% CI)   | 290      | 591     | 100%                          | 1.04   | 1.04 [0.96, 1.12]             |

Total events: 248 (FDCs), 494 (SDF)
Heterogeneity: Tau²=0; Chi²=5.32, df=2 (P=0.07); I²=62.42%
Test for overall effect: Z=0.89 (P=0.37)

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Random, 95% CI | Weight | Risk Ratio M-H, Random, 95% CI |
|------------------|----------|---------|-------------------------------|--------|-------------------------------|
| Geiter 1987      | 118/122  | 408/416 | 45.39%                        | 0.99   | 1.01 [0.95, 1.02]             |
| RCTAI 1989       | 35/95    | 37/101  | 8.8%                          | 1.01   | 1.01 [0.71, 1.45]             |
| Chaulet 1995     | 44/44    | 50/52   | 11.38%                        | 1.04   | 1.04 [0.97, 1.11]             |
| Zhu 1998         | 247/258  | 83/90   | 30.19%                        | 1.04   | 1.04 [0.97, 1.11]             |
| Su 2002          | 18/26    | 17/25   | 4.25%                         | 1.02   | 1.02 [0.71, 1.48]             |
| Total (95% CI)   | 545      | 684     | 100%                          | 1.01   | 1.01 [0.97, 1.06]             |

Total events: 462 (FDCs), 595 (SDF)
Heterogeneity: Tau²=0; Chi²=3.1, df=4 (P=0.54); I²=0%
Test for overall effect: Z=0.47 (P=0.64)
### Analysis 1.8. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 8 Acquisition of drug resistance.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-----------------------------|
| Chaulet 1995      | 1/102    | 1/107   |                             | 28.79% | 1.05[0.07,16.55]            |
| Teo 1999          | 0/121    | 1/130   |                             | 42.67% | 0.36[0.01,8.7]              |
| Lienhardt 2011    | 1/15     | 1/16    |                             | 28.54% | 1.07[0.07,15.57]            |

Total (95% CI) 238 253 100% 0.76[0.15,3.77]

Total events: 2 (FDCs), 3 (SDF)
Heterogeneity: Tau^2=0; Chi^2=0.33, df=2(P=0.85); I^2=0%
Test for overall effect: Z=0.34(P=0.74)

### Analysis 1.9. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 9 Patient satisfaction.

#### 1.9.1 General satisfaction

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-----------------------------|
| Chaulet 1995      | 108/113  | 100/109 |                             | 100%   | 1.04[0.97,1.12]            |
| Subtotal (95% CI) | 113      | 109     |                             | 100%   | 1.04[0.97,1.12]            |

Total events: 108 (FDCs), 100 (SDF)
Heterogeneity: Not applicable
Test for overall effect: Z=1.16(P=0.24)

#### 1.9.2 No problems on swallowing

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-----------------------------|
| Bartacek 2009     | 483/503  | 487/520 |                             | 100%   | 1.03[1.06]                 |
| Subtotal (95% CI) | 503      | 520     |                             | 100%   | 1.03[1.06]                 |

Total events: 483 (FDCs), 487 (SDF)
Heterogeneity: Not applicable
Test for overall effect: Z=1.71(P=0.09)

#### 1.9.3 Convenient number of tablets

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-----------------------------|
| Bartacek 2009     | 410/515  | 282/530 |                             | 100%   | 1.5[1.37,1.64]             |
| Subtotal (95% CI) | 515      | 530     |                             | 100%   | 1.5[1.37,1.64]             |

Total events: 410 (FDCs), 282 (SDF)
Heterogeneity: Not applicable
Test for overall effect: Z=8.68(P=0.0001)

#### 1.9.4 Acceptable taste

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-----------------------------|
| Bartacek 2009     | 402/515  | 298/529 |                             | 100%   | 1.39[1.27,1.51]            |
| Subtotal (95% CI) | 515      | 529     |                             | 100%   | 1.39[1.27,1.51]            |

Total events: 402 (FDCs), 298 (SDF)
Heterogeneity: Not applicable
Test for overall effect: Z=7.27(P=0.0001)
### Analysis 1.10. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 10 Serious adverse events.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-------------------------------|
| RCTAI 1989        | 1/102    | 0/108   | 1.79%                       | 3.17[0.13,77.05] |
| Munteanu 2004     | 0/20     | 0/20    | Not estimable               |        |                               |
| Zaka-Ur-Rehman 2008 | 0/194 | 1/99    | 7.29%                       | 0.17[0.01,4.16] |
| Bartacek 2009     | 29/558   | 18/564  | 65.78%                      | 1.63[0.92,2.9] |
| Lienhardt 2011    | 4/797    | 5/784   | 18.52%                      | 0.79[0.21,2.92] |
| Wu 2015           | 4/64     | 2/78    | 6.62%                       | 2.44[0.46,12.88] |
| **Total (95% CI)** | **1735** | **1653** | **100%**                   | **1.45[0.9,2.33]** |

Total events: 38 (FDCs), 26 (SDF)

Heterogeneity: Tau²=0; Chi²=3.32, df=4(P=0.51); I²=0%

Test for overall effect: Z=1.52(P=0.13)

| Favours FDCs | 0.01 | 0.1 | 1 | 10 | 100 |
|--------------|------|-----|---|----|-----|
| Favours SDF  |      |     |   |    |     |

### Analysis 1.11. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 11 Adverse events leading to discontinuation of therapy.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Random, 95% CI | Weight | Risk Ratio M-H, Random, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-------------------------------|
| Geiter 1987       | 15/122   | 29/416  | 16.77%                      | 1.76[0.98,3.18] |
| RCTAI 1989        | 22/102   | 30/108  | 17.96%                      | 0.78[0.48,1.25] |
| Chauvet 1995      | 0/118    | 3/123   | 2.94%                       | 0.15[0.01,2.85] |
| Zhang 1996        | 0/102    | 1/103   | 2.57%                       | 0.34[0.01,8.17] |
| Zhu 1998          | 0/258    | 13/90   | 3.2%                        | 0.01[0.02] |
| Teo 1999          | 7/132    | 4/139   | 10.35%                      | 1.84[0.55,6.15] |
| Su 2002           | 3/57     | 2/48    | 6.66%                       | 1.26[0.22,7.25] |
| Munteanu 2004     | 0/20     | 0/20    | Not estimable               |        |                               |
| Suryanto 2008     | 0/236    | 2/198   | 2.81%                       | 0.17[0.01,3.48] |
| Zaka-Ur-Rehman 2008 | 0/194 | 2/99    | 2.82%                       | 0.1[0.2,12] |
| Bartacek 2009     | 25/558   | 15/564  | 16.32%                      | 1.68[0.9,3.16] |
| Lienhardt 2011    | 16/797   | 9/784   | 14.29%                      | 1.75[0.78,3.93] |
| Wu 2015           | 1/64     | 1/78    | 3.32%                       | 1.22[0.08,19.1] |
| **Total (95% CI)** | **2760** | **2770** | **100%**                   | **0.96[0.56,1.66]** |

Total events: 89 (FDCs), 111 (SDF)

Heterogeneity: Tau²=0.37; Chi²=25.57, df=11(P=0.01); I²=56.99%

Test for overall effect: Z=0.13(P=0.89)

| Favours FDCs | 0.01 | 0.1 | 1 | 10 | 100 |
|--------------|------|-----|---|----|-----|
| Favours SDF  |      |     |   |    |     |

### Analysis 1.12. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 12 Other adverse events.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-------------------------------|
| Geiter 1987       | 6/122    | 8/416   | 1.43%                       | 2.56[0.9,7.23] |

| Favours FDCs | 0.2 | 0.5 | 1 | 2 | 5 |
|--------------|-----|-----|---|---|---|
| Favours SDF  |     |     |   |   |   |
## Comparison 2. Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---------------------------|----------------|---------------------|--------------------|-------------|
| **1 Treatment failure**   | 7              | 3606                | Risk Ratio (M-H, Fixed, 95% CI) | 1.28 [0.82, 2.00] |
| 1.1 High or unclear risk of selection bias | 5 | 1099 | Risk Ratio (M-H, Fixed, 95% CI) | 1.77 [0.67, 4.69] |
| 1.2 Low risk of selection bias | 2 | 2507 | Risk Ratio (M-H, Fixed, 95% CI) | 1.17 [0.70, 1.93] |
| **2 Relapse**             | 10             | 3621                | Risk Ratio (M-H, Fixed, 95% CI) | 1.28 [1.00, 1.64] |
| 2.1 High or unclear risk of selection bias | 8 | 1328 | Risk Ratio (M-H, Fixed, 95% CI) | 2.84 [1.34, 6.00] |
| 2.2 Low risk of selection bias | 2 | 2293 | Risk Ratio (M-H, Fixed, 95% CI) | 1.12 [0.86, 1.46] |
| **3 Death**               | 11             | 4800                | Risk Ratio (M-H, Fixed, 95% CI) | 0.96 [0.67, 1.39] |
| 3.1 High or unclear risk of selection bias | 9 | 2330 | Risk Ratio (M-H, Fixed, 95% CI) | 0.86 [0.57, 1.32] |
| 3.2 Low risk of selection bias | 2 | 2470 | Risk Ratio (M-H, Fixed, 95% CI) | 1.35 [0.63, 2.93] |
| **4 Sputum smear or culture conversion at 2 months of starting treatment** | 13 | 4836 | Risk Ratio (M-H, Fixed, 95% CI) | 1.01 [0.99, 1.03] |
| 4.1 High or unclear risk of selection bias | 11 | 2507 | Risk Ratio (M-H, Fixed, 95% CI) | 1.04 [1.01, 1.06] |
| 4.2 Low risk of selection bias | 2 | 2329 | Risk Ratio (M-H, Fixed, 95% CI) | 0.99 [0.95, 1.02] |
| Outcome or subgroup title                                      | No. of studies | No. of participants | Statistical method                  | Effect size          |
|---------------------------------------------------------------|----------------|---------------------|------------------------------------|----------------------|
| 5 Sputum smear or culture conversion at EOT                   | 7              | 2319                | Risk Ratio (M-H, Fixed, 95% CI)    | 0.99 [0.96, 1.02]    |
| 5.1 High or unclear risk of selection bias                    | 6              | 1160                | Risk Ratio (M-H, Fixed, 95% CI)    | 1.00 [0.98, 1.03]    |
| 5.2 Low risk of selection bias                                | 1              | 1159                | Risk Ratio (M-H, Fixed, 95% CI)    | 0.97 [0.92, 1.03]    |
| 6 Acquisition of drug resistance                              | 3              | 491                 | Risk Ratio (M-H, Fixed, 95% CI)    | 0.76 [0.15, 3.77]    |
| 6.1 High or unclear risk of selection bias                    | 2              | 460                 | Risk Ratio (M-H, Fixed, 95% CI)    | 0.64 [0.08, 4.79]    |
| 6.2 Low risk of selection bias                                | 1              | 31                  | Risk Ratio (M-H, Fixed, 95% CI)    | 1.07 [0.07, 15.57]   |
| 7 Serious adverse events                                     | 6              | 3388                | Risk Ratio (M-H, Fixed, 95% CI)    | 1.45 [0.90, 2.33]    |
| 7.1 High or unclear risk of selection bias                    | 4              | 685                 | Risk Ratio (M-H, Fixed, 95% CI)    | 1.47 [0.46, 4.71]    |
| 7.2 Low risk of selection bias                                | 2              | 2703                | Risk Ratio (M-H, Fixed, 95% CI)    | 1.44 [0.86, 2.44]    |
| 8 Adverse events leading to discontinuation of therapy        | 13             | 5530                | Risk Ratio (M-H, Random, 95% CI)   | 0.96 [0.56, 1.66]    |
| 8.1 High or unclear risk of selection bias                    | 11             | 2827                | Risk Ratio (M-H, Random, 95% CI)   | 0.67 [0.31, 1.43]    |
| 8.2 Low risk of selection bias                                | 2              | 2703                | Risk Ratio (M-H, Random, 95% CI)   | 1.71 [1.04, 2.81]    |
| 9 Other adverse events                                        | 9              | 4639                | Risk Ratio (M-H, Fixed, 95% CI)    | 0.85 [0.72, 1.00]    |
| 9.1 High or unclear risk of selection bias                    | 7              | 1936                | Risk Ratio (M-H, Fixed, 95% CI)    | 0.87 [0.71, 1.07]    |
| 9.2 Low risk of selection bias                                | 2              | 2703                | Risk Ratio (M-H, Fixed, 95% CI)    | 0.82 [0.63, 1.07]    |

**Analysis 2.1. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 1 Treatment failure.**

| Study or subgroup                                      | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|--------------------------------------------------------|----------|---------|-------------------------------|--------|-------------------------------|
| 2.1.1 High or unclear risk of selection bias           |          |         |                               |        |                               |
| Chaulet 1995                                           | 1/102    | 1/107   |                               | 2.91%  | 1.05 [0.07, 16.55]            |
| Teo 1999                                               | 2/154    | 1/153   |                               | 2.99%  | 1.99 [0.18, 21.69]            |
| Su 2002                                                | 0/26     | 0/25    |                               | 2.99%  | Not estimable                 |
| Suryanto 2008                                          | 9/236    | 4/198   |                               | 12.97% | 1.89 [0.59, 6.04]             |
| Wu 2015                                                | 0/49     | 0/49    |                               | Not estimable |                         |
| Subtotal (95% CI)                                      | 567      | 532     |                               | 18.88% | 1.77 [0.67, 4.69]            |

Favours FDCs 0.02 0.1 1 10 50 Favours SDF
### Analysis 2.2. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 2 Relapse.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| **2.2.1 High or unclear risk of selection bias** |       |       |            |        |            |
| RCTAI 1989        | 1/64 | 1/71 | 0.96%      | 0.96%  | 1.11[0.07,17.37] |
| Chaulet 1995      | 1/102| 0/107| 0.49%      | 0.49%  | 3.15[0.13,76.34] |
| Zhang 1996        | 2/101| 2/101| 2.02%      | 2.02%  | 1[0.14,6.96] |
| Teo 1999          | 11/121| 3/130| 2.93%      | 2.93%  | 3.94[1.13,13.78] |
| Su 2002           | 1/26 | 0/25 | 0.52%      | 0.52%  | 2.89[0.12,67.75] |
| Zaka-Ur-Rehman 2008 | 0/141| 0/69 | Not estimable |        |            |
| Suryanto 2008     | 10/99| 2/73 | 2.33%      | 2.33%  | 3.69[0.83,16.32] |
| Wu 2015           | 0/49 | 0/49 | Not estimable |        |            |
| **Subtotal (95% CI)** | 703  | 625  | 9.25%      | 9.25%  | 2.84[1.34,6] |
| **Total events**  | 26 (FDCs), 8 (SDF) |  |  |  |  |
| **Heterogeneity** | Tau=0; Chi²=1.94, df=5(P=0.86); I²=0% |  |  |  |  |
| **Test for overall effect** | Z=2.73(P=0.01) |  |  |  |  |
| **2.2.2 Low risk of selection bias** |       |       |            |        |            |
| Bartacek 2009     | 74/468| 69/477| 69.18%     | 69.18% | 1.09[0.81,1.48] |
| Lienhardt 2011    | 26/684| 21/664| 21.57%     | 21.57% | 1.2[0.68,2.11] |
| **Subtotal (95% CI)** | 1152 | 1141 | 90.75%     | 90.75% | 1.12[0.86,1.46] |
| **Total events**  | 100 (FDCs), 90 (SDF) |  |  |  |  |
| **Heterogeneity** | Tau=0; Chi²=0.08, df=1(P=0.77); I²=0% |  |  |  |  |
| **Test for overall effect** | Z=0.83(P=0.41) |  |  |  |  |
| **Total (95% CI)** | 1855 | 1766 | 100% | 100% | 1.28[1.16,1.44] |
| **Total events**  | 126 (FDCs), 98 (SDF) |  |  |  |  |
| **Heterogeneity** | Tau=0; Chi²=6.76, df=7(P=0.45); I²=0% |  |  |  |  |
| **Test for subgroup differences** | Chi²=0.56, df=1 (P=0.45), I²=0% |  |  |  |  |
| **Favours FDCs** | 0.02  | 0.1  | 1  | 10 | 50 |
| **Favours SDF** | 0.02  | 0.1  | 1  | 10 | 50 |
| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| **Test for overall effect:** Z=1.93 (P=0.05) <br>Test for subgroup differences: Chi²=5.28, df=1 (P=0.02), I²=81.05% |
| Favours FDCs 0.1 0.2 0.5 1 2 5 10 | Favours SDF |

**Analysis 2.3. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 3 Death.**

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| **2.3.1 High or unclear risk of selection bias** |
| Geiter 1987 | 2/122 | 13/416 | 10.67% | 0.52[0.12,2.29] |
| RCTAI 1989 | 1/102 | 0/108 | 0.88% | 3.17[0.13,77.05] |
| Zhang 1996 | 2/102 | 1/103 | 1.8% | 2.02[0.19,21.93] |
| Zhu 1998 | 0/227 | 0/81 | Not estimable |
| Teo 1999 | 8/132 | 6/139 | 10.57% | 1.4[0.5,3.94] |
| Su 2002 | 7/57 | 2/48 | 3.93% | 2.95[0.13,77.05] |
| Suryanto 2008 | 11/173 | 18/149 | 34.99% | 0.53[0.26,1.08] |
| Zaka-Ur-Rehman 2008 | 0/141 | 1/69 | Not estimable |
| Wu 2015 | 6/75 | 8/86 | 13.48% | 0.86[0.31,2.37] |
| **Subtotal (95% CI)** | 1131 | 1199 | 79.95% | 0.86[0.57,1.32] |
| **Total events:** (FD Cs), 49 (SDF) |
| Heterogeneity: Tau²=0; Chi²=7.78, df=7(P=0.35); I²=10.07% |
| Test for overall effect: Z=0.68 (P=0.49) |

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| **2.3.2 Low risk of selection bias** |
| Bartacek 2009 | 11/558 | 4/564 | 7.2% | 2.78[0.89,8.68] |
| Lienhardt 2011 | 4/684 | 7/664 | 12.85% | 0.55[0.16,1.89] |
| **Subtotal (95% CI)** | 1242 | 1228 | 20.05% | 1.35[0.63,2.93] |
| **Total events:** (FD Cs), 11 (SDF) |
| Heterogeneity: Tau²=0; Chi²=3.58, df=1(P=0.06); I²=72.03% |
| Test for overall effect: Z=0.77 (P=0.44) |

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| **Total (95% CI)** | 2373 | 2427 | 100% | 0.96[0.67,1.39] |
| **Total events:** (FD Cs), 52 (SDF) |
| Heterogeneity: Tau²=0; Chi²=12.21, df=9(P=0.05); I²=26.77% |
| Test for overall effect: Z=0.21 (P=0.84) |
| Test for subgroup differences: Chi²=1, df=1(P=0.32), I²=0.36% |

**Analysis 2.4. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment.**

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| **2.4.1 High or unclear risk of selection bias** |
| Geiter 1987 | 106/122 | 323/416 | 7.38% | 1.12[1.03,1.22] |
| RCTAI 1989 | 67/70 | 73/76 | 3.53% | 1[0.93,1.07] |
| **Favours SDF** | **Favours FDCs** |
## Analysis 2.5. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 5 Sputum smear or culture conversion at EOT.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-------------------------------|--------|-------------------------------|
| **2.5.1 High or unclear risk of selection bias** |
| RCTA 1989        | 64/66    | 71/74   |                               | 6.65%  | 1.01[0.95,1.08]               |
| Zhang 1996       | 101/102  | 101/103 |                               | 9.99%  | 1.01[0.98,1.04]               |
| Zhu 1998         | 224/227  | 79/81   |                               | 11.57% | 1.01[0.97,1.05]               |
| Su 2002          | 25/26    | 25/25   |                               | 2.58%  | 0.96[0.87,1.07]               |
| Suryanto 2008    | 188/198  | 152/160 |                               | 16.7%  | 1.0[0.95,1.05]                |
| Wu 2015          | 49/49    | 49/49   |                               | 4.92%  | 1.0[0.96,1.04]                |
| **Subtotal (95% CI)** | 668      | 492     |                               | 52.41% | 1[0.98,1.03]                  |
| Total events:    | 651 (FDCs), 477 (SDF) |
| Heterogeneity:   | Tau²=0; Chi²=5.05, df=1 (P=0.02), I²=80.2% |
| Test for overall effect: Z=0.35 (P=0.72) |

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-------------------------------|--------|-------------------------------|
| **2.5.2 Low risk of selection bias** |
| Bartacek 2009    | 468/582  | 477/577 |                               | 47.59% | 0.97[0.92,1.03]               |
| **Subtotal (95% CI)** | 582      | 577     |                               | 47.59% | 0.97[0.92,1.03]               |

Favours SDF: 1
Favours FDCs: 1
### Analysis 2.6. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 6 Acquisition of drug resistance.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Total (95% CI)    | 1250 | 1069| 0.99 [0.96, 1.02] | 100%   | 0.99 [0.96, 1.02] |
| Total events: 468 (FDCs), 477 (SDF) | | | |
| Heterogeneity: Not applicable | | | |
| Test for overall effect: Z=0.99 (P=0.32) | | | |

- **2.6.1 High or unclear risk of selection bias**
  - Chaulet 1995: 1/102 (FDCs), 1/107 (SDF), 28.79%, 1.05 [0.07, 16.55]
  - Teo 1999: 0/121 (FDCs), 1/130 (SDF), 42.67%, 0.36 [0.01, 8.7]
  - Subtotal (95% CI): 223 (FDCs), 237 (SDF), 71.46%, 0.64 [0.08, 4.79]
  - Total events: 1 (FDCs), 2 (SDF)
  - Heterogeneity: Tau²=0; Chi²=4.42, df=6 (P=0.64); I²=0%
  - Test for overall effect: Z=0.77 (P=0.44)
  - Test for subgroup differences: Chi²=1.1, df=1 (P=0.29), I²=9.42%

- **2.6.2 Low risk of selection bias**
  - Lienhardt 2011: 1/15 (FDCs), 1/16 (SDF), 28.54%, 1.07 [0.07, 15.57]
  - Subtotal (95% CI): 15 (FDCs), 16 (SDF), 28.54%, 1.07 [0.07, 15.57]
  - Total events: 1 (FDCs), 1 (SDF)
  - Heterogeneity: Not applicable
  - Test for overall effect: Z=0.44 (P=0.66)
  - Total (95% CI): 238 (FDCs), 253 (SDF), 71.46%, 0.64 [0.08, 4.79]
  - Total events: 2 (FDCs), 3 (SDF)
  - Heterogeneity: Tau²=0; Chi²=0.33, df=2 (P=0.85); I²=0%
  - Test for overall effect: Z=0.34 (P=0.74)
  - Test for subgroup differences: Chi²=0.09, df=1 (P=0.76), I²=0%

### Analysis 2.7. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 7 Serious adverse events.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Total (95% CI)    | 100% | 100%| 0.76 [0.15, 3.77] | 100%   | 0.76 [0.15, 3.77] |
| Total events: 2 (FDCs), 3 (SDF) | | | |
| Heterogeneity: Tau²=0; Chi²=0.33, df=2 (P=0.85); I²=0% | | | |
| Test for overall effect: Z=0.34 (P=0.74) | | | |
| Test for subgroup differences: Chi²=0.09, df=1 (P=0.76), I²=0% | | | |

- **2.7.1 High or unclear risk of selection bias**
  - RCTAI 1989: 1/102 (FDCs), 0/108 (SDF), 1.79%, 3.17 [0.13, 77.05]
  - Munteanu 2004: 0/20 (FDCs), 0/20 (SDF), Not estimable
  - Zaka-Un-Rehman 2008: 0/194 (FDCs), 1/99 (SDF), 7.29%, 0.17 [0.01, 4.16]

---

*Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)*

Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------------------|------|-----|------------|--------|------------|
| **Wu 2015**      | 4/64 | 2/78| M-H, Fixed, 95% CI | 6.62% | 2.44[0.46,12.88] |
| **Subtotal (95% CI)** | 380 | 305| M-H, Fixed, 95% CI | 15.7% | 1.47[0.46,4.71] |

**Total events:** 5 (FDCs), 3 (SDF)

**Heterogeneity:** Tau²=0; Chi²=2.32, df=2(P=0.31); I²=13.97%

**Test for overall effect:** Z=0.65(P=0.52)

2.7.2 **Low risk of selection bias**

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------------------|------|-----|------------|--------|------------|
| **Bartacek 2009** | 29/558| 18/564| M-H, Random, 95% CI | 65.78% | 1.63[0.92,2.90] |
| **Lienhardt 2011** | 4/797| 5/784| M-H, Random, 95% CI | 18.52% | 0.79[0.21,2.92] |
| **Subtotal (95% CI)** | 1355 | 1348| M-H, Random, 95% CI | 84.3% | 1.44[0.86,2.44] |

**Total events:** 33 (FDCs), 23 (SDF)

**Heterogeneity:** Tau²=0; Chi²=0.99, df=1(P=0.32); I²=0%

**Test for overall effect:** Z=1.38(P=0.17)

**Test for subgroup differences:** Chi²=0, df=1(P=0.98), I²=0%

### Analysis 2.8. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 8 Adverse events leading to discontinuation of therapy.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------------------|------|-----|------------|--------|------------|
| **Geiter 1987** | 15/122| 29/416| M-H, Random, 95% CI | 16.77% | 1.76[0.98,3.18] |
| **RCTAI 1989** | 22/102| 30/108| M-H, Random, 95% CI | 17.96% | 0.78[0.48,1.25] |
| **Chaulet 1995** | 0/118| 3/123| M-H, Random, 95% CI | 2.94% | 0.15[0.01,2.85] |
| **Zhang 1996** | 0/102| 1/103| M-H, Random, 95% CI | 2.57% | 0.34[0.01,8.17] |
| **Zhu 1998** | 0/258| 13/90| M-H, Random, 95% CI | 3.2% | 0.01[0.22] |
| **Teo 1999** | 7/132| 4/139| M-H, Random, 95% CI | 10.35% | 1.84[0.55,6.15] |
| **Su 2002** | 3/57| 2/48| M-H, Random, 95% CI | 6.66% | 1.26[0.22,7.25] |
| **Munteanu 2004** | 0/20| 0/20| Not estimable |  |  |
| **Zaka-Ur-Rehman 2008** | 0/194| 2/99| M-H, Random, 95% CI | 2.82% | 0.1[0.22] |
| **Suryanto 2008** | 0/236| 2/198| M-H, Random, 95% CI | 2.81% | 0.17[0.01,3.48] |
| **Wu 2015** | 1/64| 1/78| M-H, Random, 95% CI | 3.32% | 1.22[0.08,19.1] |
| **Subtotal (95% CI)** | 1405 | 1422| M-H, Random, 95% CI | 69.39% | 0.67[0.31,1.43] |

**Total events:** 48 (FDCs), 87 (SDF)

**Heterogeneity:** Tau²=0.63; Chi²=23.05, df=9(P=0.01); I²=60.95%

**Test for overall effect:** Z=1.04(P=0.3)

2.8.2 **Low risk of selection bias**

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------------------|------|-----|------------|--------|------------|
| **Bartacek 2009** | 25/558| 15/564| M-H, Random, 95% CI | 16.32% | 1.68[0.9,3.16] |
| **Lienhardt 2011** | 16/797| 9/784| M-H, Random, 95% CI | 14.29% | 1.75[0.78,3.93] |
| **Subtotal (95% CI)** | 1355 | 1348| M-H, Random, 95% CI | 30.61% | 1.71[1.04,2.81] |

**Total events:** 41 (FDCs), 24 (SDF)

**Heterogeneity:** Tau²=0; Chi²=0.01, df=1(P=0.94); I²=0%

**Test for subgroup differences:** Chi²=0, df=1(P=0.98), I²=0%
### Analysis 2.9. Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 9 Other adverse events.

#### 2.9.1 High or unclear risk of selection bias

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Geiter 1987       | 6/122| 8/416| 1.43% | 2.56[0.8,7.23] |
| Chaulet 1995      | 23/118| 41/123| 15.77% | 0.58[0.38,0.91] |
| Zhang 1996        | 12/102| 15/103| 5.86% | 0.81[0.4,1.64] |
| Zhu 1998          | 23/258| 8/90 | 4.66% | 1[0.47,2.16] |
| Teo 1999          | 45/132| 45/139| 17.22% | 1.05[0.75,1.48] |
| Muntenau 2004     | 0/20 | 0/20 | Not estimable |
| Zaka-Ur-Rehman 2008 | 40/194 | 26/99 | 13.52% | 0.79[0.51,1.21] |
| **Subtotal (95% CI)** | 946 | 990 | 58.47% | 0.87[0.71,1.07] |

Total events: 149 (FDCs), 143 (SDF)

Heterogeneity: Tau²=0; Chi²=8.83, df=5(P=0.12); I²=43.39%

Test for overall effect: Z=1.31(P=0.19)

#### 2.9.2 Low risk of selection bias

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Bartacek 2009     | 75/558| 84/564| 32.82% | 0.9[0.68,1.2] |
| Lienhardt 2011    | 11/797| 22/784| 8.71% | 0.49[0.24,1.01] |
| **Subtotal (95% CI)** | 1355 | 1348 | 41.53% | 0.82[0.63,1.07] |

Total events: 86 (FDCs), 106 (SDF)

Heterogeneity: Tau²=0; Chi²=2.38, df=1(P=0.12); I²=58.02%

Test for overall effect: Z=1.49(P=0.14)

Total (95% CI)

| Total (95% CI) | 2301 | 2338 | 100% | 0.85[0.72,1] |

Total events: 235 (FDCs), 249 (SDF)

Heterogeneity: Tau²=0; Chi²=11.33, df=7(P=0.13); I²=38.19%

Test for overall effect: Z=1.97(P=0.05)

Test for subgroup differences: Chi²=0.15, df=1 (P=0.7), I²=0%

---

**Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)**

Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
### Comparison 3. Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat (ITT)

| Outcome or subgroup title                                                                 | No. of studies | No. of participants | Statistical method | Effect size          |
|------------------------------------------------------------------------------------------|----------------|---------------------|-------------------|---------------------|
| 1 Treatment failure (ITT analysis and all losses to follow-up judged as failure)       | 7              | 4004                | Risk Ratio (M-H, Fixed, 95% CI) | 1.03 [0.93, 1.14] |
| 2 Relapse (ITT analysis and all losses to follow-up judged as relapse)                   | 10             | 4716                | Risk Ratio (M-H, Fixed, 95% CI) | 1.05 [0.95, 1.16] |
| 3 Sputum smear or culture conversion at 2 months of starting treatment (ITT analysis and all losses to follow-up judged as conversion failure) | 13             | 5731                | Risk Ratio (M-H, Fixed, 95% CI) | 1.00 [0.97, 1.03] |
| 4 Sputum smear or culture conversion at EOT (ITT analysis and all losses to follow-up judged as conversion failure) | 7              | 2552                | Risk Ratio (M-H, Fixed, 95% CI) | 0.99 [0.95, 1.02] |

### Analysis 3.1. Comparison 3 Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat (ITT), Outcome 1 Treatment failure (ITT analysis and all losses to follow-up judged as failure).

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|------------------------------|--------|-----------------------------|
| Chaulet 1995      | 23/124   | 20/126  | 3.97%                        | 0.96   | 1.17 [0.68, 2.02]           |
| Teo 1999          | 25/155   | 17/155  | 3.4%                         | 0.97   | 1.47 [0.83, 2.61]           |
| Su 2002           | 31/57    | 23/48   | 4.99%                        | 1.09   | 1.00 [0.69, 1.46]           |
| Suryanto 2008     | 93/236   | 80/194  | 17.4%                        | 0.97   | 1.00 [0.77, 1.33]           |
| Bartacek 2009     | 203/582  | 184/577 | 36.96%                       | 1.06   | 1.00 [0.83, 1.27]           |
| Lienhardt 2011    | 124/798  | 131/787 | 36.96%                       | 1.06   | 1.00 [0.83, 1.27]           |
| Wu 2015           | 26/75    | 37/86   | 6.89%                        | 0.93   | 1.00 [0.77, 1.33]           |
| Total (95% CI)    | 2027     | 1977    | 100%                         | 1.03   | 1.03 [0.93, 1.14]           |

Heterogeneity: Tau²=0; Chi²=4.89, df=6(P=0.56); I²=0%
Test for overall effect: Z=0.54(P=0.59)

### Analysis 3.2. Comparison 3 Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat (ITT), Outcome 2 Relapse (ITT analysis and all losses to follow-up judged as relapse).

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|------------------------------|--------|-----------------------------|
| RCTAI 1989        | 10/102   | 11/108  | 1.9%                         | 1.94   | 0.96 [0.43, 2.17]           |
| Chaulet 1995      | 23/124   | 19/126  | 3.35%                        | 1.72   | 1.23 [0.71, 2.14]           |
| Zhang 1996        | 6/104    | 6/105   | 1.06%                        | 1.72   | 1.23 [0.71, 2.14]           |
| Teo 1999          | 45/155   | 28/155  | 4.98%                        | 1.61   | 1.61 [1.06, 2.44]           |
| Su 2002           | 32/57    | 23/48   | 4.44%                        | 1.72   | 1.72 [1.06, 2.44]           |

Heterogeneity: Tau²=0; Chi²=4.89, df=6(P=0.56); I²=0%
Test for overall effect: Z=0.54(P=0.59)
### Analysis 3.3. Comparison 3 Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat (ITT), Outcome 3 Sputum smear or culture conversion at 2 months of starting treatment (ITT analysis and all losses to follow-up judged as conversion failure).

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio     | Weight | Risk Ratio     |
|-------------------|----------|---------|----------------|--------|----------------|
|                    |          |         | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Zaka-Ur-Rehman 2008 | 53/194   | 30/99   |                | 7.07%  | 0.9[0.62,1.31]  |
| Suryanto 2008      | 94/236   | 78/198  |                | 15.09% | 1.01[0.81,1.28] |
| Bartacek 2009      | 188/582  | 169/577 |                | 30.19% | 1.1[0.93,1.31]  |
| Lienhardt 2011     | 140/798  | 144/787 |                | 25.79% | 0.96[0.78,1.18] |
| Wu 2015            | 26/75    | 37/86   |                | 6.13%  | 0.81[0.54,1.2]  |
| **Total (95% CI)** | **2427** | **2289**|                | **100%**| **1.05[0.95,1.16]** |

Total events: 617 (FDCs), 545 (SDF)

Heterogeneity: Tau²=0; Chi²=8.2, df=9(P=0.51); I²=0%

Test for overall effect: Z=0.94(P=0.34)

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio     | Weight | Risk Ratio     |
|-------------------|----------|---------|----------------|--------|----------------|
|                    |          |         | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Geiter 1987        | 106/169  | 323/532 |                | 7.78%  | 1.03[0.9,1.18]  |
| RCTAI 1989         | 67/102   | 73/108  |                | 3.54%  | 0.97[0.8,1.18]  |
| Chaulet 1995       | 90/124   | 99/126  |                | 4.9%   | 0.92[0.8,1.06]  |
| Zhang 1996         | 101/104  | 99/105  |                | 4.92%  | 1.03[0.97,1.09] |
| Zhu 1998           | 207/258  | 70/90   |                | 5.18%  | 1.03[0.91,1.17] |
| Teo 1999           | 124/155  | 133/155 |                | 6.64%  | 0.93[0.84,1.03] |
| Su 2002            | 23/57    | 24/48   |                | 1.3%   | 0.81[0.53,1.23] |
| Munteanu 2004      | 14/20    | 15/20   |                | 0.75%  | 0.93[0.64,1.37] |
| Suryanto 2008      | 186/198  | 143/162 |                | 7.86%  | 1.06[1.19,14]   |
| Zaka-Ur-Rehman 2008| 187/194  | 94/99   |                | 6.22%  | 1.02[0.96,1.07] |
| Zhang 1996         | 449/582  | 469/577 |                | 23.52% | 0.95[0.89,1.01] |
| Lienhardt 2011     | 521/798  | 501/787 |                | 25.19% | 1.03[0.95,1.11] |
| Wu 2015            | 47/75    | 47/86   |                | 2.19%  | 1.15[0.88,1.49] |
| **Total (95% CI)** | **2836** | **2895**|                | **100%**| **1[0.97,1.03]** |

Total events: 2122 (FDCs), 2090 (SDF)

Heterogeneity: Tau²=0; Chi²=14.21, df=12(P=0.29); I²=15.56%

Test for overall effect: Z=0.18(P=0.85)

Analysis 3.4. Comparison 3 Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat (ITT), Outcome 4 Sputum smear or culture conversion at EOT (ITT analysis and all losses to follow-up judged as conversion failure).

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio     | Weight | Risk Ratio     |
|-------------------|----------|---------|----------------|--------|----------------|
|                    |          |         | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| RCTAI 1989         | 64/102   | 71/108  |                | 6.86%  | 0.95[0.78,1.17] |
| Zhang 1996         | 101/104  | 101/105 |                | 9.99%  | 1.01[0.96,1.06] |
| Zhu 1998           | 224/258  | 79/90   |                | 11.65% | 0.99[0.91,1.08] |

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio     | Weight | Risk Ratio     |
|-------------------|----------|---------|----------------|--------|----------------|
|                    |          |         | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |

**Favours SDF**

**Favours FDCs**
### Comparison 4. Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---------------------------|----------------|---------------------|--------------------|-------------|
| 1 Treatment failure       | 7              | 3606                | Risk Ratio (M-H, Fixed, 95% CI) | 1.28 [0.82, 2.00] |
| 1.1 Fixed-dose combinations (FDCs) only at intensive phase | 1 | 307 | Risk Ratio (M-H, Fixed, 95% CI) | 1.99 [0.18, 21.69] |
| 1.2 FDCs during all treatment | 6 | 3299 | Risk Ratio (M-H, Fixed, 95% CI) | 1.26 [0.80, 1.99] |
| 2 Relapse                 | 10             | 3621                | Risk Ratio (M-H, Fixed, 95% CI) | 1.28 [1.00, 1.64] |
| 2.1 FDCs only at intensive phase | 1 | 251 | Risk Ratio (M-H, Fixed, 95% CI) | 3.94 [1.13, 13.78] |
| 2.2 FDCs during all treatment | 9 | 3370 | Risk Ratio (M-H, Fixed, 95% CI) | 1.20 [0.93, 1.55] |
| 3 Death                   | 11             | 4800                | Risk Ratio (M-H, Fixed, 95% CI) | 0.96 [0.67, 1.39] |
| 3.1 FDCs only at intensive phase | 1 | 271 | Risk Ratio (M-H, Fixed, 95% CI) | 1.40 [0.50, 3.94] |
| 3.2 FDCs during all treatment | 10 | 4529 | Risk Ratio (M-H, Fixed, 95% CI) | 0.91 [0.61, 1.35] |
| 4 Sputum smear or culture conversion at 2 months of starting treatment | 13 | 4836 | Risk Ratio (M-H, Fixed, 95% CI) | 1.01 [0.99, 1.03] |
| 4.1 FDCs only at intensive phase | 1 | 269 | Risk Ratio (M-H, Fixed, 95% CI) | 1.01 [0.96, 1.07] |
| 4.2 FDCs during all treatment | 12 | 4567 | Risk Ratio (M-H, Fixed, 95% CI) | 1.01 [0.99, 1.03] |
| 5 Acquisition of drug resistance | 3 | 491 | Risk Ratio (M-H, Fixed, 95% CI) | 0.76 [0.15, 3.77] |
| 5.1 FDCs only at intensive phase | 1 | 251 | Risk Ratio (M-H, Fixed, 95% CI) | 0.36 [0.01, 8.70] |
| 5.2 FDCs during all treatment | 2 | 240 | Risk Ratio (M-H, Fixed, 95% CI) | 1.06 [0.15, 7.24] |
| 6 Adverse events leading to discontinuation of therapy | 13 | 5530 | Risk Ratio (M-H, Random, 95% CI) | 0.96 [0.56, 1.66] |
### Analysis 4.1. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 1 Treatment failure.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-----------------------------|
| **Favours FDCs**  |          |         |                             |        |                             |
| Teo 1999          | 2/154    | 1/153   | 2.99% 1.99[0.18,21.69]       |        |                             |
| **Subtotal (95% CI)** | 154 | 153 | 2.99% 1.99[0.18,21.69] |        |                             |
| **Total events:** | 2 (FDCs), 1 (SDF) | | | | |
| Heterogeneity: Not applicable | | | | | |
| Test for overall effect: Z=0.56 (P=0.57) | | | | | |
| **Favours SDF**   |          |         |                             |        |                             |
| Chaulet 1995      | 1/102    | 1/107   | 2.91% 1.05[0.07,16.55]       |        |                             |
| Su 2002           | 0/26     | 0/25    | Not estimable               |        |                             |
| Suryanto 2008     | 9/236    | 4/198   | 12.97% 1.89[0.59,6.04]       |        |                             |
| Bartacek 2009     | 22/582   | 19/577  | 56.91% 1.15[0.63,2.1]        |        |                             |
| Lienhardt 2011    | 10/864   | 8/664   | 24.21% 1.21[0.48,3.06]       |        |                             |
| Wu 2015           | 0/49     | 0/49    | Not estimable               |        |                             |
| **Subtotal (95% CI)** | 1679 | 1620 | 97.01% 1.26[0.8,1.99] |        |                             |
| **Total events:** | 42 (FDCs), 32 (SDF) | | | | |
| Heterogeneity: Tau^2=0; Chi^2=0.58, df=3(P=0.9); I^2=0% | | | | | |
| Test for overall effect: Z=1(P=0.32) | | | | | |
| **Total**         | 1833     | 1773    | 100% 1.28[0.82,2]            |        |                             |
| **Total events:** | 44 (FDCs), 33 (SDF) | | | | |
| Heterogeneity: Tau^2=0; Chi^2=0.72, df=4(P=0.95); I^2=0% | | | | | |
| Test for overall effect: Z=1.09(P=0.28) | | | | | |
| Test for subgroup differences: Chi^2=0.13, df=1 (P=0.71), I^2=0% | | | | | |
### Analysis 4.2. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 2 Relapse.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| **4.2.1 FDCs only at intensive phase** | | | | |
| Teo 1999          | 11/121 | 3/130 | 2.93% | 3.94(1.13,13.78) |
| **Subtotal (95% CI)** | 121 | 130 | 2.93% | 3.94(1.13,13.78) |
| Total events: 11 (FDCs), 3 (SDF) | | | | |
| Heterogeneity: Not applicable | | | | |
| Test for overall effect: Z=2.15(P=0.03) | | | | |
| **4.2.2 FDCs during all treatment** | | | | |
| RCTAI 1989        | 1/64 | 1/71 | 0.96% | 1.11(0.07,17.37) |
| Chaulet 1995      | 1/102 | 0/107 | 0.49% | 3.15(0.13,76.34) |
| Zhang 1996        | 2/101 | 2/101 | 2.02% | 1(0.14,6.96) |
| Su 2002           | 1/26 | 0/25 | 0.52% | 2.89(0.12,67.75) |
| Suryanto 2008     | 10/99 | 2/73 | 2.33% | 3.69(0.83,16.32) |
| Zaka-Ur-Rehman 2008 | 0/141 | | Not estimable | |
| Bartacek 2009     | 74/468 | 69/477 | 69.18% | 1.09(0.81,1.48) |
| Lienhardt 2011    | 26/684 | 21/664 | 21.57% | 1.2(0.68,2.11) |
| Wu 2015           | 0/49 | 0/49 | Not estimable | |
| **Subtotal (95% CI)** | 1734 | 1636 | 97.07% | 1.2(0.93,1.55) |
| Total events: 115 (FDCs), 95 (SDF) | | | | |
| Heterogeneity: Tau²=0; Chi²=3.23, df=6(P=0.78); I²=0% | | | | |
| Test for overall effect: Z=1.38(P=0.17) | | | | |
| **Total (95% CI)** | 1855 | 1766 | 100% | 1.28(1,1.64) |
| Total events: 126 (FDCs), 98 (SDF) | | | | |
| Heterogeneity: Tau²=0; Chi²=6.76, df=7(P=0.45); I²=0% | | | | |
| Test for overall effect: Z=1.93(P=0.05) | | | | |
| Test for subgroup differences: Chi²=3.33, df=1 (P=0.07), I²=69.99% | | | | |

### Analysis 4.3. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 3 Death.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| **4.3.1 FDCs only at intensive phase** | | | | |
| Teo 1999          | 8/132 | 6/139 | 10.57% | 1.4(0.5,3.94) |
| **Subtotal (95% CI)** | 132 | 139 | 10.57% | 1.4(0.5,3.94) |
| Total events: 8 (FDCs), 6 (SDF) | | | | |
| Heterogeneity: Not applicable | | | | |
| Test for overall effect: Z=0.64(P=0.52) | | | | |
| **4.3.2 FDCs during all treatment** | | | | |
| Geiter 1987       | 2/122 | 13/416 | 10.67% | 0.52(0.12,2.29) |
| RCTAI 1989        | 1/102 | 0/108 | 0.88% | 3.17(0.13,77.05) |
| Zhang 1996        | 2/102 | 1/103 | 1.8% | 2.02(0.19,21.93) |
| Zhu 1998          | 0/227 | 0/81 | Not estimable | |
| Su 2002           | 7/57 | 2/48 | 3.93% | 2.95(0.64,13.53) |
### Analysis 4.4. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment.

#### 4.4.1 FDCs only at intensive phase

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-------------------------------|--------|-------------------------------|
| Teo 1999          | 124/129  | 133/140 |                               | 6.42%  | 1.01[0.96,1.07]               |
| **Subtotal (95% CI)** | 129      | 140     |                               | 6.42%  | 1.01[0.96,1.07]               |

Total events: 124 (FDCs), 133 (SDF)
Heterogeneity: Not applicable
Test for overall effect: Z=0.45(P=0.65)

#### 4.4.2 FDCs during all treatment

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-------------------------------|--------|-------------------------------|
| Geiter 1987       | 106/122  | 323/416 |                               | 7.38%  | 1.12[1.03,1.22]               |
| RTCAI 1989        | 67/70    | 73/76   |                               | 3.53%  | 1.09[1.03,1.17]               |
| Chauvet 1995      | 90/95    | 99/108  |                               | 4.67%  | 1.03[0.96,1.11]               |
| Zhang 1996        | 101/102  | 99/103  |                               | 4.96%  | 1.03[0.99,1.08]               |
| Zhu 1998          | 207/227  | 70/81   |                               | 5.2%   | 1.06[0.96,1.16]               |
| Su 2002           | 23/26    | 24/25   |                               | 1.23%  | 0.92[0.79,1.08]               |
| Munteanu 2004     | 14/20    | 15/18   |                               | 0.8%   | 0.84[0.59,1.2]                |
| Zaka-Un-Rehman 2008 | 187/194  | 94/99   |                               | 6.27%  | 1.02[0.96,1.07]               |
| Suryanto 2008     | 186/198  | 143/160 |                               | 7.97%  | 1.05[0.99,1.12]               |
| Bartacek 2009     | 449/582  | 469/577 |                               | 23.72% | 0.95[0.89,1.01]               |
| Lienhardt 2011    | 521/591  | 501/579 |                               | 25.49% | 1.02[0.98,1.06]               |
| Wu 2015           | 47/49    | 47/49   |                               | 2.37%  | 1[0.92,1.09]                  |
| **Subtotal (95% CI)** | 2276     | 2291    |                               | 93.58% | 1.01[0.99,1.03]               |

Total events: 1998 (FDCs), 1957 (SDF)
Heterogeneity: Tau²=0; Chi²=15.74, df=11(P=0.15); I²=30.14%
Test for overall effect: Z=0.92(P=0.36)

Total (95% CI)
2405 2431 100% 1.01[0.99,1.03]

 Favours SDF 0.5 0.7 1 1.5 2 Favours FDCs
### Analysis 4.5. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 5 Acquisition of drug resistance.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| 4.5.1 FDCs only at intensive phase |   |   |               |        |            |
| Teo 1999          | 0/121 | 1/130 | 42.67% | 0.36 [0.01, 8.7] |
| **Subtotal (95% CI)** | 121 | 130 | 42.67% | 0.36 [0.01, 8.7] |
| Total events: 0 (FDCs), 1 (SDF) |   |   |            |        |            |
| Heterogeneity: Not applicable |   |   |            |        |            |
| Test for overall effect: Z=0.63 (P=0.53) |   |   |            |        |            |
| 4.5.2 FDCs during all treatment |   |   |            |        |            |
| Chaulet 1995      | 1/102 | 1/107 | 28.79% | 1.05 [0.07, 16.55] |
| Lienhardt 2011    | 1/15  | 1/16  | 28.54% | 1.07 [0.07, 15.57] |
| **Subtotal (95% CI)** | 117 | 123 | 57.33% | 1.06 [0.15, 7.24] |
| Total events: 2 (FDCs), 2 (SDF) |   |   |            |        |            |
| Heterogeneity: Tau²=0; Chi²=0.32, df=2(P=0.85); I²=0% |   |   |            |        |            |
| Test for overall effect: Z=0.34 (P=0.74) |   |   |            |        |            |
| Test for subgroup differences: Chi²=0.32, df=1 (P=0.57), I²=0% |   |   |            |        |            |
| **Total (95% CI)** | 238 | 253 | 100% | 0.76 [0.15, 3.77] |
| Total events: 2 (FDCs), 3 (SDF) |   |   |            |        |            |
| Heterogeneity: Tau²=0; Chi²=0.33, df=2(P=0.85); I²=0% |   |   |            |        |            |
| Test for overall effect: Z=0.34 (P=0.74) |   |   |            |        |            |
| Test for subgroup differences: Chi²=0.32, df=1 (P=0.57), I²=0% |   |   |            |        |            |

### Analysis 4.6. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 6 Adverse events leading to discontinuation of therapy.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Random, 95% CI |        | M-H, Random, 95% CI |
| 4.6.1 FDCs only at intensive phase |   |   |               |        |            |
| Teo 1999          | 7/132 | 4/139 | 10.35% | 1.84 [0.55, 6.15] |
| **Subtotal (95% CI)** | 132 | 139 | 10.35% | 1.84 [0.55, 6.15] |
| Total events: 7 (FDCs), 4 (SDF) |   |   |            |        |            |
| Heterogeneity: Not applicable |   |   |            |        |            |
| Test for overall effect: Z=0.99 (P=0.32) |   |   |            |        |            |
| 4.6.2 FDCs during all treatment |   |   |            |        |            |
| Geiter 1987       | 15/122 | 29/416 | 16.77% | 1.76 [0.98, 3.18] |
| **Total (95% CI)** | 980 | 1057 | 100% | 0.85 [0.33, 2.14] |
| Total events: 2 (FDCs), 3 (SDF) |   |   |            |        |            |
| Heterogeneity: Tau²=0; Chi²=0.33, df=2(P=0.85); I²=0% |   |   |            |        |            |
| Test for overall effect: Z=0.34 (P=0.74) |   |   |            |        |            |
| Test for subgroup differences: Chi²=0.32, df=1 (P=0.57), I²=0% |   |   |            |        |            |
| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Random, 95% CI | Weight | Risk Ratio M-H, Random, 95% CI |
|------------------|----------|----------|-------------------------------|--------|-------------------------------|
| RCTAI 1989       | 22/102   | 30/108   |                               | 17.96% | 0.78[0.48,1.25]               |
| Chaulet 1995     | 0/118    | 3/123    |                               | 2.94%  | 0.15[0.01,2.85]               |
| Zhang 1996       | 0/102    | 1/103    |                               | 2.57%  | 0.34[0.01,8.17]               |
| Zhu 1998         | 0/258    | 13/90    |                               | 3.2%   | 0.01[0.02,22]                 |
| Su 2002          | 3/57     | 2/48     |                               | 6.66%  | 1.26[0.22,7.25]               |
| Munteanu 2004    | 0/20     | 0/20     |                               | Not estimable |               |
| Zaka-Ur-Rehman 2008 | 0/194   | 2/99     |                               | 2.82%  | 0.1[0.01,2.12]                |
| Suryanto 2008    | 0/194    | 2/99     |                               | 2.81%  | 0.17[0.01,3.48]               |
| Bartacek 2009    | 25/558   | 15/564   |                               | 16.32% | 1.68[0.9,3.16]                |
| Lienhardt 2011   | 16/797   | 9/784    |                               | 14.29% | 1.75[0.78,3.93]               |
| Wu 2015          | 1/64     | 1/78     |                               | 3.32%  | 1.22[0.08,19.1]               |
| **Subtotal (95% CI)** | 2628     | 2631     |                               | 89.65% | 0.87[0.48,1.59]               |

Total events: 82 (FDCs), 107 (SDF)

Heterogeneity: Tau^2=0.42; Chi^2=25.07, df=10 (P=0.01); I^2=60.11%

Test for overall effect: Z=0.45 (P=0.66)

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|----------|-------------------------------|--------|-------------------------------|
| **4.7.1 FDCs only at intensive phase** |
| Teo 1999         | 45/132   | 45/139   |                               | 17.22% | 1.05[0.75,1.48]               |
| **Subtotal (95% CI)** | 132       | 139      |                               | 17.22% | 1.05[0.75,1.48]               |

Total events: 45 (FDCs), 45 (SDF)

Heterogeneity: Not applicable

Test for overall effect: Z=0.3 (P=0.76)

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|----------|-------------------------------|--------|-------------------------------|
| 4.7.2 FDCs during all treatment |
| Geiter 1987      | 6/122    | 8/416    |                               | 1.43%  | 2.56[0.9,7.23]               |
| Chaulet 1995     | 23/118   | 41/123   |                               | 15.77% | 0.58[0.38,0.91]               |
| Zhang 1996       | 12/102   | 15/103   |                               | 5.86%  | 0.81[0.4,1.64]               |
| Zhu 1998         | 23/258   | 8/90     |                               | 4.66%  | 1.0[0.47,2.16]               |
| Munteanu 2004    | 0/20     | 0/20     |                               | Not estimable |               |
| Zaka-Ur-Rehman 2008 | 40/194   | 26/99    |                               | 13.52% | 0.79[0.51,1.21]               |
| Bartacek 2009    | 75/558   | 84/564   |                               | 32.82% | 0.9[0.68,1.2]                |
| Lienhardt 2011   | 11/797   | 22/784   |                               | 8.71%  | 0.49[0.24,1.01]               |
| **Subtotal (95% CI)** | 2169     | 2199     |                               | 82.78% | 0.81[0.67,0.97]               |

Total events: 190 (FDCs), 204 (SDF)

Heterogeneity: Tau^2=0; Chi^2=9.49, df=6 (P=0.15); I^2=36.77%

Test for overall effect: Z=2.28 (P=0.02)
Comparison 5. Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase

| Outcome or subgroup title                                      | No. of studies | No. of participants | Statistical method                  | Effect size          |
|---------------------------------------------------------------|----------------|---------------------|-------------------------------------|----------------------|
| 1 Treatment failure                                          | 7              | 3606                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.28 [0.82, 2.00]    |
| 1.1 Daily medication for the whole treatment                 | 4              | 1517                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.14 [0.63, 2.06]    |
| 1.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase | 3              | 2089                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.49 [0.75, 2.96]    |
| 2 Relapse                                                    | 10             | 3621                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.28 [1.00, 1.64]    |
| 2.1 Daily medication for the whole treatment                 | 7              | 1850                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.12 [0.83, 1.50]    |
| 2.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase | 3              | 1771                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.72 [1.07, 2.75]    |
| 3 Death                                                      | 11             | 4800                | Risk Ratio (M-H, Fixed, 95% CI)     | 0.96 [0.67, 1.39]    |
| 3.1 Daily medication for the whole treatment                 | 8              | 2859                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.34 [0.79, 2.29]    |
| 3.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase | 3              | 1941                | Risk Ratio (M-H, Fixed, 95% CI)     | 0.69 [0.41, 1.16]    |
| 4 Sputum smear or culture conversion at 2 months of starting treatment | 13             | 4836                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.01 [0.99, 1.03]    |
| 4.1 Daily medication for the whole treatment                 | 9              | 3001                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.00 [0.98, 1.03]    |
| 4.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase | 4              | 1835                | Risk Ratio (M-H, Fixed, 95% CI)     | 1.02 [0.99, 1.05]    |
| Outcome or subgroup title                                                                 | No. of studies | No. of participants | Statistical method                      | Effect size          |
|----------------------------------------------------------------------------------------|----------------|---------------------|-----------------------------------------|----------------------|
| 5 Sputum smear or culture conversion at EOT                                              | 7              | 2319                | Risk Ratio (M-H, Fixed, 95% CI)         | 0.99 [0.96, 1.02]    |
| 5.1 Daily medication for the whole treatment                                           | 6              | 1961                | Risk Ratio (M-H, Fixed, 95% CI)         | 0.99 [0.96, 1.02]    |
| 5.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase | 1              | 358                 | Risk Ratio (M-H, Fixed, 95% CI)         | 1.00 [0.95, 1.05]    |
| 6 Acquisition of drug resistance                                                        | 3              | 491                 | Risk Ratio (M-H, Fixed, 95% CI)         | 0.76 [0.15, 3.77]    |
| 6.1 Daily medication for the whole treatment                                           | 1              | 209                 | Risk Ratio (M-H, Fixed, 95% CI)         | 1.05 [0.07, 16.55]   |
| 6.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase | 2              | 282                 | Risk Ratio (M-H, Fixed, 95% CI)         | 0.64 [0.09, 4.69]    |
| 7 Serious adverse events                                                                | 6              | 3388                | Risk Ratio (M-H, Fixed, 95% CI)         | 1.45 [0.90, 2.33]    |
| 7.1 Daily medication for the whole treatment                                           | 4              | 1767                | Risk Ratio (M-H, Fixed, 95% CI)         | 1.60 [0.95, 2.68]    |
| 7.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase | 2              | 1621                | Risk Ratio (M-H, Fixed, 95% CI)         | 0.79 [0.21, 2.92]    |
| 8 Adverse events leading to discontinuation of therapy                                  | 13             | 5530                | Risk Ratio (M-H, Random, 95% CI)        | 0.96 [0.56, 1.66]    |
| 8.1 Daily medication for the whole treatment                                           | 9              | 3204                | Risk Ratio (M-H, Random, 95% CI)        | 0.78 [0.39, 1.59]    |
| 8.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase | 4              | 2326                | Risk Ratio (M-H, Random, 95% CI)        | 1.55 [0.74, 3.25]    |
| 9 Other adverse events                                                                  | 9              | 4639                | Risk Ratio (M-H, Fixed, 95% CI)         | 0.85 [0.72, 1.00]    |
| 9.1 Daily medication for the whole treatment                                           | 6              | 2747                | Risk Ratio (M-H, Fixed, 95% CI)         | 0.84 [0.70, 1.02]    |
| 9.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase | 3              | 1892                | Risk Ratio (M-H, Fixed, 95% CI)         | 0.86 [0.64, 1.18]    |
## Analysis 5.1. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 1 Treatment failure.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|------------------------------|--------|------------------------------|
| **5.1.1 Daily medication for the whole treatment** |
| Chaulet 1995      | 1/102    | 1/107   |                             | 2.91%  | 1.05[0.07,16.55]             |
| Su 2002           | 0/26     | 0/25    |                             | Not estimable |                        |
| Bartacek 2009     | 22/582   | 19/577  |                             | 56.91% | 1.15[0.63,2.1]              |
| Wu 2015           | 0/49     | 0/49    |                             | Not estimable |                        |
| **Subtotal (95% CI)** | 759      | 758     |                             | 59.82% | 1.14[0.63,2.06]             |
| **Total events:** | 23 (FDCs), 20 (SDF) |
| Heterogeneity: Tau²=0; Chi²=0, df=1(P=0.95); I²=0% |
| Test for overall effect: Z=0.45(P=0.66) |

### Analysis 5.2. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 2 Relapse.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|------------------------------|--------|------------------------------|
| **5.2.1 Daily medication for the whole treatment** |
| RCTAI 1989        | 1/64     | 1/71    |                             | 0.96%  | 1.11[0.07,17.37]             |
| Chaulet 1995      | 1/102    | 0/107   |                             | 0.49%  | 3.15[0.13,76.34]             |
| Zhang 1996        | 2/101    | 2/101   |                             | 2.02%  | 1[0.14,6.96]                |
| Su 2002           | 1/26     | 0/25    |                             | 0.52%  | 2.89[0.12,67.75]            |
| Zaka-Ur-Rehman 2008 | 0/141   | 0/69   |                             | Not estimable |                        |
| Bartacek 2009     | 74/468   | 69/477  |                             | 69.18% | 1.09[0.81,1.48]             |
| Wu 2015           | 0/49     | 0/49    |                             | Not estimable |                        |
| **Subtotal (95% CI)** | 951      | 899     |                             | 73.17% | 1.12[0.83,1.5]             |
| **Total events:** | 79 (FDCs), 72 (SDF) |
| Heterogeneity: Tau²=0; Chi²=0.79, df=4(P=0.94); I²=0% |
| Test for overall effect: Z=0.74(P=0.46) |

### Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)

Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
### Study or subgroup

| Study or subgroup | FDCs  | SDF  | Risk Ratio | Weight | Risk Ratio |
|------------------|-------|------|------------|--------|------------|
|                  | n/N   | n/N  | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |

#### Teo 1999
- n/N: 11/121, 3/130
- Risk Ratio: 2.93%
- Weight: 2.33%
- Risk Ratio: 3.94[1.13,13.78]

#### Suryanto 2008
- n/N: 10/99, 2/73
- Risk Ratio: 21.57%
- Weight: 2.15%
- Risk Ratio: 1.2[0.68,2.11]

#### Lienhardt 2011
- n/N: 26/684, 21/664
- Risk Ratio: 1.72[1.07,2.75]

Total (95% CI): 904

#### Subtotal (95% CI)
- Total events: 47 (FDCs), 26 (SDF)
- Heterogeneity: Tau²=0; Chi²=4.23, df=2 (P=0.12); I²=52.75%
- Test for overall effect: Z=2.24 (P=0.03)

#### Total (95% CI)
- Total events: 1855
- Heterogeneity: Tau²=0; Chi²=5.44, df=7 (P=0.45); I²=0%
- Test for overall effect: Z=0.63 (P=0.53)
- Test for subgroup differences: Chi²=2.29, df=1 (P=0.13), I²=56.29%

---

### Study or subgroup

| Study or subgroup | FDCs  | SDF  | Risk Ratio | Weight | Risk Ratio |
|------------------|-------|------|------------|--------|------------|
|                  | n/N   | n/N  | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |

#### 5.3.1 Daily medication for the whole treatment

| Study or subgroup | FDCs  | SDF  | Risk Ratio | Weight | Risk Ratio |
|------------------|-------|------|------------|--------|------------|
|                  | n/N   | n/N  | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |

#### Geiter 1987
- n/N: 2/122, 13/416
- Risk Ratio: 10.67%
- Weight: 1.55%
- Risk Ratio: 0.52[0.12,2.29]

#### RCTAI 1989
- n/N: 1/102, 0/108
- Risk Ratio: 0.88%
- Weight: 3.75%
- Risk Ratio: 3.17[0.13,7.97]

#### Zhang 1996
- n/N: 2/102, 1/103
- Risk Ratio: 1.8%
- Weight: 2.02%
- Risk Ratio: 2.02[0.19,21.93]

#### Zhu 1998
- n/N: 0/227, 0/81
- Risk Ratio: Not estimable

#### Su 2002
- n/N: 7/57, 2/48
- Risk Ratio: 3.93%
- Weight: 3.10%
- Risk Ratio: 2.95[0.64,13.53]

#### Zaka-Ur-Rehman 2008
- n/N: 0/141, 0/81
- Risk Ratio: Not estimable

#### Bartacek 2009
- n/N: 11/558, 4/564
- Risk Ratio: 7.2%
- Weight: 7.20%
- Risk Ratio: 2.78[0.89,7.97]

#### Wu 2015
- n/N: 6/75, 8/86
- Risk Ratio: 13.48%
- Weight: 13.48%
- Risk Ratio: 0.86[0.31,3.63]

Total (95% CI): 1384

#### Subtotal (95% CI)
- Total events: 29 (FDCs), 29 (SDF)
- Heterogeneity: Tau²=0; Chi²=6.96, df=6 (P=0.32); I²=13.74%
- Test for overall effect: Z=1.07 (P=0.28)

#### Total (95% CI)
- Total events: 1855
- Heterogeneity: Tau²=0; Chi²=5.44, df=7 (P=0.45); I²=0%
- Test for overall effect: Z=0.63 (P=0.53)
- Test for subgroup differences: Chi²=2.29, df=1 (P=0.13), I²=56.29%

---

### Study or subgroup

| Study or subgroup | FDCs  | SDF  | Risk Ratio | Weight | Risk Ratio |
|------------------|-------|------|------------|--------|------------|
|                  | n/N   | n/N  | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |

#### 5.3.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase

| Study or subgroup | FDCs  | SDF  | Risk Ratio | Weight | Risk Ratio |
|------------------|-------|------|------------|--------|------------|
|                  | n/N   | n/N  | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |

#### Teo 1999
- n/N: 8/132, 6/139
- Risk Ratio: 10.57%
- Weight: 1.4%
- Risk Ratio: 1.4[0.5,3.94]

#### Suryanto 2008
- n/N: 11/173, 18/149
- Risk Ratio: 34.99%
- Weight: 0.53%
- Risk Ratio: 0.53[0.26,1.08]

#### Lienhardt 2011
- n/N: 4/684, 7/664
- Risk Ratio: 12.85%
- Weight: 0.55%
- Risk Ratio: 0.55[0.16,1.89]

Total (95% CI): 1384

#### Subtotal (95% CI)
- Total events: 23 (FDCs), 31 (SDF)
- Heterogeneity: Tau²=0; Chi²=2.49, df=2 (P=0.29); I²=19.75%
- Test for overall effect: Z=1.39 (P=0.16)

#### Total (95% CI)
- Total events: 1855
- Heterogeneity: Tau²=0; Chi²=5.44, df=7 (P=0.45); I²=0%
- Test for overall effect: Z=0.63 (P=0.53)
- Test for subgroup differences: Chi²=2.29, df=1 (P=0.13), I²=56.29%

---

### Analysis 5.3. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 3 Death.

#### 5.3.1 Daily medication for the whole treatment

| Study or subgroup | FDCs  | SDF  | Risk Ratio | Weight | Risk Ratio |
|------------------|-------|------|------------|--------|------------|
|                  | n/N   | n/N  | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |

#### Geiter 1987
- n/N: 2/122, 13/416
- Risk Ratio: 10.67%
- Weight: 1.06%
- Risk Ratio: 0.52[0.12,2.29]

#### RCTAI 1989
- n/N: 1/102, 0/108
- Risk Ratio: 0.88%
- Weight: 0.88%
- Risk Ratio: 3.17[0.13,7.97]

#### Zhang 1996
- n/N: 2/102, 1/103
- Risk Ratio: 1.8%
- Weight: 1.80%
- Risk Ratio: 2.02[0.19,21.93]

#### Zhu 1998
- n/N: 0/227, 0/81
- Risk Ratio: Not estimable

#### Su 2002
- n/N: 7/57, 2/48
- Risk Ratio: 3.93%
- Weight: 3.93%
- Risk Ratio: 2.95[0.64,13.53]

#### Zaka-Ur-Rehman 2008
- n/N: 0/141, 0/81
- Risk Ratio: Not estimable

#### Bartacek 2009
- n/N: 11/558, 4/564
- Risk Ratio: 7.2%
- Weight: 7.20%
- Risk Ratio: 2.78[0.89,7.97]

#### Wu 2015
- n/N: 6/75, 8/86
- Risk Ratio: 13.48%
- Weight: 13.48%
- Risk Ratio: 0.86[0.31,3.63]

Total (95% CI): 1384

#### Subtotal (95% CI)
- Total events: 29 (FDCs), 29 (SDF)
- Heterogeneity: Tau²=0; Chi²=6.96, df=6 (P=0.32); I²=13.74%
- Test for overall effect: Z=1.07 (P=0.28)

#### Total (95% CI)
- Total events: 1855
- Heterogeneity: Tau²=0; Chi²=5.44, df=7 (P=0.45); I²=0%
- Test for overall effect: Z=0.63 (P=0.53)
- Test for subgroup differences: Chi²=2.29, df=1 (P=0.13), I²=56.29%
Analysis 5.4. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight M-H, Fixed, 95% CI |
|-------------------|----------|---------|-------------------------------|--------------------------|
| **5.4.1 Daily medication for the whole treatment** | | | | |
| Geiter 1987 | 106/122 | 323/416 | 7.38% | 1.12[1.03,1.22] |
| RCTA 1989 | 67/70 | 73/76 | 3.53% | 1[0.93,1.07] |
| Chauket 1995 | 90/95 | 99/108 | 4.67% | 1.03[0.96,1.11] |
| Zhang 1996 | 101/102 | 99/103 | 4.96% | 1.03[0.99,1.08] |
| Zhu 1998 | 207/227 | 70/81 | 5.2% | 1.06[0.96,1.16] |
| Su 2002 | 23/26 | 24/25 | 1.23% | 0.92[0.79,1.08] |
| Zaka-Ur-Rehman 2008 | 187/194 | 94/99 | 6.27% | 1.02[0.96,1.07] |
| Bartacek 2009 | 449/582 | 469/577 | 23.72% | 0.95[0.89,1.01] |
| Wu 2015 | 47/49 | 47/49 | 2.37% | 1[0.92,1.09] |
| **Subtotal (95% CI)** | 1467 | 1534 | 59.32% | 1[0.98,1.03] |

Total events: 1277 (FDCs), 1298 (SDF)
Heterogeneity: Tau²=0; Chi²=13.86, df=8(P=0.09); I²=42.26%
Test for overall effect: Z=0.28(P=0.78)

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight M-H, Fixed, 95% CI |
|-------------------|----------|---------|-------------------------------|--------------------------|
| **5.4.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase** | | | | |
| Teo 1999 | 124/129 | 133/140 | 6.42% | 1.01[0.96,1.07] |
| Munteanu 2004 | 14/20 | 15/18 | 0.8% | 0.84[0.59,1.2] |
| Suryanto 2008 | 186/198 | 143/160 | 7.97% | 1.05[0.99,1.12] |
| Lienhardt 2011 | 521/591 | 501/579 | 25.49% | 1.02[0.98,1.06] |
| **Subtotal (95% CI)** | 938 | 897 | 40.68% | 1.02[0.99,1.05] |

Total events: 845 (FDCs), 792 (SDF)
Heterogeneity: Tau²=0; Chi²=2.09, df=3(P=0.55); I²=0%
Test for overall effect: Z=1.25(P=0.21)

**Total (95% CI)**

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight M-H, Fixed, 95% CI |
|-------------------|----------|---------|-------------------------------|--------------------------|
| **5.5.1 Daily medication for the whole treatment** | | | | |
| RCTAI 1989 | 64/66 | 71/74 | 6.65% | 1.01[0.95,1.08] |
| Zhang 1996 | 101/102 | 101/103 | 9.99% | 1.01[0.98,1.04] |
| Zhu 1998 | 224/227 | 79/81 | 11.57% | 1.01[0.97,1.05] |
| Su 2002 | 25/26 | 25/25 | 2.58% | 0.96[0.87,1.07] |

**Analysis 5.5. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 5 Sputum smear or culture conversion at EOT.**

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight M-H, Fixed, 95% CI |
|-------------------|----------|---------|-------------------------------|--------------------------|
| **5.5.1 Daily medication for the whole treatment** | | | | |
| RCTAI 1989 | 64/66 | 71/74 | 6.65% | 1.01[0.95,1.08] |
| Zhang 1996 | 101/102 | 101/103 | 9.99% | 1.01[0.98,1.04] |
| Zhu 1998 | 224/227 | 79/81 | 11.57% | 1.01[0.97,1.05] |
| Su 2002 | 25/26 | 25/25 | 2.58% | 0.96[0.87,1.07] |

Favours SDF 1 Favor FDCs
### Analysis 5.6. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 6 Acquisition of drug resistance.

| Study or subgroup | FDCs  | SDF  | Risk Ratio | Weight | Risk Ratio |
|-------------------|-------|------|------------|--------|------------|
|                   | n/N   | n/N  | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Bartacek 2009     | 468/582 | 477/577 | 47.59% | 0.97[0.92,1.03] |
| Wu 2015           | 49/49  | 49/49  | 4.92%  | 1[0.96,1.04]   |
| **Subtotal (95% CI)** | **1052** | **909** | **83.3%** | **0.99[0.96,1.02]** |
| **Total events:**  | 931 (FDCs), 802 (SDF) |       |       |            |
| **Heterogeneity:** tau^2=0; Chi^2=4.93, df=5 (P=0.42); I^2=0% |       |       |       |            |
| **Test for overall effect:** Z=0.8 (P=0.43) |       |       |       |            |

**5.6.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase**

| Study or subgroup | FDCs  | SDF  | Risk Ratio | Weight | Risk Ratio |
|-------------------|-------|------|------------|--------|------------|
|                   | n/N   | n/N  | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Bartacek 2009     | 468/582 | 477/577 | 47.59% | 0.97[0.92,1.03] |
| Wu 2015           | 49/49  | 49/49  | 4.92%  | 1[0.96,1.04]   |
| **Subtotal (95% CI)** | **1052** | **909** | **83.3%** | **0.99[0.96,1.02]** |
| **Total events:**  | 931 (FDCs), 802 (SDF) |       |       |            |
| **Heterogeneity:** Not applicable |       |       |       |            |
| **Test for overall effect:** Z=0.8 (P=0.43) |       |       |       |            |

| Study or subgroup | FDCs  | SDF  | Risk Ratio | Weight | Risk Ratio |
|-------------------|-------|------|------------|--------|------------|
|                   | n/N   | n/N  | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Suryanto 2008     | 188/198 | 152/160 | 16.7% | 1[0.95,1.05]   |
| **Subtotal (95% CI)** | **198** | **160** | **16.7%** | **1[0.95,1.05]** |
| **Total events:**  | 188 (FDCs), 152 (SDF) |       |       |            |
| **Heterogeneity:** Not applicable |       |       |       |            |
| **Test for overall effect:** Z=0.8 (P=0.43) |       |       |       |            |

| Study or subgroup | FDCs  | SDF  | Risk Ratio | Weight | Risk Ratio |
|-------------------|-------|------|------------|--------|------------|
|                   | n/N   | n/N  | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Chaulet 1995      | 1/102 | 1/107 | 28.79% | 1.05[0.07,16.55] |
| **Subtotal (95% CI)** | **102** | **107** | **28.79%** | **1.05[0.07,16.55]** |
| **Total events:**  | 1 (FDCs), 1 (SDF) |       |       |            |
| **Heterogeneity:** Not applicable |       |       |       |            |
| **Test for overall effect:** Z=0.03 (P=0.97) |       |       |       |            |

| Study or subgroup | FDCs  | SDF  | Risk Ratio | Weight | Risk Ratio |
|-------------------|-------|------|------------|--------|------------|
|                   | n/N   | n/N  | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Teo 1999          | 0/121 | 1/130 | 42.67% | 0.36[0.01,8.7]   |
| Lienhardt 2011    | 1/15  | 1/16  | 28.54% | 1.07[0.07,15.57] |
| **Subtotal (95% CI)** | **136** | **146** | **71.21%** | **0.64[0.09,4.69]** |
| **Total events:**  | 1 (FDCs), 2 (SDF) |       |       |            |
| **Heterogeneity:** tau^2=0; Chisquare=4.2, df=6 (P=0.62); I^2=0% |       |       |       |            |
| **Test for overall effect:** Z=0.44 (P=0.66) |       |       |       |            |

| Study or subgroup | FDCs  | SDF  | Risk Ratio | Weight | Risk Ratio |
|-------------------|-------|------|------------|--------|------------|
|                   | n/N   | n/N  | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| **Subtotal (95% CI)** | **238** | **253** | **100%** | **0.76[0.15,3.77]** |
| **Total events:**  | 2 (FDCs), 3 (SDF) |       |       |            |
| **Heterogeneity:** Not applicable |       |       |       |            |
| **Test for overall effect:** Z=0.34 (P=0.74) |       |       |       |            |
| **Test for subgroup differences:** Chisquare=0.08, df=1 (P=0.78), I^2=0% |       |       |       |            |
### Analysis 5.7. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 7 Serious adverse events.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|----------------------------|--------|----------------------------|
| **5.7.1 Daily medication for the whole treatment** | | | | | |
| RCTAI 1989 | 1/102 | 0/108 | 1.79% | 3.17[0.13,77.05] | |
| Zaka-Ur-Rehman 2008 | 0/194 | 1/99 | 7.29% | 0.17[0.01,4.16] | |
| Bartacek 2009 | 29/558 | 18/564 | 65.78% | 1.63[0.92,2.9] | |
| Wu 2015 | 4/64 | 2/78 | 6.62% | 2.44[0.46,12.88] | |
| **Subtotal (95% CI)** | 918 | 849 | 81.48% | 1.6[0.95,2.68] | |
| Total events: 34 (FDCs), 21 (SDF) | | | | | |
| Heterogeneity: Tau²=0; Chi²=2.31, df=3(P=0.51); I²=0% | | | | | |
| Test for overall effect: Z=1.78(P=0.08) | | | | | |

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|----------------------------|--------|----------------------------|
| **5.7.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase** | | | | | |
| Munteanu 2004 | 0/20 | 0/20 | Not estimable | | |
| Lienhardt 2011 | 4/797 | 5/784 | 18.52% | 0.79[0.21,2.92] | |
| **Subtotal (95% CI)** | 817 | 804 | 18.52% | 0.79[0.21,2.92] | |
| Total events: 4 (FDCs), 5 (SDF) | | | | | |
| Heterogeneity: Not applicable | | | | | |
| Test for overall effect: Z=0.36(P=0.72) | | | | | |

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Random, 95% CI | Weight | Risk Ratio M-H, Random, 95% CI |
|-------------------|----------|---------|----------------------------|--------|----------------------------|
| **5.8.1 Daily medication for the whole treatment** | | | | | |
| Geiter 1987 | 15/122 | 29/416 | 16.77% | 1.76[0.98,3.18] | |
| RCTAI 1989 | 22/102 | 30/108 | 17.96% | 0.78[0.48,1.25] | |
| Chaulet 1995 | 0/118 | 3/123 | 2.94% | 0.15[0.01,2.85] | |
| Zhang 1996 | 0/102 | 1/103 | 2.57% | 0.34[0.01,8.17] | |
| Zhu 1998 | 0/258 | 13/90 | 3.2% | 0.01[0.22] | |
| Su 2002 | 3/57 | 2/48 | 6.66% | 1.26[0.22,7.25] | |
| Zaka-Ur-Rehman 2008 | 0/194 | 2/99 | 2.82% | 0.1[0.21] | |
| Bartacek 2009 | 25/558 | 15/564 | 16.32% | 1.68[0.9,3.16] | |
| Wu 2015 | 1/64 | 1/78 | 3.32% | 1.22[0.08,19.1] | |
| **Subtotal (95% CI)** | 1575 | 1629 | 72.55% | 0.78[0.39,1.59] | |
| Total events: 66 (FDCs), 96 (SDF) | | | | | |
| Heterogeneity: Tau²=0.51; Chi²=22.54, df=8(P=0); I²=64.51% | | | | | |
| Test for overall effect: Z=0.68(P=0.49) | | | | | |

### Analysis 5.8. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 8 Adverse events leading to discontinuation of therapy.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Random, 95% CI | Weight | Risk Ratio M-H, Random, 95% CI |
|-------------------|----------|---------|----------------------------|--------|----------------------------|
| **5.8.1 Daily medication for the whole treatment** | | | | | |
| Geiter 1987 | 15/122 | 29/416 | 16.77% | 1.76[0.98,3.18] | |
| RCTAI 1989 | 22/102 | 30/108 | 17.96% | 0.78[0.48,1.25] | |
| Chaulet 1995 | 0/118 | 3/123 | 2.94% | 0.15[0.01,2.85] | |
| Zhang 1996 | 0/102 | 1/103 | 2.57% | 0.34[0.01,8.17] | |
| Zhu 1998 | 0/258 | 13/90 | 3.2% | 0.01[0.22] | |
| Su 2002 | 3/57 | 2/48 | 6.66% | 1.26[0.22,7.25] | |
| Zaka-Ur-Rehman 2008 | 0/194 | 2/99 | 2.82% | 0.1[0.21] | |
| Bartacek 2009 | 25/558 | 15/564 | 16.32% | 1.68[0.9,3.16] | |
| Wu 2015 | 1/64 | 1/78 | 3.32% | 1.22[0.08,19.1] | |
| **Subtotal (95% CI)** | 1575 | 1629 | 72.55% | 0.78[0.39,1.59] | |
### Analysis 5.9. Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 9 Other adverse events.

#### Study or subgroup

| FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------|-----|------------|--------|------------|
| **5.9.1 Daily medication for the whole treatment** | | | | |
| Geiter 1987 | 6/122 | 8/416 | 1.43% | 2.56[0.9,7.23] |
| Chaulet 1995 | 23/118 | 41/123 | 15.77% | 0.58[0.38,0.91] |
| Zhang 1996 | 12/102 | 15/103 | 5.86% | 0.81[0.4,1.64] |
| Zhu 1998 | 23/258 | 8/90 | 4.66% | 1[0.47,2.16] |
| Zaka-Ur-Rehman 2008 | 40/194 | 26/99 | 13.52% | 0.79[0.51,1.21] |
| Bartacek 2009 | 75/558 | 84/564 | 32.82% | 0.9[0.68,1.2] |
| **Subtotal (95% CI)** | 1352 | 1395 | 74.07% | 0.84[0.7,1.02] |

**Total events: 179 (FDCs), 182 (SDF)**

Heterogeneity: \( \tau^2=0; \) Chi\(^2=7.52, \) df=5\( (P=0.18); \) I\(^2=33.54\%

Test for overall effect: Z=1.74\( (P=0.08)\)

#### Study or subgroup

| FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------|-----|------------|--------|------------|
| **5.9.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase** | | | | |
| Teo 1999 | 45/132 | 45/139 | 17.22% | 1.05[0.75,1.48] |
| Munteanu 2004 | 0/20 | 0/20 | Not estimable | |
| Lienhardt 2011 | 11/797 | 22/784 | 8.71% | 0.49[0.24,1.01] |
| **Subtotal (95% CI)** | 949 | 943 | 25.93% | 0.86[0.64,1.18] |

**Total events: 56 (FDCs), 67 (SDF)**

Heterogeneity: \( \tau^2=0; \) Chi\(^2=3.69, \) df=1\( (P=0.05); \) I\(^2=72.89\%

Test for overall effect: Z=0.93\( (P=0.35)\)

**Total (95% CI)**

**Total events: 235 (FDCs), 249 (SDF)**

Heterogeneity: \( \tau^2=0; \) Chi\(^2=11.33, \) df=7\( (P=0.13); \) I\(^2=38.19\%

Test for overall effect: Z=1.97\( (P=0.05)\)
### Comparison 6. Supervised treatment versus self-administered treatment during the intensive phase

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---------------------------|----------------|---------------------|--------------------|-------------|
| 1 Treatment failure       | 6              | 2447                | Risk Ratio (M-H, Fixed, 95% CI) | 1.46 [0.75, 2.84] |
| 1.1 Supervised treatment during the intensive phase | 4             | 1962                | Risk Ratio (M-H, Fixed, 95% CI) | 1.27 [0.56, 2.89] |
| 1.2 Self-administered treatment during the intensive phase | 2             | 485                 | Risk Ratio (M-H, Fixed, 95% CI) | 1.89 [0.59, 6.04] |
| 2 Relapse                 | 9              | 2676                | Risk Ratio (M-H, Fixed, 95% CI) | 1.69 [1.09, 2.63] |
| 2.1 Supervised treatment during the intensive phase | 6             | 2318                | Risk Ratio (M-H, Fixed, 95% CI) | 1.52 [0.94, 2.45] |
| 2.2 Self-administered treatment during the intensive phase | 3             | 358                 | Risk Ratio (M-H, Fixed, 95% CI) | 2.93 [0.89, 9.59] |
| 3 Death                   | 10             | 3678                | Risk Ratio (M-H, Fixed, 95% CI) | 0.82 [0.55, 1.22] |
| 3.1 Supervised treatment during the intensive phase | 6             | 2503                | Risk Ratio (M-H, Fixed, 95% CI) | 0.89 [0.50, 1.58] |
| 3.2 Self-administered treatment during the intensive phase | 4             | 1175                | Risk Ratio (M-H, Fixed, 95% CI) | 0.76 [0.44, 1.32] |
| 4 Sputum smear or culture conversion at 2 months of starting treatment | 12            | 3677                | Risk Ratio (M-H, Fixed, 95% CI) | 1.03 [1.01, 1.05] |
| 4.1 Supervised treatment during the intensive phase | 8             | 2584                | Risk Ratio (M-H, Fixed, 95% CI) | 1.02 [0.99, 1.05] |
| 4.2 Self-administered treatment during the intensive phase | 4             | 1093                | Risk Ratio (M-H, Fixed, 95% CI) | 1.06 [1.01, 1.11] |
| 5 Sputum smear or culture conversion at EOT | 6             | 1160                | Risk Ratio (M-H, Fixed, 95% CI) | 1.00 [0.98, 1.03] |
| 5.1 Supervised treatment during the intensive phase | 2             | 513                 | Risk Ratio (M-H, Fixed, 95% CI) | 1.01 [0.99, 1.04] |
| 5.2 Self-administered treatment during the intensive phase | 4             | 647                 | Risk Ratio (M-H, Fixed, 95% CI) | 1.00 [0.97, 1.03] |
| Outcome or subgroup title                                                                 | No. of studies | No. of participants | Statistical method                                      | Effect size       |
|------------------------------------------------------------------------------------------|----------------|---------------------|--------------------------------------------------------|-------------------|
| 6 Treatment adherence at 8 weeks of starting treatment                                   | 3              | 881                 | Risk Ratio (M-H, Random, 95% CI)                       | 1.04 [0.96, 1.12] |
| 6.1 Supervised treatment during the intensive phase                                       | 1              | 142                 | Risk Ratio (M-H, Random, 95% CI)                       | 1.01 [0.97, 1.06] |
| 6.2 Self-administered treatment during the intensive phase                               | 2              | 739                 | Risk Ratio (M-H, Random, 95% CI)                       | 1.09 [0.90, 1.31] |
| 7 Treatment adherence at EOT                                                               | 5              | 1229                | Risk Ratio (M-H, Fixed, 95% CI)                        | 1.01 [0.97, 1.06] |
| 7.1 Supervised treatment during the intensive phase                                       | 1              | 96                  | Risk Ratio (M-H, Fixed, 95% CI)                        | 1.04 [0.97, 1.11] |
| 7.2 Self-administered treatment during the intensive phase                               | 4              | 1133                | Risk Ratio (M-H, Fixed, 95% CI)                        | 1.01 [0.96, 1.06] |
| 8 Serious adverse events                                                                 | 5              | 2266                | Risk Ratio (M-H, Fixed, 95% CI)                        | 1.10 [0.46, 2.60] |
| 8.1 Supervised treatment during the intensive phase                                       | 4              | 2056                | Risk Ratio (M-H, Fixed, 95% CI)                        | 0.99 [0.40, 2.44] |
| 8.2 Self-administered treatment during the intensive phase                               | 1              | 210                 | Risk Ratio (M-H, Fixed, 95% CI)                        | 3.17 [0.13, 77.05]|
| 9 Adverse events leading to discontinuation of therapy                                   | 12             | 4408                | Risk Ratio (M-H, Random, 95% CI)                       | 0.82 [0.43, 1.57] |
| 9.1 Supervised treatment during the intensive phase                                       | 8              | 3121                | Risk Ratio (M-H, Random, 95% CI)                       | 0.44 [0.11, 1.71] |
| 9.2 Self-administered treatment during the intensive phase                               | 4              | 1287                | Risk Ratio (M-H, Random, 95% CI)                       | 1.06 [0.55, 2.04] |
| 10 Other adverse events                                                                  | 8              | 3517                | Risk Ratio (M-H, Fixed, 95% CI)                        | 0.82 [0.68, 1.00] |
| 10.1 Supervised treatment during the intensive phase                                      | 7              | 2979                | Risk Ratio (M-H, Fixed, 95% CI)                        | 0.79 [0.64, 0.96] |
| 10.2 Self-administered treatment during the intensive phase                              | 1              | 538                 | Risk Ratio (M-H, Fixed, 95% CI)                        | 2.56 [0.90, 7.23] |

### Analysis 6.1. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 1 Treatment failure.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|------------------------------|--------|-----------------------------|
| 6.1.1 Supervised treatment during the intensive phase | Favours FDCs | 0.05 | 0.2 | 1 | 5 | 20 | Favours SDF |
### Analysis 6.2. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 2 Relapse.

#### 6.2.1 Supervised treatment during the intensive phase

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|---------|---------|-----------------------------|--------|-----------------------------|
| Chaulet 1995     | 1/102  | 1/107   |                             | 6.76%  | 1.05[0.07,16.55]             |
| Zhang 1996       | 2/101  | 2/101   |                             | 6.57%  | 1[0.14,6.96]                 |
| Teo 1999         | 11/121 | 3/130   |                             | 9.5%   | 3.94[1.13,13.78]             |
| Zaka-Ur-Rehman 2008 | 0/141 | 0/69    |                             | Not estimable |
| Lienhardt 2011   | 26/684 | 21/664  |                             | 69.98% | 1.2[0.68,2.11]               |
| Wu 2015          | 0/49   | 0/49    |                             | Not estimable |
| **Subtotal (95% CI)** | **1198** | **1120** |                             | **87.65%** | **1.52[0.94,2.45]**         |

Total events: 40 (FDCs), 26 (SDF)

Heterogeneity: Tau²=0; Chi²=3.26, df=3(P=0.35); I²=8.04%

Test for overall effect: Z=1.71(P=0.09)

#### 6.2.2 Self-administered treatment during the intensive phase

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|---------|---------|-----------------------------|--------|-----------------------------|
| RCTAI 1989       | 1/64    | 1/71    |                             | 3.11%  | 1.11[0.07,17.37]             |
| Su 2002          | 1/26    | 0/25    |                             | 1.67%  | 2.89[0.12,67.75]             |
| Suryanto 2008    | 10/99   | 2/73    |                             | 7.56%  | 3.69[0.83,16.32]             |
| **Subtotal (95% CI)** | **189** | **169** |                             | **12.35%** | **2.93[0.89,9.59]**         |

Total events: 12 (FDCs), 3 (SDF)

Heterogeneity: Tau²=0; Chi²=0.57, df=2(P=0.75); I²=0%

Test for overall effect: Z=1.78(P=0.08)
| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Total (95% CI)    | 1387 | 1289|                      | 100%   | 1.69 [1.09, 2.63] |

- Total events: 52 (FDCs), 29 (SDF)
- Heterogeneity: Tau²=0; Chi²=4.84, df=6 (P=0.56); I²=0%
- Test for overall effect: Z=2.33 (P=0.02)
- Test for subgroup differences: Chi²=1.01, df=1 (P=0.31), I²=1.14%

---

Analysis 6.3. Comparison 6. Supervised treatment versus self-administered treatment during the intensive phase, Outcome 3 Death.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| 6.3.1 Supervised treatment during the intensive phase |       |     |             |        |             |
| Zhang 1996        | 2/102| 1/103|                   | 1.94%  | 2.02 [0.19, 21.93] |
| Zhu 1998          | 0/227| 0/81 |                   |        | Not estimable |
| Teo 1999          | 8/132| 6/139|                   | 11.39% | 1.4 [0.5, 3.94] |
| Zaka-Ur-Rehman 2008 | 0/141 | 1/69 |               | 3.92%  | 0.16 [0.01, 3.98] |
| Lienhardt 2011    | 4/684| 7/664|               | 13.85% | 0.55 [0.16, 1.89] |
| Wu 2015           | 6/75 | 8/86 |               | 14.53% | 0.86 [0.31, 2.37] |
| Subtotal (95% CI) | 1361 | 1142| 45.63%       | 0.89 [0.5, 1.58] |

- Total events: 20 (FDCs), 23 (SDF)
- Heterogeneity: Tau²=0; Chi²=2.86, df=4 (P=0.58); I²=0%
- Test for overall effect: Z=0.39 (P=0.7)

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| 6.3.2 Self-administered treatment during the intensive phase |       |     |             |        |             |
| Geiter 1987       | 2/122| 13/416|          | 11.49% | 0.52 [0.12, 2.29] |
| RCTAI 1989        | 1/102| 0/108|       | 0.95%  | 3.17 [0.13, 77.05] |
| Su 2002           | 7/57 | 2/48 |       | 4.23%  | 2.95 [0.64, 13.53] |
| Suryanto 2008     | 11/173| 18/149|     | 37.7%  | 0.53 [0.26, 1.08] |
| Subtotal (95% CI) | 454  | 721 | 54.37%     | 0.76 [0.44, 1.32] |

- Total events: 21 (FDCs), 33 (SDF)
- Heterogeneity: Tau²=0; Chi²=5.06, df=3 (P=0.17); I²=40.73%
- Test for overall effect: Z=0.97 (P=0.33)

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
|                   | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Total (95% CI)    | 1815 | 1863| 100%        | 0.82 [0.55, 1.22] |

- Total events: 41 (FDCs), 56 (SDF)
- Heterogeneity: Tau²=0; Chi²=8.19, df=8 (P=0.42); I²=2.33%
- Test for overall effect: Z=0.97 (P=0.33)
- Test for subgroup differences: Chi²=0.16, df=1 (P=0.69), I²=0%
Analysis 6.4. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|---------|---------|-----------------------------|--------|-----------------------------|
| **6.4.1 Supervised treatment during the intensive phase** |
| Chaulet 1995      | 90/95   | 99/108  | 6.12%                        | 1.03[0.96,1.11] |
| Zhang 1996        | 101/102 | 99/103  | 6.51%                        | 1.03[0.99,1.08] |
| Zhu 1998          | 207/227 | 70/81   | 6.81%                        | 1.06[0.96,1.16] |
| Teo 1999          | 124/129 | 133/140 | 8.42%                        | 1.01[0.96,1.07] |
| Munteanu 2004     | 14/20   | 15/18   | 1.04%                        | 0.84[0.59,1.2]  |
| Zaka-Ur-Rehman 2008 | 187/194 | 94/99   | 8.22%                        | 1.02[0.96,1.07] |
| Lienhardt 2011    | 521/591 | 501/579 | 33.42%                       | 1.02[0.98,1.06] |
| Wu 2015           | 47/49   | 47/49   | 3.1%                         | 1.09[0.92,1.19] |
| **Subtotal (95% CI)** | 1407   | 1177   | 73.64%                       | 1.02[0.99,1.05] |
| **Total events:** | 1291 (FDCs), 1058 (SDF) |
| **Heterogeneity:** | Tau²=0.0; Ch²=2.32, df=7(P=0.94); I²=90% |
| **Test for overall effect:** | Z=1.54(P=0.12) |
| **6.4.2 Self-administered treatment during the intensive phase** |
| Geiter 1987       | 106/122 | 323/416 | 9.67%                        | 1.12[1.03,1.12] |
| RCTAI 1989        | 67/70   | 73/76   | 4.62%                        | 1.03[0.93,1.07] |
| Su 2002           | 23/26   | 24/25   | 1.62%                        | 0.92[0.79,1.08] |
| Suryanto 2008     | 186/198 | 143/160 | 10.44%                       | 1.05[0.99,1.12] |
| **Subtotal (95% CI)** | 416   | 677   | 26.36%                       | 1.06[1.01,1.11] |
| **Total events:** | 382 (FDCs), 563 (SDF) |
| **Heterogeneity:** | Tau²=0.0; Ch²=7.61, df=3(P=0.05); I²=60.59% |
| **Test for overall effect:** | Z=2.55(P=0.01) |
| **Total (95% CI)** | 1823   | 1854   | 100%                         | 1.03[1.01,1.05] |
| **Total events:** | 1673 (FDCs), 1621 (SDF) |
| **Heterogeneity:** | Tau²=0.0; Ch²=9.76, df=11(P=0.55); I²=0% |
| **Test for overall effect:** | Z=2.67(P=0.01) |
| **Test for subgroup differences:** | Ch²=2.09, df=1 (P=0.15), I²=52.16% |

Analysis 6.5. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 5 Sputum smear or culture conversion at EOT.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|---------|---------|-----------------------------|--------|-----------------------------|
| **6.5.1 Supervised treatment during the intensive phase** |
| Zhang 1996        | 101/102 | 101/103 | 19.05%                       | 1.01[0.98,1.04] |
| Zhu 1998          | 224/227 | 79/81   | 22.07%                       | 1.01[0.97,1.05] |
| **Subtotal (95% CI)** | 329   | 184   | 41.13%                       | 1.01[0.99,1.04] |
| **Total events:** | 325 (FDCs), 180 (SDF) |
| **Heterogeneity:** | Tau²=0.0; Ch²=0.01, df=1(P=0.94); I²=0% |
| **Test for overall effect:** | Z=0.83(P=0.41) |
| **6.5.2 Self-administered treatment during the intensive phase** |
| RCTAI 1989        | 64/66   | 71/74   | 12.69%                       | 1.01[0.95,1.08] |
| Su 2002           | 25/26   | 25/25   | 4.93%                        | 0.96[0.87,1.07] |

Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)
### Analysis 6.6. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 6 Treatment adherence at 8 weeks of starting treatment.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Random, 95% CI | Weight | Risk Ratio M-H, Random, 95% CI |
|-------------------|----------|---------|--------------------------------|--------|-------------------------------|
| **6.6.1 Supervised treatment during the intensive phase** |
| Chaulet 1995      | 70/71    | 69/71   | 1.01[0.97,1.06]                | 48.11% | 1.01[0.97,1.06] |
| **Subtotal (95% CI)**     | 71       | 71      | 48.11%                        | 1.01[0.97,1.06] |
| Total events: 70 (FDCs), 69 (SDF) |
| Heterogeneity: Not applicable |
| Test for overall effect: Z=0.58(P=0.56) |
| **6.6.2 Self-administered treatment during the intensive phase** |
| Geiter 1987       | 108/122  | 363/416 | 1.01[0.94,1.09]                | 39.2%  | 1.01[0.94,1.09] |
| RCTAI 1989        | 70/97    | 62/104  | 1.21[0.99,1.48]                | 12.69% | 1.21[0.99,1.48] |
| **Subtotal (95% CI)**     | 219      | 520     | 51.89%                        | 1.09[0.9,1.31] |
| Total events: 178 (FDCs), 425 (SDF) |
| Heterogeneity: Tau^2=0.01; Chi^2=3.31, df=1(P=0.07); I^2=69.77% |
| Test for overall effect: Z=0.85(P=0.39) |
| Total (95% CI)     | 290      | 591     | 100%                          | 1.04[0.96,1.12] |
| Total events: 248 (FDCs), 494 (SDF) |
| Heterogeneity: Tau^2=0; Chi^2=5.32, df=2(P=0.07); I^2=62.42% |
| Test for overall effect: Z=0.35(P=0.72) |
| Test for subgroup differences: Chi^2=0.47, df=1 (P=0.5), I^2=0% |

### Analysis 6.7. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 7 Treatment adherence at EOT.

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|--------------------------------|--------|-------------------------------|
| **6.7.1 Supervised treatment during the intensive phase** |
| Favours SDF       | 1        | Favours FDCs | 1 | 1 |

---

*Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)*

Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
### 6.7.2 Self-administered treatment during the intensive phase

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-----------------------------|
| Chaulet 1995      | 44/44    | 50/52   | 11.38%                      | 1.04   | [0.97,1.11]                 |
| **Subtotal (95% CI)** | **44**   | **52**  | **11.38%**                  | **1.04** | **[0.97,1.11]** |

**Total events:** 44 (FDCs), 50 (SDF)

**Heterogeneity:** Not applicable

**Test for overall effect:** Z=1.08 (P=0.28)

**Total events:** 418 (FDCs), 545 (SDF)

**Heterogeneity:** Tau²=0; Chi²=2.21, df=3 (P=0.53); I²=0%

**Test for overall effect:** Z=0.09 (P=0.77)

### Analysis 6.8. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 8 Serious adverse events.

#### 6.8.1 Supervised treatment during the intensive phase

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-----------------------------|
| Muñteanu 2004     | 0/20     | 0/20    |                             | Not estimable |  |
| Zakrzewska-Rehm 2008 | 0/194 | 1/99 | 21.29% | 0.17 | [0.01,4.16] |
| Lienhardt 2011    | 4/797    | 5/784   | 54.13% | 0.79 | [0.21,2.92] |
| Wu 2015           | 4/64     | 2/78    | 19.36% | 2.44 | [0.46,12.88] |
| **Subtotal (95% CI)** | **1075** | **981** | **94.78%** | **0.99** | **[0.4,2.44]** |

**Total events:** 8 (FDCs), 8 (SDF)

**Heterogeneity:** Tau²=0; Chi²=2.1, df=4 (P=0.54); I²=0%

**Test for overall effect:** Z=0.47 (P=0.64)

**Test for subgroup differences:** Chi²=0.49, df=1 (P=0.49), I²=0%

#### 6.8.2 Self-administered treatment during the intensive phase

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-----------------------------|
| RCTAI 1989        | 1/102    | 0/108   | 5.22% | 3.17 | [0.13,77.05] |
| **Subtotal (95% CI)** | **102**  | **108** | **5.22%** | **3.17** | **[0.13,77.05]** |

**Total events:** 1 (FDCs), 0 (SDF)

**Heterogeneity:** Not applicable

**Test for overall effect:** Z=0.71 (P=0.48)

**Total events:** 9 (FDCs), 8 (SDF)

**Heterogeneity:** Tau²=2.86, df=3 (P=0.41); I²=0%

**Test for overall effect:** Z=0.22 (P=0.83)
Analysis 6.9. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 9 Adverse events leading to discontinuation of therapy.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------------------|------|-----|------------|--------|------------|
|                  | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Chaulet 1995     | 0/118| 3/123| 3.96% | 0.15[0.01, 2.85] |
| Zhang 1996       | 0/102| 1/103| 3.48% | 0.34[0.01, 8.17] |
| Zhu 1998         | 0/258| 13/90| 4.29% | 0.01[0.00, 22] |
| Teo 1999         | 7/132| 4/139| 12.58%| 1.84[0.55, 6.15] |
| Munteanu 2004    | 0/20 | 0/20 | Not estimable |        |            |
| Zaka-Ur-Rehman 2008 | 0/194| 2/99 | 3.8% | 0.10[0.2, 12] |
| Lienhardt 2011   | 16/797| 9/784| 16.51%| 1.75[0.78, 3.93] |
| Wu 2015          | 1/64 | 1/78 | 4.44% | 1.22[0.08, 19.1] |
| Subtotal (95% CI)| 1685 | 1436 | 49.07%| 0.44[0.11, 1.71] |

Total events: 24 (FDCs), 33 (SDF)
Heterogeneity: Tau^2=1.98; Chi^2=19.45, df=6 (P=0); I^2=69.15%
Test for overall effect: Z=1.19 (P=0.23)

6.9.2 Self-administered treatment during the intensive phase

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------------------|------|-----|------------|--------|------------|
|                  | n/N  | n/N | M-H, Random, 95% CI |        | M-H, Random, 95% CI |
| Geiter 1987      | 15/122| 29/416| 18.79%| 1.76[0.98, 3.18] |
| RTCAI 1989       | 22/102| 30/108| 19.84%| 0.78[0.48, 1.25] |
| Su 2002          | 3/57 | 2/48 | 8.5% | 1.26[0.22, 7.25] |
| Suryanto 2008    | 0/236| 2/198| 3.79% | 0.17[0.01, 3.48] |
| Subtotal (95% CI)| 517  | 770 | 50.93%| 1.06[0.55, 2.04] |

Total events: 40 (FDCs), 63 (SDF)
Heterogeneity: Tau^2=0.19; Chi^2=5.95, df=3 (P=0.11); I^2=49.58%
Test for overall effect: Z=0.19 (P=0.85)

Total (95% CI) = 2202
Total events: 64 (FDCs), 96 (SDF)
Heterogeneity: Tau^2=0.49; Chi^2=24.29, df=10 (P=0.01); I^2=58.83%
Test for overall effect: Z=0.6 (P=0.55)
Test for subgroup differences: Chi^2=1.33, df=1 (P=0.25), I^2=24.88%

Analysis 6.10. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 10 Other adverse events.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------------------|------|-----|------------|--------|------------|
|                  | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Chaulet 1995     | 23/118| 41/123| 23.48%| 0.58[0.38, 0.91] |
| Zhang 1996       | 12/102| 15/103| 8.73% | 0.81[0.4, 1.64] |

Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)
### Study or subgroup

| Study or subgroup | FDCs n/N  | SDF n/N  | Risk Ratio (M-H, Fixed, 95% CI) | Weight | Risk Ratio (M-H, Fixed, 95% CI) |
|------------------|----------|----------|--------------------------------|--------|--------------------------------|
| Zhu 1998         | 23/258   | 8/90     |                                | 6.94%  | 1[0.47,2.16]                   |
| Teo 1999         | 45/132   | 45/139   |                                | 25.63% | 1.05[0.75,1.48]                |
| Munteanu 2004    | 0/20     | 0/20     |                                | Not estimable |
| Zaka-Ur-Rehman 2008 | 40/194  | 26/99     |                                | 20.13% | 0.79[0.51,1.21]                |
| Lienhardt 2011   | 11/797   | 22/784   |                                | 12.97% | 0.49[0.24,1.01]                |
| **Subtotal (95% CI)** | **1621** | **1358** |                                | **97.88%** | **0.79[0.64,0.96]** |

Total events: 154 (FDCs), 157 (SDF)
Heterogeneity: Tau²=0; Chi²=6.63, df=5(P=0.25); I²=24.53%
Test for overall effect: Z=2.35(P=0.02)

#### 6.10.2 Self-administered treatment during the intensive phase

| Study or subgroup | FDCs n/N  | SDF n/N  | Risk Ratio (M-H, Fixed, 95% CI) | Weight | Risk Ratio (M-H, Fixed, 95% CI) |
|------------------|----------|----------|--------------------------------|--------|--------------------------------|
| Geiter 1987      | 6/122    | 8/416    |                                | 2.12%  | 2.56[0.9,7.23]                 |
| **Subtotal (95% CI)** | **122**  | **416**  |                                | **2.12%** | **2.56[0.9,7.23]** |

Total events: 6 (FDCs), 8 (SDF)
Heterogeneity: Not applicable
Test for overall effect: Z=1.77(P=0.08)

#### Total (95% CI)

| Study or subgroup | FDCs n/N  | SDF n/N  | Risk Ratio (M-H, Fixed, 95% CI) | Weight | Risk Ratio (M-H, Fixed, 95% CI) |
|------------------|----------|----------|--------------------------------|--------|--------------------------------|
| **Total (95% CI)** | **1743** | **1774** |                                | **100%** | **0.82[0.68,1]** |

Total events: 160 (FDCs), 165 (SDF)
Heterogeneity: Tau²=0; Chi²=11.18, df=6(P=0.08); I²=46.34%
Test for overall effect: Z=1.95(P=0.05)
Test for subgroup differences: Chi²=4.78, df=1 (P=0.03), I²=79.06%

---

### Comparison 7. Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---------------------------|----------------|---------------------|--------------------|-------------|
| **1 Treatment failure**   | 7              | 3606                | Risk Ratio (M-H, Fixed, 95% CI) | 1.28 [0.82, 2.00] |
| 1.1 Four drugs as FDCs during the intensive phase | 3 | 2941 | Risk Ratio (M-H, Fixed, 95% CI) | 1.27 [0.80, 2.01] |
| 1.2 Three or 2 drugs as FDCs during the intensive phase | 4 | 665 | Risk Ratio (M-H, Fixed, 95% CI) | 1.52 [0.26, 9.08] |
| **2 Relapse**             | 9              | 3523                | Risk Ratio (M-H, Fixed, 95% CI) | 1.28 [1.00, 1.64] |
| 2.1 Four drugs as FDCs during the intensive phase | 4 | 2675 | Risk Ratio (M-H, Fixed, 95% CI) | 1.18 [0.91, 1.54] |
| 2.2 Three or 2 drugs as FDCs during the intensive phase | 5 | 848 | Risk Ratio (M-H, Fixed, 95% CI) | 2.55 [1.07, 6.06] |
| **3 Death**               | 11             | 4800                | Risk Ratio (M-H, Fixed, 95% CI) | 0.96 [0.67, 1.39] |
| Outcome or subgroup title                                      | No. of studies | No. of participants | Statistical method                              | Effect size                |
|---------------------------------------------------------------|----------------|---------------------|------------------------------------------------|---------------------------|
| 3.1 Four drugs as FDCs during the intensive phase             | 4              | 3002                | Risk Ratio (M-H, Fixed, 95% CI)                 | 0.79 [0.48, 1.30]         |
| 3.2 Three or 2 drugs as FDCs during the intensive phase       | 7              | 1798                | Risk Ratio (M-H, Fixed, 95% CI)                 | 1.21 [0.70, 2.10]         |
| 4 Adverse events leading to discontinuation of therapy        | 13             | 5530                | Risk Ratio (M-H, Random, 95% CI)                | 0.96 [0.56, 1.66]         |
| 4.1 Four drugs as FDCs during the intensive phase             | 4              | 3430                | Risk Ratio (M-H, Random, 95% CI)                | 1.21 [0.53, 2.78]         |
| 4.2 Three or 2 drugs as FDCs during the intensive phase       | 9              | 2100                | Risk Ratio (M-H, Random, 95% CI)                | 0.81 [0.37, 1.77]         |
| 5 Sputum smear or culture conversion at EOT                   | 7              | 2319                | Risk Ratio (M-H, Fixed, 95% CI)                 | 0.99 [0.96, 1.02]         |
| 5.1 Four drugs as FDCs during the intensive phase             | 2              | 1517                | Risk Ratio (M-H, Fixed, 95% CI)                 | 0.98 [0.94, 1.02]         |
| 5.2 Three or 2 drugs as FDCs during the intensive phase       | 5              | 802                 | Risk Ratio (M-H, Fixed, 95% CI)                 | 1.01 [0.98, 1.03]         |
| 6 Acquisition of drug resistance                              | 3              | 491                 | Risk Ratio (M-H, Fixed, 95% CI)                 | 0.76 [0.15, 3.77]         |
| 6.1 Four drugs as FDCs during the intensive phase             | 1              | 31                  | Risk Ratio (M-H, Fixed, 95% CI)                 | 1.07 [0.07, 15.57]        |
| 6.2 Three or 2 drugs as FDCs during the intensive phase       | 2              | 460                 | Risk Ratio (M-H, Fixed, 95% CI)                 | 0.64 [0.08, 4.79]         |
| 7 Serious adverse events                                     | 6              | 3388                | Risk Ratio (M-H, Fixed, 95% CI)                 | 1.45 [0.90, 2.33]         |
| 7.1 Four drugs as FDCs during the intensive phase             | 3              | 2996                | Risk Ratio (M-H, Fixed, 95% CI)                 | 1.34 [0.81, 2.23]         |
| 7.2 Three or 2 drugs as FDCs during the intensive phase       | 3              | 392                 | Risk Ratio (M-H, Fixed, 95% CI)                 | 2.59 [0.59, 11.34]        |
| 8 Sputum smear or culture conversion at 2 months of starting treatment | 13             | 4836                | Risk Ratio (M-H, Fixed, 95% CI)                 | 1.01 [0.99, 1.03]         |
| 8.1 Four drugs as FDCs during the intensive phase             | 4              | 2980                | Risk Ratio (M-H, Fixed, 95% CI)                 | 1.00 [0.97, 1.03]         |
| 8.2 Three or 2 drugs as FDCs during the intensive phase       | 9              | 1856                | Risk Ratio (M-H, Fixed, 95% CI)                 | 1.04 [1.01, 1.07]         |
| 9 Other adverse events                                       | 9              | 4639                | Risk Ratio (M-H, Fixed, 95% CI)                 | 0.85 [0.72, 1.00]         |
### Analysis 7.1. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 1 Treatment failure.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------------------|------|-----|------------|--------|------------|
|                  | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| 7.1.1 Four drugs as FDCs during the intensive phase | Suryanto 2008 | 9/236 | 4/198 | 12.97% | 1.89 [0.59, 6.04] |
|                  | Bartacek 2009 | 22/582 | 19/577 | 56.91% | 1.15 [0.63, 2.1] |
|                  | Lienhardt 2011 | 10/684 | 8/664 | 24.21% | 1.21 [0.48, 3.06] |
| Subtotal (95% CI) | 1502 | 1439 | 94.1% | 1.27 [0.8, 2.01] |
| Total events: 41 (FDCs), 31 (SDF) | Heterogeneity: Tau²=0; Chi²=0.56, df=2(P=0.75); I²=0% |
| Test for overall effect: Z=1(P=0.32) | |
| 7.1.2 Three or 2 drugs as FDCs during the intensive phase | Chaulet 1995 | 1/102 | 1/107 | 2.91% | 1.05 [0.07, 16.55] |
|                  | Teo 1999 | 2/154 | 1/153 | 2.99% | 1.99 [0.18, 21.69] |
|                  | Su 2002 | 0/26 | 0/25 | Not estimable |
|                  | Wu 2015 | 0/49 | 0/49 | Not estimable |
| Subtotal (95% CI) | 331 | 334 | 5.9% | 1.52 [0.26, 9.08] |
| Total events: 33 (FDCs), 2 (SDF) | Heterogeneity: Tau²=0; Chi²=0.04, df=1(P=0.84); I²=0% |
| Test for overall effect: Z=0.46(P=0.64) | |

### Analysis 7.2. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 2 Relapse.

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------------------|------|-----|------------|--------|------------|
|                  | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| 7.2.1 Four drugs as FDCs during the intensive phase | Zaka-Ur-Rehman 2008 | 0/141 | 0/69 | Not estimable |
|                  | Suryanto 2008 | 10/99 | 2/73 | 2.33% | 3.69 [0.83, 16.32] |
|                  | Bartacek 2009 | 74/468 | 69/477 | 69.18% | 1.09 [0.81, 1.48] |

---

**Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)**

Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
## Study or subgroup

| Study or subgroup           | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|----------------------------|----------|---------|------------------------------|--------|------------------------------|
| Lienhardt 2011             | 26/684   | 21/664  | 0.68[0.68,2.11]              | 21.57% | 1.21[0.68,2.11]              |
| **Subtotal (95% CI)**      | 1392     | 1283    |                              | 93.08% | 1.18[0.91,1.54]              |
| Total events: 110 (FDCs), 92 (SDF) |  |  | | | |
| Heterogeneity: Tau²=0; Chi²=2.51, df=2(P=0.29); I²=20.28% |  |  | | | |
| Test for overall effect: Z=1.26(P=0.21) |  |  | | | |

### 7.2.2 Three or 2 drugs as FDCs during the intensive phase

| Study or subgroup           | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|----------------------------|----------|---------|------------------------------|--------|------------------------------|
| RCTAI 1989                 | 1/64     | 1/71    | 1.11[0.07,17.37]             | 0.96%  | 1.11[0.07,17.37]             |
| Chaulet 1995               | 1/102    | 0/107   | 3.15[0.13,76.34]            | 0.49%  | 3.15[0.13,76.34]            |
| Zhang 1996                 | 2/101    | 2/101   | 1.0[0.14,6.96]              | 2.02%  | 1.0[0.14,6.96]              |
| Teo 1999                   | 11/121   | 3/130   | 3.94[1.13,13.78]           | 2.93%  | 3.94[1.13,13.78]           |
| Su 2002                    | 1/26     | 0/25    | 2.89[0.12,67.75]           | 0.52%  | 2.89[0.12,67.75]           |
| **Subtotal (95% CI)**      | 414      | 434     | 6.92%                       | 2.55%  | 2.55[1.07,6.06]           |
| Total events: 16 (FDCs), 6 (SDF) |  |  | | | |
| Heterogeneity: Tau²=0; Chi²=6.76, df=7(P=0.045); I²=0% |  |  | | | |
| Test for overall effect: Z=1.27(P=0.03) |  |  | | | |

### Analysis 7.3. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 3 Death.

#### 7.3.1 Four drugs as FDCs during the intensive phase

| Study or subgroup           | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|----------------------------|----------|---------|------------------------------|--------|------------------------------|
| Zaka-Un-Rehman 2008        | 0/141    | 1/69    | 0.16[0.01,3.98]             | 3.63%  | 0.16[0.01,3.98]             |
| Suryanto 2008              | 11/173   | 18/149  | 0.53[0.26,1.08]            | 34.99% | 0.53[0.26,1.08]            |
| Bartacek 2009              | 11/558   | 4/564   | 2.78[0.89,8.68]            | 7.2%   | 2.78[0.89,8.68]            |
| Lienhardt 2011             | 4/684    | 7/664   | 0.55[0.16,1.89]            | 12.85% | 0.55[0.16,1.89]            |
| **Subtotal (95% CI)**      | 1556     | 1446    | 58.67%                      | 0.79%  | 0.79[0.48,1.3]             |
| Total events: 26 (FDCs), 30 (SDF) |  |  | | | |
| Heterogeneity: Tau²=0; Chi²=7.17, df=3(P=0.07); I²=58.15% |  |  | | | |
| Test for overall effect: Z=0.94(P=0.35) |  |  | | | |

#### 7.3.2 Three or 2 drugs as FDCs during the intensive phase

| Study or subgroup           | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|----------------------------|----------|---------|------------------------------|--------|------------------------------|
| Geiter 1987                | 2/122    | 13/416  | 1.0[0.12,2.29]             | 10.67% | 1.0[0.12,2.29]             |
| RCTAI 1989                 | 1/102    | 0/108   | 3.17[0.13,77.05]           | 0.88%  | 3.17[0.13,77.05]           |
| Zhang 1996                 | 2/103    | 1/103   | 2.02[0.19,21.93]           | 1.8%   | 2.02[0.19,21.93]           |
| Zhu 1998                   | 0/227    | 0/81    | Not estimable               | 1.4[0.5,3.94] | 1.4[0.5,3.94] |
| Teo 1999                   | 8/132    | 6/139   | 2.95[0.64,13.53]           | 10.57% | 2.95[0.64,13.53]           |
| Su 2002                    | 7/57     | 2/48    | 2.63[0.13,23.7]           | 3.93%  | 2.63[0.13,23.7]           |
| Wu 2015                    | 6/75     | 8/86    | 0.86[0.31,2.37]           | 13.48% | 0.86[0.31,2.37]           |
| **Subtotal (95% CI)**      | 817      | 981     | 41.33%                      | 1.21%  | 1.21[0.7,2.1]             |
| Total events: 26 (FDCs), 30 (SDF) |  |  | | | |
### Study or subgroup

| FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------|-----|------------|--------|------------|
| n/N  | n/N | M-H, Fixed, 95% CI | M-H, Random, 95% CI |

**Total (95% CI)**: 2373 / 2427, 100%: 0.96 [0.67, 1.39]

**Total events**: 52 (FDCs), 60 (SDF)

**Heterogeneity**: Tau²=0; Chi²=12.21, df=9 (P=0.2); I²=26.27%

**Test for overall effect**: Z=0.68 (P=0.5)

**Test for subgroup differences**: Chi²=1.29, df=1 (P=0.26), I²=22.74%

---

### Analysis 7.4. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 4 Adverse events leading to discontinuation of therapy.

#### 7.4.1 Four drugs as FDCs during the intensive phase

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
| n/N               | n/N  | M-H, Fixed, 95% CI | M-H, Random, 95% CI |

**Suryanto 2008**

0/236 / 2/198, 2.81%: 0.17 [0.01, 3.48]

**Zaka-Ur-Rehman 2008**

0/194 / 2/99, 2.82%: 0.1 [0.01, 2.12]

**Bartacek 2009**

25/558 / 15/564, 16.32%: 1.68 [0.9, 3.16]

**Lienhardt 2011**

16/797 / 9/784, 14.29%: 1.75 [0.78, 3.93]

**Subtotal (95% CI)**: 1785 / 1645, 36.24%: 1.21 [0.53, 2.78]

**Total events**: 41 (FDCs), 28 (SDF)

**Heterogeneity**: Tau²=0.28; Chi²=5.38, df=3 (P=0.15); I²=44.23%

**Test for overall effect**: Z=0.46 (P=0.65)

**Test for subgroup differences**: Chi²=1.29, df=1 (P=0.26), I²=22.74%

---

#### 7.4.2 Three or 2 drugs as FDCs during the intensive phase

| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|-------------------|------|-----|------------|--------|------------|
| n/N               | n/N  | M-H, Random, 95% CI | M-H, Random, 95% CI |

**Geiter 1987**

15/122 / 29/416, 16.77%: 1.76 [0.98, 3.18]

**RCTAI 1989**

22/102 / 30/108, 17.96%: 0.78 [0.48, 1.25]

**Chaulet 1995**

0/118 / 3/123, 2.94%: 0.15 [0.01, 2.85]

**Zhang 1996**

0/102 / 1/103, 2.57%: 0.34 [0.01, 8.17]

**Zhu 1998**

0/258 / 13/90, 3.2%: 0.1 [0.01, 2.12]

**Teo 1999**

7/132 / 4/139, 10.35%: 1.84 [0.55, 6.15]

**Su 2002**

3/57 / 2/48, 6.66%: 1.26 [0.22, 7.25]

**Munteanu 2004**

0/20 / 0/20, 3.32%: 1.22 [0.08, 19.1]

**Wu 2015**

1/64 / 1/78, 3.32%: 1.22 [0.08, 19.1]

**Subtotal (95% CI)**: 975 / 1125, 63.76%: 0.81 [0.37, 1.77]

**Total events**: 48 (FDCs), 83 (SDF)

**Heterogeneity**: Tau²=0.58; Chi²=19.23, df=7 (P=0.01); I²=63.6%

**Test for overall effect**: Z=0.52 (P=0.6)

**Test for subgroup differences**: Chi²=0.48, df=1 (P=0.49), I²=0%

---

**Favours FDCs**

0.005 / 0.1 / 0.1 / 10 / 100 / 200

**Favours SDF**

0.01 / 0.1 / 0.1 / 10 / 100 / 200

---

**Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)**

Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
**Analysis 7.5. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 5 Sputum smear or culture conversion at EOT.**

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-----------------------------|
| **7.5.1 Four drugs as FDCs during the intensive phase** | | | | | |
| Suryanto 2008 | 188/198 | 152/160 | 16.7% | 1[0.95,1.05] |
| Bartacek 2009 | 468/582 | 477/577 | 47.59% | 0.97[0.92,1.03] |
| **Subtotal (95% CI)** | 780 | 737 | 64.3% | 0.98[0.94,1.02] |
| Total events: 656 (FDCs), 629 (SDF) | | | | |
| Heterogeneity: Tau^2=0; Chi^2=0.74, df=1(P=0.39); I^2=0% | | | | |
| Test for overall effect: Z=0.95(P=0.34) | | | | |

| **7.5.2 Three or 2 drugs as FDCs during the intensive phase** | | | | | |
| RCTAI 1989 | 64/66 | 71/74 | 6.65% | 1.01[0.95,1.08] |
| Zhang 1996 | 101/102 | 101/103 | 9.99% | 1.01[0.98,1.04] |
| Zhu 1998 | 224/227 | 79/81 | 11.57% | 1.01[0.97,1.05] |
| Su 2002 | 25/26 | 25/25 | 2.58% | 0.96[0.87,1.07] |
| Wu 2015 | 49/49 | 49/49 | 4.92% | 1[0.96,1.04] |
| **Subtotal (95% CI)** | 470 | 332 | 35.7% | 1.01[0.96,1.03] |
| Total events: 463 (FDCs), 325 (SDF) | | | | |
| Heterogeneity: Tau^2=0; Chi^2=0.9, df=4(P=0.92); I^2=0% | | | | |
| Test for overall effect: Z=0.53(P=0.59) | | | | |
| Total (95% CI) | 1250 | 1069 | 100% | 0.99[0.96,1.02] |
| Total events: 1119 (FDCs), 954 (SDF) | | | | |
| Heterogeneity: Tau^2=0; Chi^2=4.42, df=6(P=0.62); I^2=0% | | | | |
| Test for overall effect: Z=0.77(P=0.44) | | | | |
| Test for subgroup differences: Chi^2=1.19, df=1 (P=0.28), I^2=15.76% | | | | |

**Favours SDF** 1 **Favours FDCs**

**Analysis 7.6. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 6 Acquisition of drug resistance.**

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-----------------------------|--------|-----------------------------|
| **7.6.1 Four drugs as FDCs during the intensive phase** | | | | | |
| Lienhardt 2011 | 1/15 | 1/16 | 28.54% | 1.07[0.07,15.57] |
| **Subtotal (95% CI)** | 15 | 16 | 28.54% | 1.07[0.07,15.57] |
| Total events: 1 (FDCs), 1 (SDF) | | | | |
| Heterogeneity: Not applicable | | | | |
| Test for overall effect: Z=0.05(P=0.96) | | | | |

| **7.6.2 Three or 2 drugs as FDCs during the intensive phase** | | | | | |
| Chaulet 1995 | 1/102 | 1/107 | 28.79% | 1.05[0.07,16.55] |
| Teo 1999 | 0/121 | 1/130 | 42.67% | 0.36[0.01,8.7] |
| **Subtotal (95% CI)** | 223 | 237 | 71.46% | 0.64[0.08,4.79] |
| Total events: 1 (FDCs), 2 (SDF) | | | | |
| Heterogeneity: Tau^2=0; Chi^2=0.25, df=1(P=0.62); I^2=0% | | | | |
| Test for overall effect: Z=0.44(P=0.66) | | | | |
| Total (95% CI) | 238 | 253 | 100% | 0.76[0.15,3.77] |
| Favor FDCs 0.001 0.1 1 10 100 Favor SDF |

**Favours FDCs** 1 **Favours SDF**

**Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)**

Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
### Analysis 7.7. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 7 Serious adverse events.

#### Study or subgroup

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| 7.7.1 Four drugs as FDCs during the intensive phase |          |         |                             |        |                             |
| Zaka-Ur-Rehman 2008 | 0/194    | 1/99    | 7.29%                       | 0.17[0.01,4.16] |                             |
| Bartacek 2009    | 29/558   | 18/564  | 65.78%                      | 1.63[0.92,2.9]  |                             |
| Lienhardt 2011   | 4/797    | 5/784   | 18.52%                      | 0.79[0.21,2.92] |                             |
| **Subtotal (95% CI)** | **1549** | **1447** | **91.59%**                  | **1.34[0.81,2.13]** |                             |
| Total events: 33 (FDCs), 24 (SDF) |          |         |                             |        |                             |
| Heterogeneity: Tau²=0; Chi²=2.67, df=2(P=0.26); I²=25.11% |          |         |                             |        |                             |
| Test for overall effect: Z=1.14(P=0.26) |          |         |                             |        |                             |

#### Study or subgroup

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| 7.7.2 Three or 2 drugs as FDCs during the intensive phase |          |         |                             |        |                             |
| RCTAI 1989       | 1/102    | 0/108   | 1.79%                       | 3.17[0.13,77.05] |                             |
| Munteanu 2004    | 0/20     | 0/20    | Not estimable               |        |                             |
| Wu 2015          | 4/64     | 2/78    | 6.62%                       | 2.44[0.46,12.88] |                             |
| **Subtotal (95% CI)** | **186** | **206** | **8.41%**                   | **2.59[0.59,11.34]** |                             |
| Total events: 5 (FDCs), 2 (SDF) |          |         |                             |        |                             |
| Heterogeneity: Tau²=0; Chi²=0.02, df=1(P=0.89); I²=0% |          |         |                             |        |                             |
| Test for overall effect: Z=1.27(P=0.21) |          |         |                             |        |                             |

#### Total (95% CI)

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| **Total (95% CI)** | **1735** | **1653** | **100%**                   | **1.45[0.9,2.33]** |                             |
| Total events: 38 (FDCs), 26 (SDF) |          |         |                             |        |                             |
| Heterogeneity: Tau²=0; Chi²=3.32, df=4(P=0.51); I²=0% |          |         |                             |        |                             |
| Test for overall effect: Z=1.52(P=0.13) |          |         |                             |        |                             |
| Test for subgroup differences: Chi²=0.68, df=1 (P=0.41), I²=0% |          |         |                             |        |                             |

### Analysis 7.8. Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 8 Sputum smear or culture conversion at 2 months of starting treatment.

#### Study or subgroup

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| 7.8.1 Four drugs as FDCs during the intensive phase |          |         |                             |        |                             |
| Suryanto 2008    | 186/198  | 143/160 | 7.97%                       | 1.05[0.99,1.12] |                             |
| Zaka-Ur-Rehman 2008 | 187/194  | 94/99   | 6.27%                       | 1.02[0.96,1.07] |                             |
| Bartacek 2009    | 449/582  | 469/577 | 23.72%                      | 0.95[0.89,1.01] |                             |
| Lienhardt 2011   | 521/591  | 501/579 | 25.49%                      | 1.02[0.98,1.06] |                             |
| **Subtotal (95% CI)** | **1** | **1** | **100%**                   | **1** | **1**                       |

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|------------------|----------|---------|-----------------------------|--------|-----------------------------|
| 7.8.1 Four drugs as FDCs during the intensive phase |          |         |                             |        |                             |
| Suryanto 2008    | 186/198  | 143/160 | 7.97%                       | 1.05[0.99,1.12] |                             |
| Zaka-Ur-Rehman 2008 | 187/194  | 94/99   | 6.27%                       | 1.02[0.96,1.07] |                             |
| Bartacek 2009    | 449/582  | 469/577 | 23.72%                      | 0.95[0.89,1.01] |                             |
| Lienhardt 2011   | 521/591  | 501/579 | 25.49%                      | 1.02[0.98,1.06] |                             |
| **Subtotal (95% CI)** | **1** | **1** | **100%**                   | **1** | **1**                       |
# Analysis 7.9

## 7.9.1 Four drugs as FDCs during the intensive phase

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-------------------------------|--------|-------------------------------|
| Zaka-Un-Rehman 2008 | 40/194   | 26/99   | 1.352                         | 13.52% | 0.79[0.51,1.21]              |
| Bartacek 2009     | 75/558   | 84/564  | 3.282                         | 32.82% | 0.9[0.68,1.2]               |
| Lienhardt 2011    | 11/797   | 22/784  | 8.71%                         | 8.71%  | 0.49[0.24,1.01]             |
| **Subtotal (95% CI)** | **1549** | **1447** | **55.06%**                    | **55.06%** | **0.81[0.64,1.02]**        |

Total events: 126 (FDCs), 132 (SDF)
Heterogeneity: Tau²=0; Chi²=17.39, df=2(P=0.03); I²=17.39%
Test for overall effect: Z=1.83(P=0.07)

## 7.9.2 Three or 2 drugs as FDCs during the intensive phase

| Study or subgroup | FDCs n/N | SDF n/N | Risk Ratio M-H, Fixed, 95% CI | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|----------|---------|-------------------------------|--------|-------------------------------|
| Geiter 1987       | 106/122  | 323/416 | 7.38%                         | 7.38%  | 1.12[1.03,1.22]             |
| Geiter 2009       | 67/70    | 73/76   | 3.53%                         | 3.53%  | 1.03[0.96,1.11]             |
| Chauvet 1995      | 90/95    | 99/103  | 4.67%                         | 4.67%  | 1.03[0.99,1.08]             |
| Zhu 1998          | 207/227  | 70/81   | 5.2%                          | 5.2%   | 1.06[0.96,1.16]             |
| Teo 1999          | 124/129  | 133/140 | 6.42%                         | 6.42%  | 1.01[0.96,1.07]             |
| Su 2002           | 23/26    | 24/25   | 1.23%                         | 1.23%  | 0.92[0.79,1.08]             |
| Munteanu 2004     | 14/20    | 15/18   | 0.8%                          | 0.8%   | 0.84[0.59,1.2]              |
| Wu 2015           | 47/49    | 47/49   | 2.37%                         | 2.37%  | 1.02[0.92,1.09]             |
| **Subtotal (95% CI)** | **840**  | **1016** | **36.55%**                    | **36.55%** | **1.04[1.01,1.07]**        |

Total events: 779 (FDCs), 883 (SDF)
Heterogeneity: Tau²=0; Chi²=9.49, df=8(P=0.03); I²=15.67%
Test for overall effect: Z=2.36(P=0.02)

Total (95% CI): 2405 / 2431 = 100%
Heterogeneity: Tau²=0; Chi²=23.74, df=9(P=0.03); I²=23.74%
Test for overall effect: Z=0.98(P=0.33)
Test for subgroup differences: Chi²=3.33, df=1(P=0.07), I²=70.01%

Favours SDFs 1

Favours FDCs 0.2 1 2 5

---

**Analysis 7.9.** Comparison 7 Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 9 Other adverse events.
| Study or subgroup | FDCs | SDF | Risk Ratio | Weight | Risk Ratio |
|------------------|------|-----|------------|--------|------------|
|                  | n/N  | n/N | M-H, Fixed, 95% CI |        | M-H, Fixed, 95% CI |
| Total events: 109 (FDCs), 117 (SDF) |     |     |             |        |             |
| Total events: 235 (FDCs), 249 (SDF) |     |     |             |        |             |
| Total (95% CI) | 2301 | 2338 |                   | 100%   | 0.85[0.72,1] |

Heterogeneity: Tau^2=0; Chi^2=8.51, df=4(P=0.07); I^2=52.97%
Test for overall effect: Z=0.9(P=0.37)

Test for overall effect: Z=1.97(P=0.05)
Test for subgroup differences: Chi^2=0.41, df=1 (P=0.52), I^2=0%

**A D D I T I O N A L T A B L E S**

**Table 1. Suggested definitions of main outcomes according to the authors of included trials**

| Trial | Outcomes | Definitions | Notes |
|-------|----------|-------------|-------|
| Bartacek 2009 | Treatment failure | “sputum smear still or again positive after 4 and/or 6 months of treatment” | Treatment efficacy based on bacteriological response rate (sputum smear conversion rate) on 2 smears |
| | Relapse | “patient cured at end of treatment (EOT) and sputum smear again positive at months 9 or 12” | |
| Chaulet 1995 | Treatment failure | “two positive cultures with or without radiological deterioration at EOT (treatment failure) or during the follow-up (relapse) and consequently resulting in a new course of treatment” | Treatment efficacy based on bacteriological criteria (2 negative cultures) |
| | Relapse | | |
| | Treatment adherence | Not defined | Determined by testing urine for isoniazid metabolites by biochemical methods |
| | Acquisition of drug resistance | | Determined by drug sensitivity test for isoniazid, rifampicin and streptomycin |
| Geiter 1987 | Treatment adherence | Not defined | Asking patients for missed doses, by pill counts and by testing urine for isoniazid metabolites |
| Lienhardt 2011 | Treatment failure | “One culture of at least 20 colonies’ growth or 2 cultures of 10 or more colonies growth at EOT not identified as a reinfection” | Treatment efficacy based on bacteriological results: 2 sputum smears and cultures. One case of relapse was reported based only in radiologic deterioration |
| | Relapse | “One culture of at least 20 colonies’ growth or 2 cultures of 10 or more colonies growth in the follow-phase not identified as reinfection” | |
| Study               | Acquisition of drug resistance | Relapse | Treatment adherence |
|---------------------|--------------------------------|---------|---------------------|
| RCTAI 1989          | Not defined                    | Efficacy based on bacteriological results (sputum smear and culture) | Assessed by delay in drug collection and surprise pill counting |
| Su 2002             | Not defined                    | Treatment efficacy based on clinical, bacteriological (3 sputum smears and cultures) and radiographic criteria | Efficacy based on bacteriological results (3 sputum smears and cultures) |
|                     |                                 |         | Assessed by “cases lost to follow-up and cases who changed to another regimen during treatment” |
| Suryanto 2008       | Treatment failure               | “Smear positive at 5 months or later” | Efficacy based on bacteriological results (sputum smear) |
|                     |                                 | Relapse | Efficacy based on bacteriological results (1 smear sputum and culture) and information from interviews and verbal autopsies |
|                     |                                 | Treatment adherence | Treatment efficacy based on bacteriological results (sputum smear and culture) |
| Teo 1999            | Treatment failure               | “Bacteriological relapse after chemotherapy was defined as a positive culture with a growth of 10 or more colonies in 2 different months during any 3-month period up to 30 months, and during any 6-month period up to 60 months” | Efficacy based on bacteriological results (sputum smear and culture). One case of relapse was reported based on radiological deterioration |
|                     |                                 | Relapse | Determined by drug sensitivity test for isoniazid, rifampicin, and streptomycin |
| Zaka-Ur-Rehman 2008 | Relapse                        | Not defined | Efficacy based on bacteriological results (sputum smear) |
Relapse: Not defined

Efficacy based on bacteriological results (sputum smear and culture)

Treatment adherence: Not defined

There were 3 kinds of treatment management (whole-course hospitalization; hospitalization only during intensive phase and outpatient treatment), combined with 3 supervision model respectively (supervision by medical staff; supervision by no-medical staff who had been trained by the medical staff [relatives, colleagues] and supervision by medical staff in the intensive phase but non-medical staff in the continuation phase). Treatment and supervision were established according to participants economic status.

**Table 2. Numbers of randomized participants and treatment regimens of trials included in the meta-analysis**

| Trial                | Number of participants | Treatment regimens |
|----------------------|------------------------|--------------------|
| Bartacek 2009        | 1159                   | 2HRZE/4HR          |
| Chaulet 1995         | 250                    | 2HRZ/4HR           |
| Geiter 1987          | 701                    | 2HRZ/4HR           |
| Lienhardt 2011       | 1585                   | 2HRZE/4HR¹         |
| Munteanu 2004        | 40                     | 2HRZE/4HR          |
| RCTAI 1989           | 229                    | 2HRZ/4HR¹          |
| Su 2002              | 105                    | 2HRZE/4HRE         |
| Suryanto 2008        | 434                    | 2HRZE/3HR          |
| Teo 1999             | 310                    | 3 different regimes were given² |
| Wu 2015              | 161                    | 2HRZE/4HRE         |
| Zaka-Ur-Rehman 2008  | 293                    | 2HRZE/4HRE         |
| Zhang 1996           | 209                    | 2HRZ/4HR           |
| Zhu 1998             | 348                    | 2HRZ/4HR           |

**Abbreviations:** H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; S: streptomycin.

¹In Lienhardt 2011 and RCTAI 1989 the treatment regimen was 8 weeks for intensive phase and 18 weeks for continuation phase.
²Intensive phase: Regimen 1: 2SHRZ, Regimen 2: 1SHRZ or Regimen 3: 2HRZ and continuation phase: H and R to complete 6 months of treatment (4HR or 5HR).
## Table 3. Comparison of given dose between fixed-dose combinations and single-drug formulations during the intensive phase in the included studies

| Trial          | Regimen treatment | Directly observed therapy | Dosing                                                                 | Dose simulation during intensive phase | Comment                                                                                                                                                                                                 |
|----------------|-------------------|---------------------------|------------------------------------------------------------------------|----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Bartacek 2009  | 2HRZE/4HR         | Mode of drugs administration: not reported | By weight categories                                                   | Unclear                                | The trial authors state: "The mean daily doses of INH, PZA and EMB administered during the initiation phase in the 4-FDC group were significantly lower than those administered in the ST group; RMP doses were similar in both groups". |
| Chaulet 1995   | 2HRZ/4HR          | At the beginning of intensive phase | By weight categories                                                   | H: 250 mg R: 600 mg Z: 1500 mg         | During directly observed treatment (DOT), “health personal” supervised treatment. Time with DOT is unclear.                                                                                                   |
| Geiter 1987    | 2HRZ/4HR          | No                        | By weight categories only for FD-Cs                                    | H: 225 mg R: 450 mg Z: 1200 mg         | Self-administered treatment was done during the whole treatment. Dose used for single-drug formulations: not reported.                                                                                           |
| Lienhardt 2011 | 2HRZE/4HR         | During 6 days a week       | By weight categories                                                   | H: 225 mg R: 450 mg Z: 1200 mg E: 825 mg | The trial authors state: "In the majority of the trial centers, treatment was fully supervised for a minimum of 6 days a week". Every treatment dose was taken under the supervision of the medical staff. |
| Munteanu 2004  | 2HRZE/4HR         | During the intensive phase | Not reported                                                          | H: 320 mg R: 480 mg Z: 1000 mg         | The supervision mechanism during DOT is unclear, and only mention "strictly supervised". Self-administered treatment was done during the continuation phase.                                             |
| RCTAI 1989     | 2HRZ/4HR          | No                        | By weight categories                                                   | H: 320 mg R: 480 mg Z: 1000 mg         | Self-administered treatment during the whole treatment.                                                                                                                                                   |
| Study     | Drug Regimen | Mode of Administration | By Weight Categories | Average Dose | Short Description |
|-----------|--------------|------------------------|----------------------|--------------|------------------|
| Semenova 2003 | 4HRZE        | Not reported           | Mairin-P: 4 tablets + H: 225 mg R: 450 mg Z: 900 mg E: 1125 mg | H: 450 mg R: 450 mg Z: 300 mg E: 600 mg | Streptomycin was added in 2 of the 4 randomized groups.
| Su 2002  | 2HRZE/4HRE   | No                     | H: 200 mg R: 480 mg Z: 1000 mg E: not reported | H: 300 mg R: 600 mg Z: 1200 mg E: 1500 mg | Self-administered treatment during the whole treatment.
| Suryanto 2008 | 2HRZE/3HR  | Once a weekly          | Average H: 225 mg R: 450 mg Z: 1200 mg E: 825 mg | Average H: 300 mg R: 600 mg Z: 1500 mg E: 750 mg | The study authors state: "The loose drug regimen contained higher dosages of H and Z and lower dosage for E compared to the FDCs".
| Teo 1999 | Three different regimes were given | During the whole treatment | H: 250 mg R: 600 mg Z: 1500 mg S: 750 mg | H: 300 mg R: 720 mg Z: 1800 mg S: 750 mg | The supervision mechanism during DOT is not clear. And only mention: DOT was given "at the community health clinic".
| Wu 2015 | 2HRZE/4HRE   | TDO 5 days per week and self-administered during weekends | H: 320 mg R: 480 mg Z: 1000 mg E: 900 mg | H: 300 mg R: 600 mg Z: 1250 mg E: 1200 mg | DOT was supervised by "health workers". The ethambutol dose in FDCs groups was not reported.
| Study          | Dose Combination | Phase          | By Weight Categories | Dose          | Dose          | Dose          | The supervision mechanism during DOT is unclear and only mention: “directly observed therapy was followed for each patient on a daily basis”. |
|----------------|------------------|----------------|----------------------|---------------|---------------|---------------|---------------------------------------------------------------------------------------------------------------------------------|
| **Zaka-Ur-Rehman 2008** | 2H RZE/4H R      | During the intensive phase | By weight categories | 5H: 300 mg | H: 300 mg | 5H: 375 mg | H: 400 mg | The trial authors state: “All drugs were taken under close supervision of a health care provider”. |
|                |                  |                |                      | R: 480 mg    | R: 450 mg   | R: 600 mg    | R: 600 mg            |                                                                                                                                |
|                |                  |                |                      | Z: 1400 mg   | Z: 1500 mg  | Z: 1750 mg   | Z: 2000 mg          |                                                                                                                                |
|                |                  |                |                      | E: 1000 mg   | E: 1200 mg  | E: 1250 mg   | E: 1600 mg          |                                                                                                                                |
| **Zhang 1996**  | 2HRZ/4HR         | During the intensive phase | By weight categories | H: 320 mg   | H: 300 mg   | H: 400 mg    | H: 300 mg | There were 3 kinds of treatment management combined with 3 supervision models.                                                 |
|                |                  |                |                      | R: 400 mg    | R: 450 mg   | R: 600 mg    | R: 600 mg            |                                                                                                                                |
|                |                  |                |                      | Z: 1000 mg   | Z: 1500 mg  | Z: 1250 mg   | Z: 1500 mg          |                                                                                                                                |
| **Zhu 1998**   | 2HRZ/4HR         | Only for a part of participants | By weight categories | H: 320 mg   | H: 300 mg   | H: 320 mg    | H: 300 mg | There were 3 kinds of treatment management combined with 3 supervision models.                                                 |
|                |                  |                |                      | R: 480 mg    | R: 450 mg   | R: 480 mg    | R: 600 mg            |                                                                                                                                |
|                |                  |                |                      | Z: 1000 mg   | Z: 1500 mg  | Z: 1000 mg   | Z: 1500 mg          |                                                                                                                                |

**Abbreviations:** kg: kilograms of body weight; H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; FDCs: fixed-dose combinations; SDF: single-dose formulations; mg: milligrams; DOT: directly-observed treatment.

1. In Lienhardt 2011 the treatment regimen was 8 weeks for intensive phase and 18 weeks for continuation phase.
2. In RCTAI 1989 the treatment regimen was 8 weeks for intensive phase and 18 weeks for continuation phase.
3. Data and dosage simulation done only for the groups 1 and 3. (In Semenova 2003 there were another two regimens for the intensive phase: 2 and 4).
4. Data extracted and dosage simulation done only for the regimen 1: 2SHRZ. (In Teo 1999 there were another two regimens for the intensive phase: 1SHRZ and 2HRZ).
5. In the FDCs group, data and dosage simulation presented for the regimen A. (In Zaka-Ur-Rehman 2008 there was another FDCs regimen: regimen B).
6. In Zhu 1998 there were 3 modes of treatment supervision.
Table 4. 'Summary of findings' table 2

Fixed-dose combinations (FDCs) compared to single-drug formulations for treating newly diagnosed pulmonary tuberculosis (TB)

| Outcomes                                                                 | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | Number of participants (trials) | Quality of the evidence (GRADE) |
|--------------------------------------------------------------------------|-----------------------------------------|--------------------------|---------------------------------|---------------------------------|
| Assumed risk                                                             | Corresponding risk                       |                          |                                 |                                 |
| single-drug formulations                                                 | FDCs                                     |                          |                                 |                                 |
| Combined endpoint of treatment failure, relapse, or death**              | —                                       | RR 1.17 (0.70 to 1.93)   | (0 RCTs)                        | ◼◼◼◼ moderate1,2,3,4             |
| Treatment failure                                                       | 22 per 1000 (15 to 42)                  | RR 1.12 (0.86 to 1.46)   | 2293 (2 RCTs)                   | ◼◼◼◼ moderate1,2,3,4             |
| Relapse                                                                 | 79 per 1000 (68 to 115)                 | RR 1.35 (0.63 to 2.93)   | 2470 (2 RCTs)                   | ◼◼◼◼ moderate2,4,5,6             |
| Death                                                                   | 9 per 1000 (6 to 26)                    | RR 0.97 (0.92 to 1.03)   | 1159 (1 RCT)                    | ◼◼◼◼ high2,4,7,8                |
| Sputum smear or culture conversion at end of treatment                  | 827 per 1000 (761 to 851)               | RR 0.97 (0.92 to 1.03)   | 1159 (1 RCT)                    | ◼◼◼◼ high2,4,7,8                |
| Serious adverse events                                                  | 17 per 1000 (15 to 42)                  | RR 1.44 (0.86 to 2.44)   | 2703 (2 RCTs)                   | ◼◼◼◼ moderate1,2,3,4             |
| Adverse events leading to discontinuation of therapy                    | 18 per 1000 (19 to 50)                  | RR 1.71 (1.04 to 2.81)   | 2703 (2 RCTs)                   | ◼◼◼◼ moderate1,2,3,4             |

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
**Outcome not reported.

Abbreviations: CI: confidence interval; RR: risk ratio; TB: tuberculosis; FDCs: fixed-dose combinations; RCTs: randomized controlled trial.

GRADE Working Group grades of evidence

High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1 We did not downgrade the quality due to inconsistency. I² statistic = 0%.
2 We did not downgrade the quality for risk of bias. There were no limitations in the design and execution of the trials.
3 Downgraded by 1 for imprecision. The optimal information size, considering an absolute > 0.5% non-inferiority margin as clinically meaningful, is not reached. In addition, 1 side of the 95% CI does not exclude potential harm associated to FDCs.

4 We did not downgrade quality for indirectness. Differences in dosages probably do not affect the comparability of groups.

5 We did not downgrade quality due to inconsistency. Large heterogeneity ($I^2$ statistic = 72%) can be explained by the limited number of events and the effect of chance.

6 Downgraded by 1 for imprecision. The optimal information size, considering an absolute > 0.1% non-inferiority margin as clinically meaningful, is not reached. In addition, the number of events is very limited.

7 We did not downgrade the quality due to inconsistency. There was only a single included trial.

8 We did not downgrade the quality due to imprecision. Although the optimal information size considering an absolute > 0.5% non-inferiority margin as clinically meaningful is not reached, the total sample size and number of events are very large.

Table 5. Optimal information size calculations: fixed-dose combinations versus single-drug formulations (Comparison 1)

| Outcomes                                      | Assumed risk | Clinically important reduction | Optimal sample size $^{1,2}$ |
|-----------------------------------------------|--------------|--------------------------------|------------------------------|
|                                               | Single-drug formulations | Absolute | Relative |                               |
| Treatment failure                             | 2.2%         | 0.5%                           | 25% | 6092                           |
| Relapse                                       | 2.3%         | 0.5%                           | 25% | 4718                           |
| Death $^3$                                     | 0.9%         | 0.1%                           | 4.5% | 737,340                        |
| Sputum/culture conversion at end of treatment | 88.7%        | 0.5%                           | 0.6% | 95,044                         |
| Serious adverse events                        | 1.5%         | 0.1%                           | 6.7% | 12,356                         |
| Adverse events leading to discontinuation of therapy | 4.1%         | 0.5%                           | 24.4% | 325,024                        |

$^1$We based all calculations are based on: 1-sided tests, with a ratio of 1:1, power of 0.9, and confidence level of 0.05.

$^2$We performed all calculations using: http://www.sealedenvelope.com/power/binary-noninferior/.

$^3$If there is truly no difference between the standard and experimental treatment, then 737,340 participants are required to be 90% sure that the upper limit of a 1-sided 95% confidence interval (CI) (or equivalently a 90% 2-sided CI) will exclude a difference in favour of the standard group of more than 0.1%.

APPENDICES

Appendix 1. Search strategy for identification of studies

| Search set | CIDG SR$^1$ | CENTRAL | MEDLINE$^2$ | EMBASE$^2$ | LILACS$^2$ |
|------------|-------------|---------|------------|------------|------------|
| 1          | tuberculosis | Tuberculosis [MeSH] | Tuberculosis [MeSH] | Tuberculosis [MeSH] | tuberculosis |
| 2          | Fixed dose | Tuberculosis ti, ab | Tuberculosis ti, ab | Tuberculosis ti, ab | Fixed dose |
| 3          | multidose | 1 or 2 | 1 or 2 | 1 or 2 | multidose |
| 4          | Drug combination | Drug Therapy, Combination [Mesh] | Drug Therapy, Combination [Mesh] | Drug Combination [Emtree] | Drug combination |
(Continued)

|   |   | Drug combinations [Mesh] | Drug combinations [Mesh] | Fixed dose ti, ab |   |   |
|---|---|--------------------------|--------------------------|------------------|---|---|
| 5 | 2 or 3 or 4 | 2 or 3 or 4 | 2 or 3 or 4 |
| 6 | 1 and 5 | Fixed dose ti, ab | Fixed dose ti, ab | Combination* ti, ab | 1 and 5 |
| 7 | — | Combination* ti, ab | Combination* ti, ab | Combined ti |
| 8 | — | Combined ti | Combined ti | Fixed multidose ti, ab |
| 9 | — | Fixed multidose ti, ab | Fixed multidose ti, ab | Blister pack ti, ab |
| 10 | — | Blister pack ti, ab | Blister pack ti, ab | 4-9/OR |
| 11 | — | 4-8/OR | 4-10/OR | 3 AND 10 |
| 12 | — | 3 AND 9 | 3 AND 11 | Limit 11 to human |
| 13 | — | — | Limit 12 to Humans |

1Cochrane Infectious Diseases Group Specialized Register.
2Search terms used in combination with the search strategy for retrieving trials developed by Cochrane (Lefebvre 2011).

**Contributions of Authors**

1. CRG, DRC, and XB conceived and designed the idea for this Cochrane review. All review authors contributed to the protocol development. CRG wrote the protocol (Gallardo 2012).
2. CRG, MR, and AVR extracted data from the included trials.
3. CRG, AVR, and DRC assessed risk of bias in the included trials.
4. CRG and MR entered data into RevMan (RevMan 2014).
5. MR and CRG performed and interpreted the analyses.
6. DRC drafted the ‘Summary of findings’ tables.
7. All review authors drafted the final review version and critically reviewed the content.
8. CRG wrote the final review version.
9. All review authors approved the final review version.

**Declaration of Interest**

CRG has no known conflicts of interest.
DRC has no known conflicts of interest.
AVR has no known conflicts of interest.
MR has no known conflicts of interest.
LP has no known conflicts of interest.
JC has no known conflicts of interest.
XB has no known conflicts of interest.

**Sources of Support**

- **Internal sources**
  - Cochrane Infectious Disease Group, UK.
  - Liverpool School of Tropical Medicine, UK.

- **External sources**
  - Department for International Development (DFID), UK.
  - Grant: 5242
DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We updated references in the Background section and added the latest World Health Organization (WHO) report (WHO 2015) and the last version of the International Standard of Tuberculosis Care (ISTC) (ISTC 2014). Both documents were published after the Cochrane protocol, Gallardo 2012, was published.

In the Methods section, we redefined some aspects.

1. Types of intervention: for this review we considered that all drugs should be used ideally for a minimum of two months, but should not exceed nine months. We clarified the inclusion of studies with at least 60% of participants treated with each drug for a minimum of two months, although the rest of the participants had been treated only for one month with at least one of the drugs used.

2. Types of outcome measures: for primary outcomes (especially treatment failure and relapse) we considered the definitions suggested by trial authors instead of the WHO’s definitions, due to different definitions given in each trial. Differences in definitions can be justified by the wide range in the publication years of included studies (1987 to 2015). We clarified the definitions as suggested by the trial authors (Table 1). For sputum smear or culture conversion, we took culture data instead of sputum smear data when both were available. We added ‘patient satisfaction’ as a secondary outcome and we also clarified that data for death included all reported causes of death (see Types of outcome measures).

3. Assessment of heterogeneity: we clearly redacted this section to better explain the methodology we used.

4. Data synthesis: we did the main analysis with ‘available data’, according to data given in the included trials.

5. We performed a sensitivity analysis as an intention-to-treat analysis and we assumed all losses to follow-up as a negative outcome for the primary dichotomous outcomes relating to treatment efficacy (treatment failure and relapse). Losses were not taken into account for the analysis of sputum smear or culture conversion.

We added data of baseline drug susceptibility to the ‘Characteristics of included studies’ section, when available.

In addition, we performed the analyses using RevMan (RevMan 2014). We also assessed the quality of the evidence using the GRADE approach.

INDEX TERMS

Medical Subject Headings (MeSH)

Antitubercular Agents [*administration & dosage]; Drug Combinations; Drug Therapy, Combination [methods]; Medication Adherence; Randomized Controlled Trials as Topic; Tuberculosis, Pulmonary [*drug therapy]

MeSH check words

Adolescent; Adult; Female; Humans; Male; Middle Aged